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Background: People with multiple sclerosis have problems with memory and attention. The effectiveness
of cognitive rehabilitation has not been established.
Objectives: The objectives were to assess the clinical effectiveness and cost-effectiveness of a cognitive
rehabilitation programme for people with multiple sclerosis.
Design: This was a multicentre, randomised controlled trial in which participants were randomised in a
ratio of 6 : 5 to receive cognitive rehabilitation plus usual care or usual care alone. Participants were
assessed at 6 and 12 months after randomisation.
Setting: The trial was set in hospital neurology clinics and community services.
Participants: Participants were people with multiple sclerosis who had cognitive problems, were aged
18–69 years, could travel to attend group sessions and gave informed consent.
Intervention: The intervention was a group cognitive rehabilitation programme delivered weekly by an
assistant psychologist to between four and six participants for 10 weeks.
Main outcome measures: The primary outcome was the Multiple Sclerosis Impact Scale – Psychological
subscale at 12 months. Secondary outcomes included results from the Everyday Memory Questionnaire,
the 30-Item General Health Questionnaire, the EuroQol-5 Dimensions, five-level version and a service use
questionnaire from participants, and the Everyday Memory Questionnaire – relative version and the
Modified Carer Strain Index from a relative or friend of the participant.
Results: Of the 449 participants randomised, 245 were allocated to cognitive rehabilitation (intervention
group) and 204 were allocated to usual care (control group). Of these, 214 in the intervention group and
173 in the control group were included in the primary analysis. There was no clinically important difference
in the Multiple Sclerosis Impact Scale – Psychological subscale score between the two groups at the
12-month follow-up (adjusted difference in means –0.6, 95% confidence interval –1.5 to 0.3; p = 0.20).
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There were no important differences between the groups in relation to cognitive abilities, fatigue,
employment, or carer strain at follow-up. However, there were differences, although small, between
the groups in the Multiple Sclerosis Impact Scale – Psychological subscale score at 6 months (adjusted
difference in means –0.9, 95% confidence interval –1.7 to –0.1; p = 0.03) and in everyday memory on
the Everyday Memory Questionnaire as reported by participants at 6 (adjusted difference in means –5.3,
95% confidence interval –8.7 to –1.9) and 12 months (adjusted difference in means –4.4, 95% confidence
interval –7.8 to –0.9) and by relatives at 6 (adjusted difference in means –5.4, 95% confidence interval
–9.1 to –1.7) and 12 months (adjusted difference in means –5.5, 95% confidence interval –9.6 to –1.5)
in favour of the cognitive rehabilitation group. There were also differences in mood on the 30-Item
General Health Questionnaire at 6 (adjusted difference in means –3.4, 95% confidence interval –5.9 to
–0.8) and 12 months (adjusted difference in means –3.4, 95% confidence interval –6.2 to –0.6) in favour
of the cognitive rehabilitation group. A qualitative analysis indicated perceived benefits of the intervention.
There was no evidence of a difference in costs (adjusted difference in means –£574.93, 95% confidence
interval –£1878.93 to £729.07) or quality-adjusted life-year gain (adjusted difference in means 0.00,
95% confidence interval –0.02 to 0.02). No safety concerns were raised and no deaths were reported.
Limitations: The trial included a sample of participants who had relatively severe cognitive problems in
daily life. The trial was not powered to perform subgroup analyses. Participants could not be blinded to
treatment allocation.
Conclusions: This cognitive rehabilitation programme had no long-term benefits on quality of life for
people with multiple sclerosis.
Future work: Future research should evaluate the selection of those who may benefit from cognitive
rehabilitation.
Trial registration: Current Controlled Trials ISRCTN09697576.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 4.
See the National Institute for Health Research Journals Library website for further project information.
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Plain English summary
Cognitive (or mental processing) problems, particularly those affecting memory and attention, arecommon in people with multiple sclerosis. Multiple sclerosis is a condition that affects the brain and
causes nerve damage. Cognitive rehabilitation can involve:
l retraining cognitive skills, which are the core skills your brain uses to think, read, learn, remember,
reason and concentrate
l teaching strategies to cope in daily life.
Cognitive rehabilitation is rarely provided for people with multiple sclerosis.
A trial was carried out to determine whether or not providing a group cognitive rehabilitation programme
improved quality of life more than usual clinical care, which did not involve any cognitive rehabilitation.
The effects on daily memory problems, mood, fatigue and employment were examined and also the
cost-effectiveness of the treatment.
A total of 449 people with multiple sclerosis took part in the trial. They all agreed to be part of the
research trial, had cognitive problems, were aged 18–69 years and could travel to attend group sessions.
Participants were then allocated to receive cognitive rehabilitation or not, on the basis of chance (i.e.
randomly). All participants were followed up for 1 year.
Although both groups showed no differences in quality of life after 1 year, those who received cognitive
rehabilitation had fewer memory problems in daily life and reported better mood than those who received
only their usual clinical care. There were no differences in their levels of fatigue or disability, or in
employment status. The qualitative results indicated that participants found the intervention useful.
Treatment cost slightly less than usual care but had modest benefits.
Overall, the results suggest that there may be modest short-term benefits of cognitive rehabilitation, and
future studies will consider how such benefits can be maintained and whether or not some people benefit
more than others.
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Scientific summary
Background
Cognitive problems are common in people with multiple sclerosis, and include impairments of attention,
information processing, executive function and memory. Cognitive rehabilitation is a structured set of
therapeutic activities designed to retrain an individual’s cognitive functions and to teach strategies to
cope with these problems in daily life. Cognitive rehabilitation often distinguishes between ‘restoration’
or ‘restitution’ (whereby domain-specific and task-focused activities are repeated a number of times to
improve specific functions, e.g. improved attention) and ‘compensation’ or ‘adaptation’ (whereby people
are taught to use strategies to overcome their cognitive limitations, e.g. setting reminders on mobile phones).
There are recommendations for the management of cognitive problems for people with multiple sclerosis
in The National Service Framework for Long-term Conditions (Department of Health and Social Care.
The National Service Framework for Long-term Conditions. London: DHSC; 2005) and the National Institute
for Health and Care Excellence clinical guidelines [National Institute for Health and Care Excellence. Multiple
Sclerosis in Adults: Management. Clinical Guideline 186 (CG186). London: NICE; 2014] for the management
of adults with multiple sclerosis. However, the guidelines are based partly on expert opinions and make
recommendations that further evidence is needed for the provision of cognitive rehabilitation.
Some randomised controlled trials have evaluated the effectiveness of cognitive rehabilitation for people
with multiple sclerosis. Studies of computerised cognitive rehabilitation have demonstrated that it is
possible to improve cognitive abilities with retraining, but there remains uncertainty about whether or
not the gains made persist over time and whether or not there are beneficial effects on people’s daily
lives. Studies of compensatory strategy training have suggested that they may lead to greater use of
strategies and fewer reports of cognitive problems in daily life, but it is unclear whether or not these benefits
persist over time. Cochrane systematic reviews have not found overall evidence to support or refute the
effectiveness of cognitive rehabilitation for people with multiple sclerosis (das Nair R, Martin KJ, Lincoln NB.
Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev 2016;3:CD008754
and Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane
Database Syst Rev 2014;2:CD009131). However, these reviews suggested that more high-quality trials
were needed.
Two small-scale pilot randomised controlled trials used two cognitive rehabilitation programmes that were
similar to each other, and their results suggested that this programme may help reduce cognitive problems
in people with multiple sclerosis [das Nair R, Lincoln NB. Evaluation of Rehabilitation of Memory in
Neurological Disabilities (ReMiND): a randomized controlled trial. Clin Rehabil 2012;26:894–903, and
Carr SE, das Nair R, Schwartz AF, Lincoln NB. Group memory rehabilitation for people with multiple
sclerosis: a feasibility randomized controlled trial. Clin Rehabil 2014;28:552–61]. The ReMiND trial
(das Nair and Lincoln, 2012) was conducted in people with a range of neurological disabilities, including
many who had multiple sclerosis. This trial evaluated the effectiveness of group memory rehabilitation
programmes in participants with memory problems by comparing compensation strategy training,
restitution strategies and a self-help control. Both quantitative and qualitative data from the study indicated
that the interventions were worthy of further evaluation. The ReMiND-MS trial (Carr et al. 2014) was a
modified version of the intervention in the ReMiND trial (das Nair and Lincoln, 2012), combining restitution
and compensation strategies compared with a usual-care control of people with multiple sclerosis (total
participants, n = 48). The results showed a significant effect on mood, favouring the intervention group.
These two pilot randomised controlled trials suggested that the intervention required further evaluation.
This trial was designed to assess the clinical effectiveness and cost-effectiveness of a group cognitive
rehabilitation programme.
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Objectives
The primary objective was to determine whether or not attending a group cognitive rehabilitation programme
(the intervention) in addition to usual care was associated with reduced psychological impact of multiple
sclerosis on quality of life, as measured on the Multiple Sclerosis Impact Scale – Psychological subscale,
compared with usual care alone (control). The secondary objectives were to assess the cost-effectiveness of
the intervention and whether or not the intervention was associated with improvements in participants’
attention and memory abilities, self-reported cognitive problems in daily life, mood, fatigue, employment
status and carer strain.
Methods
This was a multicentre, parallel-group, pragmatic randomised controlled trial with follow-up at 6 and
12 months after randomisation. A subset of participants took part in a qualitative study to assess the
perceived effects of the intervention.
Participants were identified through NHS hospitals, charities (e.g. Multiple Sclerosis Society branches)
and the UK multiple sclerosis register. Participants with multiple sclerosis were included if they were aged
18–69 years, reported having cognitive problems on the Multiple Sclerosis Neuropsychological Screening
Questionnaire, had cognitive deficits on the Brief Repeatable Battery of Neuropsychological Tests, were
able to travel to one of the centres to attend group sessions, were able to speak English and gave
informed consent. Potential participants were excluded if they had vision or hearing problems, concurrent
severe medical or psychiatric conditions, or were involved in other psychological intervention trials.
Once 9–11 participants, who could all attend the intervention sessions at the same time should they be
randomised to receive it, had been recruited at a site, they were randomly allocated, to intervention or
usual care on a 6 : 5 ratio. The randomisation was stratified by trial site and minimised by multiple sclerosis
type (relapsing–remitting or progressive) and gender.
Those allocated to the intervention received 10 weekly sessions of a manualised group cognitive
rehabilitation programme in addition to their usual care. Participants were taught restitution strategies to
retrain impaired attention and memory functions and compensation strategies to enable them to cope
with their memory problems. Some sessions were video-recorded in order to ascertain the fidelity of the
intervention.
Outcomes were assessed 6 and 12 months after randomisation by using questionnaires and at visits.
The primary outcome was the psychological impact of multiple sclerosis, measured using the Multiple
Sclerosis Impact Scale – Psychological subscale at 12 months after randomisation. Secondary outcomes
included measures of memory problems in everyday life from a subjective and relative’s perspective,
mood, fatigue, quality of life, attention and memory abilities, and cost-effectiveness as determined by
the EuroQol-5 Dimensions, five-level version, and a service use questionnaire. The effect on carers was
assessed on the Modified Carer Strain Index.
The sample size needed for the trial was 400 participants, to detect a minimum clinically relevant difference
in the means of three points with a type I error of 0.05 and 80% power, assuming a standard deviation of 9
(Multiple Sclerosis Impact Scale version 1) and accounting for 15% lost to follow-up and the potential for
clustering in the cognitive rehabilitation group because of the group intervention. The Multiple Sclerosis
Impact Scale version 2 was used in the trial.
Analysis was according to randomised group, regardless of whether or not cognitive rehabilitation sessions
were attended, without imputation for missing data (i.e. modified intention to treat). Outcomes were
analysed using a multilevel linear model with site, gender, multiple sclerosis type and baseline score as
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covariates, with a random effect for the cognitive rehabilitation group in the intervention group and
allowing the participant-level variance to differ between the intervention and control groups.
A subset of participants was interviewed by a researcher or a patient and public involvement member who
was a relative of a person with multiple sclerosis. Neither was involved with the participants’ assessment or
treatment.
Results
A total of 818 people with multiple sclerosis were screened for inclusion between 1 March 2015 and
31 March 2017. Of these, 579 (71%) gave consent and 449 (55%) were randomised: 245 to cognitive
rehabilitation and 204 to usual care. A total of 173 (85%) participants in the usual-care group and 214
(87%) participants in the cognitive rehabilitation group were included in the primary analysis.
The mean age of participants was 49.4 years (standard deviation 9.9 years); 326 participants (73%) were
women and 432 (96%) were white. About two-thirds (65%) reported having relapsing–remitting multiple
sclerosis. The characteristics assessed at baseline were well balanced between the intervention and control
groups.
Attendance at the cognitive rehabilitation groups was good. Participants attended a median of 10 sessions
(interquartile range 7–10; range 0–10), with 208 (85%) participants attending at least three sessions.
Fidelity analysis indicated that the intervention was delivered as intended.
At the 6-month follow-up, 405 participants (90%) returned the questionnaire booklet and 412 participants
(92%) completed the assessment visit. Questionnaire booklet return and visit completion were similar in
the two groups. At the 12-month follow-up, 392 participants (87%) returned the questionnaire booklet
and 387 (86%) completed the assessment visit; and again, booklet return and visit completion were similar
in the two groups.
There was no clinically important difference on the Multiple Sclerosis Impact Scale – Psychological subscale
between the two groups at the 12-month follow-up [intervention group, mean 22.2 (standard deviation 6.1)
and control group, mean 23.4 (standard deviation 6.0), adjusted difference in means –0.6, 95% confidence
interval –1.5 to 0.3; p = 0.20], with lower scores indicating a lower impact of multiple sclerosis on quality of
life. There was no evidence of a difference in the effect of cognitive rehabilitation across subgroups based
on multiple sclerosis type, baseline Multiple Sclerosis Neuropsychological Screening Questionnaire score,
the Doors and People test or the Symbol Digit Modalities test (p-value for interaction effect = 0.38 to 0.92).
There were small differences between the groups in the Multiple Sclerosis Impact Scale – Psychological
subscale score at 6 months (adjusted difference in means –0.9, 95% confidence interval –1.7 to –0.1;
p = 0.03) in favour of the cognitive rehabilitation group.
There were differences between the groups in that the frequencies of participant-reported memory
problems in everyday life on the Everyday Memory Questionnaire at 6 months (–5.3, 95% confidence
interval –8.7 to –1.9) and 12 months (–4.4, 95% confidence interval –7.8 to –0.9) and in the relative-
reported Everyday Memory Questionnaire at 6 months (–5.4, 95% confidence interval –9.1 to –1.7) and
12 months (–5.5, 95% confidence interval –9.6 to –1.5) were lower in the cognitive rehabilitation group.
There were also differences in mood on the 30-Item General Health Questionnaire at 6 months (–3.4,
95% confidence interval –5.9 to –0.8) and 12 months (–3.4, 95% confidence interval –6.2 to –0.6), in
that those in the intervention group reported fewer mood problems. There were no differences in fatigue,
employment rate, level of physical disability or physical aspects of quality of life. Scores from the cognitive
tests were similar in both groups at the 6- and 12-month follow-ups. No safety concerns were raised and
no deaths reported.
DOI: 10.3310/hta24040 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 4
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Lincoln et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxvii
The cost of the cognitive rehabilitation programme was estimated at £209 per participant. The primary
cost–utility analysis indicated that cognitive rehabilitation was less expensive than usual care (–£574.93,
95% confidence interval –£1878.93 to £729.07) with negligible quality-adjusted life-year gain (0.00, 95%
confidence interval –0.02 to 0.02), with no evidence of a difference between the groups. Similar conclusions
were also reached for the cost-effectiveness analysis of the primary outcome and the cost–utility analysis of
the Multiple Sclerosis Impact Scale – 8 Dimensions.
A total of 36 participants were interviewed: 18 from each group. The main findings were that usual care did
not include cognitive rehabilitation; many people noticed changes in their cognitive abilities, particularly those
in the intervention group; and these changes were attributed to increased strategy use, the educational
aspects of the intervention and the support received through the group environment.
Conclusions
Implications for health care
l People with multiple sclerosis have problems with attention and memory and are seeking help for
these problems.
l This trial has not shown any long-term effect of this cognitive rehabilitation programme on quality of life
for people with multiple sclerosis, measured using the Multiple Sclerosis Impact Scale – Psychological
subscale, but there was a short-term effect.
l There was some evidence that cognitive rehabilitation improved both memory problems in daily life
and mood.
l Participant feedback was positive, with some participants reporting daily life benefits of attending the
cognitive rehabilitation programme.
l There was no evidence of an effect on costs or quality-adjusted life-years.
l The results support the provision of this intervention in clinical practice, given the short-term clinical
effects and the lack of alternative, more effective, treatments.
l However, further evaluation of those with multiple sclerosis who may benefit most is needed.
Recommendations for research
l There needs to be more small-scale efficacy studies to establish the appropriate selection criteria for
cognitive rehabilitation programmes, so that the intervention is tailored to those who may benefit most.
l Future studies should attempt to control for the effects of the group environment, in order to ascertain
whether it is the contact with others with similar problems or the content of the programme that is
most important.
l Further research is needed to explore how the short-term benefits of cognitive rehabilitation can be
maintained in the long term.
Trial registration
This trial is registered as ISRCTN09697576.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Multiple sclerosis (MS) is a progressive neurological condition that affects ≈127,000 people in the UK.1
It is an incurable, progressive disease usually diagnosed in young adulthood or early middle age, and is a
leading cause of neurological disability in young adults.2 Cognitive problems are common in people with
MS, affecting about 70% of people with MS, and include impairments of attention, information processing,
executive function and memory.3–6 Impairment of memory and impairment of information processing speed
are the most common cognitive deficits in people with MS.7–10
Cognitive impairment has a detrimental effect on daily life activities and quality of life. People with MS with
cognitive problems are less independent in activities of daily living than those with MS without cognitive
problems.11–14 In particular, cognitive problems have a detrimental effect on employment.15–18 There is also
some evidence that they also negatively affect overall quality of life.16,19–21
People with cognitive problems may be offered cognitive rehabilitation to retrain cognitive skills or to
improve their ability to cope with cognitive problems in daily life. Cognitive rehabilitation is a structured
set of therapeutic activities designed to improve cognitive function and to reduce the impact of cognitive
impairment on daily life. There are recommendations for the provision of rehabilitation for specific symptoms
for people with MS in The National Service Framework for Long-term Conditions.22 The National Institute
for Health and Care Excellence (NICE) clinical guidelines for the management of adults with MS23 mention
the need to refer people with MS and persisting memory or cognitive problems to both an occupational
therapist and a neuropsychologist to assess and manage these symptoms. They also identify the need for
research on the clinical effectiveness and cost-effectiveness of cognitive rehabilitation for people with MS.23
In clinical practice in the UK, people with MS may receive an assessment of their cognitive abilities and
general advice on strategies to cope with their cognitive problems. In addition, information is available on
the web pages of MS charities, such as the MS Society and MS Trust. Very few people with MS receive
a systematic retraining of cognitive skills or structured training in strategies to cope with their cognitive
difficulties. A recent survey of professionals and clinical staff in the UK24 found that ≈58% of those
surveyed used some cognitive assessment to screen for cognitive problems and ≈49% of those surveyed
provided some form of cognitive rehabilitation when problems were identified, but only about 3% used a
manualised rehabilitation approach.
Research evidence
An early systematic review by O’Brien et al.25 considered a range of evidence from randomised trials,
non-randomised trials and case series studies. The authors found low-level evidence for positive effects of
neuropsychological rehabilitation in people with MS, but suggested that more high-quality randomised
trials were needed. More recent reviews (in the years 2013–18)3,10,26–28 have reached similar conclusions.
Amato et al.3 considered a broad range of evidence for cognitive rehabilitation, including non-randomised
trials, and concluded that some interventions showed promise, but that further evaluations were needed.
D’Amico et al.27 highlighted that targeted training in specific cognitive domains improved the trained
function in studies with people with mixed types of MS and in people with relapsing–remitting MS.
Mitolo et al.28 reviewed 33 studies and considered controlled clinical trials and before-and-after studies,
in addition to randomised controlled trials (RCTs). They highlighted that recent studies, which have focused
on cognitive domains other than memory (i.e. attention, speed of processing and executive abilities),
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seem to provide the best evidence for beneficial effects of intervention. Goverover et al.26 identified 16
RCTs published between 2007 and 2016, but did not include a statistical analysis of results.
Systematic reviews restricted to RCTs of cognitive rehabilitation have generally concluded that, overall,
there is insufficient evidence to support the effectiveness of cognitive rehabilitation for people with
multiple sclerosis.29–31 Both Cochrane reviews29,31 reported that there was some evidence of benefit on
measures of cognitive function. Das Nair et al.29 also found some evidence of benefit on measures of
quality of life. However, neither review29,31 found any evidence of benefit on emotional outcomes. These
conclusions were not supported by a more selective review that was confined to RCTs with a low risk of
bias,30 but this review included only five studies. Hämäläinen and Rosti-Otajärvi10 also suggested that the
weak evidence emerging from the Cochrane reviews29,31 may stem from the strict analysis methods used,
and that such methods may not be best suited for the evaluation of rehabilitation studies. They advocate
more consideration for a more qualitative analysis of best evidence.
Research has also examined the evidence for effectiveness according to the type of intervention. Some
controlled trials32–43 have demonstrated the effectiveness of computerised cognitive rehabilitation to retrain
cognitive skills in people with MS and some have also shown changes in brain activation on imaging
outcomes.44–48 However, these studies have rarely included any long-term follow-up to assess whether or
not the observed benefits persist. A few studies have evaluated whether or not the effects of computerised
cognitive rehabilitation continue for up to 1 year. Some have shown persisting effects on cognitive abilities
and quality of life41,49,50 but some have not.32,45 In addition, some non-computerised strategies have been
used to retrain cognitive skills, such as the Story Memory Technique,51,52 self-generated learning53 and
paper-and-pencil exercises.54 These studies have demonstrated the short-term effects of retraining cognitive
skills and provide limited evidence that the benefits persist. However, it has been questioned whether or not
interventions that involve retraining of cognitive skills produce clinically meaningful effects.55
An alternative approach in cognitive rehabilitation is to teach people skills to cope with the cognitive
impairment and provide aids to enable them to compensate for the loss of cognitive abilities. These skills
may be taught early in cognitive decline to prevent the functional consequences of cognitive decline
affecting daily life, or later on to enable people to cope better with their cognitive impairments.
One study evaluated using an electronic memory aid as a compensatory strategy for people with MS.56
It found that participants receiving reminder text messages encountered fewer problems in daily life as
recorded in a daily diary and were less distressed than those receiving non-specific text messages. Some
studies have combined this compensatory approach with either computerised cognitive training57,58 or
non-computerised practice on cognitive tasks.59,60
The studies that combined computerised cognitive rehabilitation with strategy training showed a few
benefits on cognitive outcomes but also reported differences in the number of perceived cognitive deficits58
and in the use of memory strategies.57 However, neither study57,58 found any evidence of effects on mood or
quality of life.
The two trials59,60 that combined non-computerised activities with compensatory strategy training both
used a similar cognitive rehabilitation programme. The Rehabilitation of Memory in Neurological Disabilities
(ReMiND) trial59 was conducted with people with a range of neurological disabilities, including many who
had MS. This trial evaluated the effectiveness of group memory rehabilitation programmes in participants
with memory problems by comparing compensation strategy training, restitution strategy training and a
self-help control. Both quantitative and qualitative data from the study indicated that the interventions
were worthy of further evaluation.59,61,62 The ReMIND-MS trial60 was a modified version of the group
intervention, combining restitution and compensation strategies, compared with a control group receiving
usual care (total participants, n = 48); all participants had MS. The results showed a significant effect on
mood, favouring the intervention.
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Thus, overall, despite the suggestion that compensatory strategy training may be the most appropriate
intervention for people who have not benefited from retraining,63 the evidence to support the provision of
such an intervention is weak. Therefore, the present trial was designed to assess the clinical effectiveness
and cost-effectiveness of a group cognitive rehabilitation programme, which combined training in
strategies to restore cognitive function with compensatory strategies for people with MS.
Rationale
Currently, people with MS with attention or memory problems do not routinely receive cognitive
rehabilitation. This is in part because of the current lack of evidence for the clinical effectiveness and
cost-effectiveness of cognitive rehabilitation, and also because of resource limitations.
Research question
What is the clinical effectiveness and cost-effectiveness of cognitive rehabilitation for people with MS with
attention and memory problems?
Objectives
Primary objective
The primary objective was to determine whether or not attending a cognitive rehabilitation programme
(the intervention) in addition to usual care was associated with reduced psychological impact of MS on
quality of life, as measured on the Multiple Sclerosis Impact Scale – Psychological Subscale64 (MSIS-Psy)
compared with usual care alone (control).
Secondary objectives
The secondary objectives were to assess cost-effectiveness of the intervention, and whether or not the
intervention was associated with improvements in participants’ attention and memory abilities or in
self-reported memory problems in daily life, mood, fatigue, employment status and carer strain.
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Chapter 2 Methods
Parts of this chapter have been reproduced from the Cognitive Rehabilitation for Attention and Memory inpeople with Multiple Sclerosis (CRAMMS) trial protocol.65 This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit
to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Design
This was a multicentre, parallel-group, pragmatic RCT of a cognitive rehabilitation programme, provided in
addition to usual care and compared with usual care alone.
An economic analysis was conducted to determine the costs and cost-effectiveness of cognitive
rehabilitation compared with usual care (see Chapter 6). Treatment fidelity was assessed (see Chapter 4)
and a qualitative study was conducted to explore participants’ experiences of the cognitive rehabilitation
and usual care (see Chapter 5).
Trial setting and participants
Sites
The trial was conducted in five sites in England (see Appendix 1, Table 25). Each site was an NHS trust
providing neurology services for people with MS.
Three sites were opened to recruitment between March 2015 and May 2015. A fourth site opened in
February 2016 and a fifth site in September 2016. All sites were open to recruitment until March 2017.
Identification of participants
Participants were identified through NHS hospitals and participant identification centres (PICs) near to sites.
An invitation pack – which included a letter of invitation, a participant information sheet, a consent form,
a contact details slip and a prepaid reply envelope – was sent to individuals with MS on hospital neurology
and neuropsychology databases. Those who were interested in taking part were asked to return the contact
slip to the assistant psychologist (AP) at their nearest site. In addition, people with MS attending neurology
and rehabilitation clinics were invited to take part by members of the clinical teams. The clinician asked for
permission to pass on their contact details to the AP at the site, who then sent them the invitation pack.
Posters about the CRAMMS trial, giving contact details of the AP at the nearest site, were displayed in
MS therapy centres and at MS Society branch offices in areas covered by the recruiting sites. There was
information about the trial on the MS Society and MS Trust websites. Members of the research team also
attended MS Society branch meetings to talk about the study and invite those who were interested to take
part. Self-referral was possible for those who accessed public-facing information on the study website,
newsletters and posters. Those who contacted the sites were then sent the information pack.
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An invitation to complete the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ)66
was sent to those who were enrolled on the UK MS Register who were in the study age range and had a
registered postcode in the areas covered by the sites. The replies were reviewed anonymously and those
who scored > 27 on the MSNQ were sent an invitation pack through the MS Register.
Informed consent
Written informed consent was obtained by the AP, and participants were given a copy for their records.
Participant information sheets and consent forms were based on those developed for the pilot study and
had been checked for clarity and readability by a service user representative. Potential participants had the
opportunity to read and discuss the study with other clinical staff, family and friends, and the research
team before they decided to take part. They were given at least 24 hours to do this.
Inclusion and exclusion criteria
The inclusion and exclusion criteria were based on those used in the pilot studies.59,60
Inclusion criteria
People with MS were eligible for the trial if they met the following inclusion criteria:
l Aged 18–69 years. The upper age limit was to ensure that memory problems were likely to be because
of MS rather than age-related memory impairments.
l Reported having relapsing–remitting or progressive MS.
l Diagnosed with MS at least 3 months prior to the screening assessment.
l Reported having cognitive problems as determined by a cut-off score of > 27 on the patient version
of the MSNQ.66 The cut-off score was based on the original validation study by Benedict et al.66 with
50 participants with MS. The cut-off score was used to identify those with cognitive impairment on a
neuropsychological test battery.
l Had cognitive deficits, defined as performance more than one standard deviation (SD) below the mean
of healthy control participants corrected for age and education67 on at least one of the Brief Repeatable
Battery of Neuropsychological Tests (BRBN).68
l Able to travel to one of the centres to attend group sessions. Participants had to live in the
geographical area covered by the sites and be able to get to the sites independently. Travel expenses
were offered to those who needed them.
l Willing to receive treatment in a group if allocated to intervention.
l Able to speak English sufficiently to complete the cognitive assessments and take part in group sessions.
l Gave informed consent.
Exclusion criteria
Potential participants were excluded if they:
l had vision or hearing problems, such that they were unable to complete the cognitive assessments
l had concurrent severe medical or psychiatric conditions that prevented them from engaging in treatment
l were involved in other psychological intervention trials.
Initial screening assessment
The AP conducted an initial telephone screening with those who expressed an interest in taking part in the
trial. The screening included confirmation of the diagnosis of MS and a participant’s age. The MSNQ was
administered to those who were willing to complete the questionnaire over the telephone. If it was not
METHODS
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administered over the telephone, it was administered at the screening visit. For those recruited through the
UK MS Register, the MSNQ was included in the online form to identify potential participants, but repeated
at the screening visit, as scores were not available for specific individuals from the online version. The scale
comprises 15 questions about the frequency of cognitive failures in daily life. Each question is rated on a
four-point scale from ‘never’ to ‘very often’. Scores range from 0 to 60 and higher scores indicate more
cognitive complaints. There is some evidence to support the reliability and validity of the scale.57,69–72
Initial screening visit
At the screening visit, the AP explained the trial and obtained written consent.
Assessments were completed in the participant’s home, unless they preferred to be seen elsewhere.
A quiet room was used whenever possible and an attempt was made to keep distractions to a minimum.
The AP explained that the initial assessments were required to check that the participant met the inclusion
criteria, and to obtain demographic and clinical data.
Demographic information included gender, date of birth, ethnicity, marital status, living arrangements and
years of education. Clinical information included type of MS and number of relapses in the previous 6 months.
All assessment measures were selected on the basis of their clinical utility, relevant psychometric properties
and ease of use for participants. Furthermore, the measures reflect the three levels of the International
Classification of Function domains: impairment, activity limitations and participation restrictions.73
The following assessments were completed:
l The BRBN.68 This is a cognitive screening battery that mainly assesses attention and memory and takes
motor problems into consideration. It consists of the Selective Reminding, 10/36 Spatial Recall, Symbol
Digit Modalities, Paced Auditory Serial Addition and Controlled Oral Word Association tests. The BRBN
is a brief cognitive screening measure for people with MS, which is sensitive to detect cognitive
impairment more so than other similar batteries and has been widely used in trials of medical
interventions with people with MS. Higher scores indicate better cognitive function.
l Guy’s Neurological Disability Scale (GNDS).74 The self-report postal version of this measure75 was used to
document the symptoms of MS. It comprises questions on 11 domains, including cognition and mood;
the optional sexual function domain was excluded. Higher scores indicate greater disability. There is
evidence to support its reliability and validity,76,77 responsiveness to change78 and to support the use of a
total score.79 It was chosen in preference to the more commonly used Expanded Disability Status Scale
(EDSS)80 because it covers a wider range of activities and is less focused on mobility. The EDSS has also
been criticised for being insensitive to cognitive dysfunction.81 The GNDS has been compared directly
with the EDSS and demonstrated good validity.75,82
The results from the MSNQ and BRBN were used to assess the inclusion criteria. Participants who met the
inclusion criteria were given the following questionnaires to complete in their own time, to be collected at
the baseline assessment visit:
l Multiple Sclerosis Impact Scale (MSIS).64 This is a MS-specific quality-of-life scale that encompasses both
the physical and psychological effects of MS on everyday life. It comprises 29 questions: 20 on the physical
subscale and 9 on the psychological subscale. Each item is rated in four categories: ‘not at all’, ‘a little’,
‘moderately’ and ‘extremely’. Scores on the physical impact scale range from 20 to 80 and scores on the
psychological impact scale range from 9 to 36, with higher scores indicating greater negative impact of
MS. The scale has good psychometric properties83–88 and has been used as an outcome measure
in rehabilitation trials.89–92 The psychological and physical subscales of version two93 were both used.
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l Everyday Memory Questionnaire – patient version (EMQ-p).94 This assesses the frequency of participants’
everyday attention and memory problems in daily life. It has good ecological and face validity and has
been previously used as an outcome measure in cognitive rehabilitation studies.59,60,95 The EMQ-p consists
of 28 items asking about the frequency of memory failures in everyday life over the previous month. Each
item is rated on a five-point Likert scale (from ‘once or less in the last month/never’ to ‘once or more a
day’). Total scores range from 0 to 112, with higher scores indicating more frequent memory problems.
l Fatigue Severity Scale (FSS).96 The five-item, Rasch-analysed version of the FSS97 was used to document
the severity of fatigue. This assesses patient-perceived fatigue over the previous week. Each item was
scored from 0 to 7, with higher scores indicating more severe fatigue. The sum of the five items was
then converted to the Rasch person location using the table provided by Mills et al.,97 and ranged from
–3.4 to 3.4. Several studies have supported the reliability and validity of the FSS in people with MS.98,99
l The 30-Item General Health Questionnaire (GHQ-30).100 This questionnaire was designed to detect
psychological distress in the general population. It assesses a participant’s mood over the previous few
weeks compared with their usual mood. The GHQ-30 was chosen as it is suitable for postal administration
and is easy to complete. The GHQ (12-, 28- or 30-item versions) has also been shown to be responsive
to the effects of psychological interventions in people with neurological conditions.60,89,101 Likert scoring
was used for the clinical outcome, with scores ranging from 0 to 90; higher scores indicate more
psychological distress.
Participants who did not meet the eligibility criteria following the initial screening visit were notified by
letter to thank them for their interest in the trial; a brief report of their test results was also provided, if
requested. Those who met the inclusion criteria were invited to complete the baseline assessment visit.
Participants were asked to nominate a relative or friend who knew about their cognitive problems in
daily life. A questionnaire booklet for the relative or friend was sent to participants following the initial
screening visit and they were asked to pass this on to their friend or relative. The questionnaire booklet
consisted of the Everyday Memory Questionnaire – relative version (EMQ-r). The EMQ-r is identical to the
patient version, but is completed by a relative or friend who knows the participant and their cognitive
problems. This version tends to correlate more highly with the presence of ‘objectively’ identified cognitive
problems than participant self-report, which can be influenced by mood102 or fatigue.103 The EMQ-r was
included to identify any effect of treatment on daily life problems as observed by another person, which
might not have been detected by participants themselves. EMQ-r scores range from 0 to 112, with higher
scores indicating more frequent memory problems. Participants were asked to return completed relative/
friend questionnaires at the baseline assessment visit or they could be returned by post.
Baseline assessment visit
The participant questionnaires that had been completed were collected at the baseline visit, which was
conducted within 2 weeks of the screening visit. If they had not been completed, they were administered
at the visit if time allowed, or the participant was asked to complete them after the visit and return them
by post.
In addition, the following assessments were completed:
l Doors and People.104 This is a measure of memory function in four domains: verbal, visual, immediate
and delayed. This was used to determine the type of memory problems and was used when planning
treatment sessions to ensure that the treatment was adjusted according to the nature of each
participant’s memory problems. Higher scores indicate better memory ability.
l Trail Making Test from the Delis–Kaplan Executive Function System.105 This was administered as a
measure of attention and executive abilities. Conditions two (letter sequencing) and four (letter–number
sequencing) were used. The difference in the time taken between the two conditions was used. A
smaller difference indicates less interference effect, which indicates better executive functioning.
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l EuroQol-5 Dimensions, five-level version (EQ-5D-5L).106 This is a generic health-related quality-of-life
measure, used for health economic evaluations. Utility scores were derived from the EQ-5D-5L
descriptive system and used to estimate quality-adjusted life-years (QALYs) and incremental
cost-effectiveness ratios (ICERs).
l Use of Health and Social Services Questionnaire (UHSSQ). This bespoke self-report questionnaire was
used to assess NHS health-care use. It included questions on the frequency with which participants
accessed NHS services, such as visits to general practitioners (GPs), neurologists and MS nurses, and
services provided by charities, such as MS Society groups. Use of hospital services, including outpatient
appointments, rehabilitation services and hospitalisation, were recorded. Current medication and
medications prescribed over the previous 3 months were recorded. The period covered by the
questionnaire was the previous 3 months; this time period was chosen so that people would have
received a range of services, and they would still remember what they had received. The UHSSQ was
adapted from previous studies.107
Current employment status and the number of relapses in the previous 3 months were also documented.
If a participant was randomised to receive cognitive rehabilitation, the AP checked whether or not that
participant could attend groups on certain days. Participants were randomised only if they were able to
attend on the days that groups were due to take place. Those who were unable to attend on the planned
days were held in reserve until such time that a new group, matching their availability, was formed. While
participants were waiting for sufficient participants to form a group, the AP remained in regular contact to
keep individuals aware of probable timescales.
The AP also checked whether participants would prefer to receive the outcome questionnaires by post or
to complete them online.
Randomisation
Clusters of between 9 and 11 participants were formed by the AP at each site; in case they would be
allocated to the cognitive rehabilitation group, cluster formation was based on participants’ availability
to attend for treatment at the same time and same venue. Randomisation took place once there were
9–11 individuals in a cluster.
Participants were individually randomised to the intervention or control group on a 6 : 5 ratio, to allow for
clustering in the intervention group. Allocation was stratified by recruitment site, and minimised by MS
type (relapsing–remitting or progressive) and gender. Those who were allocated to the intervention group
were offered cognitive rehabilitation. Those who were allocated to the control condition were not offered
cognitive rehabilitation and received only their usual care.
The allocation algorithm was created by the Nottingham Clinical Trials Unit (NCTU), in accordance with
their standard operating procedure, and held on a secure server. A remote, internet-based randomisation
system was used by APs to obtain the group allocation for each participant. Access to the sequence was
confined to the NCTU information technology (IT) manager. The sequence of group allocations was
concealed from the trial statistician until all participants had been allocated, and recruitment, data
collection and all other trial-related assessments were complete.
Participants who were waiting to be randomised at the time their site closed to recruitment were sent a
letter informing them that the AP had not been able to recruit enough people to create a group at a time
and place that was convenient for that participant, and that their participation in the trial was at an end.
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Interventions
Usual care
All participants received their usual clinical care. In the standard NHS care pathway, people with MS with
cognitive problems may get general advice from MS specialist nurses and occupational therapists on how
to manage any cognitive difficulties. There are information sheets available on web pages of MS charities,
which include suggestions for coping with cognitive problems. However, usual care does not normally
include any specific intervention for cognitive problems or cognitive rehabilitation.
Other clinical services available to participants included employment rehabilitation services, self-help groups
and support from specialist charities, such as the MS Society. Any input, including psychological or medical
interventions, that participants received during the trial was recorded on the UHSSQ.
Cognitive rehabilitation
Cognitive rehabilitation is a structured set of therapeutic activities designed to improve cognitive function
and to reduce the impact of cognitive impairment on daily life.65 The emphasis of the intervention was on
identifying the most appropriate strategies to help individuals overcome their cognitive problems and in
providing participants with a range of techniques that they could use and adapt in accordance with their own
needs. Although the intervention was delivered in a group format, every effort was made to ‘personalise’ or
‘individualise’ the intervention to meet the needs of each participant. For instance, if a participant found it
particularly difficult and stressful to remember faces, the strategies taught were focused on this problem.
Each cognitive rehabilitation group consisted of four to six participants. Sessions were held at NHS sites or
community venues. Participants received 10 sessions, each of 1.5 hours’ duration, which included a break
mid-way through. Sessions were held once a week for 10 weeks. The content of each session was defined in a
treatment manual.60 The intervention included restitution strategies to retrain attention and memory functions.,
and methods to improve encoding and retrieval. In addition, participants were taught compensation strategies,
such as internal mnemonics (e.g. chunking, first letter cues and rhymes), the use of external memory aids (e.g.
diaries, notebooks and mobile phones) and methods of coping with attention and memory problems in daily
life. The programme was adjusted according to each participant’s cognitive abilities, as determined during
the baseline assessment, yet it also provided a systematic framework for addressing problems with attention
and memory. Homework assignments were set at the end of each session to help participants practise the
strategies learnt in their everyday life. These were reviewed each week at the following session. Carers and
family members were invited to attend the final session, if participants agreed, and this session was used to
summarise the previous sessions.
The AP recorded whether or not participants attended each of the intervention sessions and the reasons
why any sessions were not attended. Participants who missed sessions were offered a half-hour catch-up
session prior to the next session. If a participant was no longer able to attend their allocated group for the
remaining number of treatment sessions, they could attend another group, provided the sessions were
completed by the 6-month outcome assessment and the same AP was delivering the sessions. Participants’
travel expenses were reimbursed.
Treatment fidelity
The fidelity of the cognitive rehabilitation programme was assured in two ways:
1. Manualised treatment – the cognitive rehabilitation programme followed a manual that was developed
and tested in a pilot study.60 A detailed description of the manual has been published elsewhere108 and in
the Template for Intervention Description and Replication (TIDieR)109 checklist (see Appendix 2, Table 26).
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2. Training and supervision – staff delivering the intervention (i.e. APs) were psychology graduates with
clinical experience. They received supervision from a clinical psychologist based at their site. A clinical
psychologist provided training on the delivery of the intervention. Monthly teleconferences were
conducted to provide peer group supervision. In addition, individual telephone supervision was provided
monthly with a clinical psychologist for the discussion of specific challenges relating to treatment or
assessment. When staff changes occurred, former staff completed a ‘handover’ document for new staff,
to ensure continuity. The new staff were trained by the same trainers to ensure consistency.
Formal assessment of the fidelity of the cognitive rehabilitation was undertaken through analysis of
video-recordings of treatment sessions. This is described in detail in Chapter 4.
Outcome assessment
Outcomes were assessed at 6 and 12 months after randomisation to determine the immediate and
longer-term effects of the intervention. The primary outcome was 12 months after randomisation, in order
to determine whether or not any treatment gains had been maintained over time. The 6-month assessment
was to determine the immediate effects of the intervention, allowing time for completing 10 sessions,
including allowing for sessions to be rescheduled if they had to be cancelled through illness or holidays.
Outcomes were assessed by questionnaire and at an outcome assessment visit.
Questionnaire outcomes
A questionnaire pack was posted to each participant 2 weeks before the 6- and 12-month appointments
were due. They were asked to complete this questionnaire pack at home and hand it to the research
assistant (RA) during the follow-up visit. Those who requested to complete questionnaires online were
sent an e-mail with a link to open the questionnaires. Prior to the follow-up visit, the RAs checked if the
questionnaires had been returned or competed online.
The pack included the following:
l the MSIS
l the EMQ-p
l the GHQ-30
l the FSS
l GNDS
l a question about the number of relapses in the previous 6 months.
In addition, the EMQ-r and Modified Carer Strain Index (MCSI) were posted for completion by the
participant’s nominated relative/friend.
The MCSI110 is a measure of burden on carers and family members. It comprises 13 items from the Carer
Strain Index111 that, in the modified version, are rated according to the frequency of their occurrence as
‘yes, on a regular basis’ (score 2), ‘yes, sometimes’ (score 1) and ‘no’ (score 0). Scores range from 0 to 26;
the higher the score, the higher the level of caregiver strain. The internal reliability and test–retest reliability
are high.110
Returned questionnaires were checked for completeness at the visit so that if items were missing or
clarification was needed about responses (e.g. unclear marking on questionnaires), these could be corrected.
The RA also took a copy of the questionnaires to the visit so that these could be completed during the visit if
they had not already been completed. If there was not sufficient time to complete the questionnaires during
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the visit, and they had not been done previously, the RA left a copy of the questionnaires and a prepaid
envelope so that these could be completed and returned to the co-ordinating centre after the visit.
Outcome assessment visits
Research assistants were responsible for conducting outcome visits 6 and 12 months after randomisation.
The RAs were not involved in recruitment to the trial of or delivery of the intervention to any of the
participants that they followed up, and were blind to treatment allocation. At the start of the appointment,
the RA reminded the participants of the importance of them remaining blind to group allocation and asked
participants not to discuss any aspects of their involvement in the trial. Before conducting the outcome
visit assessments, the RA recorded whether or not they had been unblinded and their opinion as to which
group the participant had been allocated to, using the categories definitely usual care, probably usual care,
probably intervention or definitely intervention. At the end of the visit, the RA recorded whether or not
they had been unblinded during the visit and also what treatment they thought the participant had received.
The following assessments were completed at the follow-up visits:
l the EQ-5D-5L
l the UHSSQ
l the BRBN
l Doors and People
l Trail Making.
The schedule of outcome assessments is summarised in Appendix 3, Table 27.
All participants were contacted in order to complete all assessments. Participants were initially contacted
by telephone when follow-up visits were due. If telephone contact failed, then a letter was sent to the
participant’s last known address, asking the participant to contact the outcome assessor. Any changes in
contact details were recorded.
Feedback interviews
A feedback interview was conducted between the 6- and 12-month appointments, with 36 purposefully
selected and willing participants: this qualitative component of the trial is described in detail in Chapter 5.
End of the study
Participants completed the trial when the 12-month follow-up was completed. The end of the trial was
defined as being the last 12-month follow-up appointment. However, questionnaires returned after
completion of the final visit were accepted to allow for any delays in the post.
If participants discontinued the intervention or withdrew from follow-up, this was reported and the reasons
were documented, if they were given. Outcome data collection was completed if a participant discontinued
treatment but agreed to remain in the trial. Participants were informed at the start of the trial that data
collected up to the point of withdrawal would be retained and used in the final analysis. Participants who
withdrew from the trial were not replaced with other participants.
METHODS
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Assessment of safety and adverse events
The risks of taking part in the trial were assessed as being low. However, non-specific risks for participants
involved travelling to the research sites. In addition, participants may have experienced some distress if they
found that they were not performing as well as they expected on cognitive assessments. However, such
distress was considered improbable and likely to be mild. Any distress was managed by the APs, who were
trained to deal with such situations. They discussed any concerns with the supervising clinical psychologists
and made referrals to a participant’s GP, if needed. Distress during the course of the intervention was
managed similarly. As the risk, overall, was assessed as being low, no adverse events or serious adverse
events were reported. However, as a safety outcome, the number of participants who showed an increase
in scores on the GHQ-30 of > 30 points between baseline and the 6-month assessment were monitored
by the independent Data Monitoring Committee (DMC), and any concerns were discussed with the clinical
teams. In addition, adverse outcomes, such as hospitalisation, distress and death, were recorded.
‘Notable events’ occurring during assessments or the intervention were recorded by the APs or RAs
throughout the trial. Notable events were any events that were considered to be out of the ordinary, such
as problems arising during cognitive rehabilitation sessions or any events that may pose a risk to either the
participants or the researchers. These were reviewed during supervision.
Research governance
The trial was conducted in accordance with the recommendations for clinicians involved in research on
human subjects adopted by the 18th World Medical Association General Assembly, Helsinki, 1964,112 and
later revisions, the UK Policy Framework for Health and Social Care Research113 and the principles of the
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use – Good Clinical Practice (ICH-GCP) guidelines.114
Trial registration
The trial was prospectively registered as ISRCTN09697576 (International Standard Randomised Controlled
Trial Number) on 14 August 2014.
Ethics
The National Research Ethics Service West Midlands, South Birmingham Committee gave ethics approval
for the study (reference number 14/WM/1083).
Site initiation and training
Prior to the commencement of the trial, a meeting was held between members of the central research
team (i.e. the chief investigator, the co-chief investigator and NCTU staff) and trial collaborators from the
initial three sites to discuss implementation and training issues to ensure that all members were familiar
with all aspects of the trial. For sites that were involved after this initial meeting, training was carried out
on an individual basis. NCTU staff provided trial-specific training on the trial documentation and database,
a clinical neuropsychologist provided training on conducting baseline assessments and, as part of ensuring
treatment fidelity, a clinical psychologist provided training on the delivery of the intervention (as detailed in
Treatment fidelity).
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Protocol deviations
A protocol deviation was defined as an unanticipated or unintentional divergence or departure from the
expected conduct of the trial that was inconsistent with the protocol, consent document or other trial
procedures This was based on standard practice within NCTU.
The APs and RAs recorded protocol deviations on the electronic case report form. Protocol violations were
reviewed by the Trial Management Group (TMG) and defined as those deviations that affected participant
eligibility or outcome measures.
Oversight
A number of oversight groups monitored the progress and conduct of the trial. The roles and
responsibilities of these groups were described in the protocol,65 and specific charters were developed for
the independent Trial Steering Committee (TSC) and DMC.
Trial Management Group
The TMG comprised the co-chief investigators, members of NCTU responsible for the running of the trial
and the health economists. They met regularly to monitor the day-to-day running of the trial.
Trial Steering Committee
The TSC was responsible for the overall conduct of the trial. The TSC had an independent chairperson and
four independent members. The independent members were rehabilitation professionals and service user
representatives who were not otherwise involved in the trial. Members of the trial team, including the
chief investigator, co-chief investigator and trial manager, were also part of the TSC. The TSC advised on
recruitment strategies, monitored progress with recruitment and checked adherence to the trial protocol.
Representatives of the sponsor were also invited to TSC meetings.
Data Monitoring Committee
The DMC was an independent group, the members of which had no other involvement with the trial.
Members of the DMC included two rehabilitation professionals and a professor of health service research
with expertise in statistics. The role of the DMC was to safeguard the interests of trial participants, with
particular reference to the safety of the intervention; monitor the overall progress and conduct of the trial;
and protect the validity and credibility of the trial.
The TSC and the DMC met independently of each other, with the DMC providing reports to the TSC.
Patient and public involvement
During the planning of the trial, four service users were identified through the MS Society research network
and one service user co-applicant had been involved in the pilot study for the trial. All commented on the
trial design and documentation, particularly the participant information sheet and consent form. Two service
user representatives were directly involved in the trial as members of the TSC. In addition, one of the service
user representatives assisted with interviewing participants as part of the qualitative component of the
trial. This service user representative was also involved in preparing a video to disseminate the results to
participants and to people with MS. Three participants also contributed to the dissemination of results by
taking part in a video to illustrate the cognitive rehabilitation sessions. All service users were invited to
comment on the lay summary.
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Statistical methods
The primary outcome was the psychological impact of MS on everyday life at 12 months, as a reflection of
health-related quality of life (HRQoL), as measured using the MSIS-Psy.
Sample size
The sample size was estimated using the primary outcome of the MSIS-Psy scores at 12 months post
randomisation. A clinically meaningful effect using this outcome is probably in the range of 3.0–3.5 (using
version 1 of the MSIS-Psy, scored 9–45). Based on a two-sample test, 143 participants per group were
required for analysis in order to detect a difference of 3 points on the MSIS-Psy, assuming a SD of 9 points,
with 80% power and 5% two-sided alpha. However, a clustering effect may be expected to occur in
the intervention group as a result of the cognitive rehabilitation being delivered in groups. Based on an
average cluster size of five evaluable participants (those providing primary outcome data at 12 months after
randomisation), an intracluster correlation (ICC) of 0.1 in the intervention group and an optimal allocation
ratio of 6 : 5 in favour of the intervention group, a total of 336 evaluable patients would provide 80%
power to detect such a difference (182 to the intervention and 154 to usual care). A sample size of 400
randomised participants was set (216 to the intervention and 184 to usual care) to allow for non-collection
of primary outcome data for 15% of participants.
Version 2 of the MSIS-Psy was used in this trial, with scores ranging from 9 to 36. The SD of the MSIS-Psy
version 2 in the UK South West Impact of Multiple Sclerosis (SWIMS) cohort was 6.4 points.115 Differences
of between 2 and 3 points on version 2 of the MSIS-Psy are detectable based on the effect size specified
above (assuming a SD of between 6 and 9), with assumed similar clinical importance as for version 1.
Statistical analysis
The planned analyses were described in the statistical analysis plan (SAP), which was finalised prior to
database lock and release of the treatment allocation codes for analysis. All analyses were carried out
using Stata®/SE version 15.1 (StataCorp LP, College Station, TX, USA) and R studio version 3.4.2
(The R Foundation for Statistical Computing, Vienna, Austria).
Preliminary analysis
Descriptive statistics were used to examine balance between the two groups on demographic and
clinical measures.
Analysis populations
The main approach for the analysis was to analyse participants as randomised, regardless of the number of
cognitive rehabilitation sessions attended for all primary and secondary outcomes.
The data used at each time point were as follows:
l questionnaires/visits completed within 9 months of randomisation (i.e. within 275 nights of
randomisation) for the outcomes at 6 months
l questionnaires/visits completed within 15 months of randomisation (i.e. within 456 nights of
randomisation) for the outcomes at 12 months.
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Outcomes completed outside these time periods were used only in a sensitivity analysis for the primary
outcome and for the safety outcome. The main analyses were conducted on data from participants with
available data; no imputation was undertaken for participants who had missing outcomes.
Descriptive analyses
The adherence to the intervention was described by tabulating the attendance at each session and
summarising the number of sessions that each participant attended (with and without catch-up sessions).
The reasons for non-attendance at sessions were also described and summarised.
The number of participants returning the questionnaire booklet/completing the follow-up visit at 6 and
12 months was summarised in the two groups, along with the number of days between randomisation
and completion. The pattern of missing outcome data was explored, overall and in the two groups, and
the baseline characteristics were compared between participants with and participants without primary
outcome data.
Unblinding of RAs at a follow-up visits was reported descriptively. The kappa statistic was used to assess
the agreement between a participant’s actual treatment allocation and the RA’s opinion of treatment
allocation, collapsing probably and definitely into one category.
Missing data in questionnaires
Missing items in questionnaires were imputed with the mean of the completed items if ≥ 8 of the 9 items
on the MSIS-Psy were completed, ≥ 17 of the 20 items on the Multiple Sclerosis Impact Scale – Physical
Subscale (MSIS-Phy) were completed, ≥ 25 of the 28 items on the Everyday Memory Questionnaire (EMQ)
were completed, ≥ 27 of the 30 items on the GHQ-30 were completed and ≥ 12 of the 13 items on the
MCSI were completed. Otherwise, scores from questionnaires were treated as missing.
To be able to include all participants in the regression analysis of the outcome score, if scores from the
questionnaires remained missing at baseline after the process outlined above, baseline data were imputed
for the analysis using the mean score at each centre. These simple imputation methods are better than
more complicated imputation methods in which baseline variables are included in an adjusted analysis to
improve the precision of the treatment effect.116 This imputation was done only for the regression analyses
and not for summarising the baseline scores.
Primary outcome
The primary analysis estimated the difference in the mean MSIS-Psy score at 12 months between the
two groups using a multilevel linear model, with baseline MSIS-Psy score, gender, MS type and centre as
covariates. Participants in the usual-care group had no contact with each other; therefore, outcomes in this
group were assumed to be independent. However, participants in the intervention group received cognitive
rehabilitation sessions together, which needed to be taken into account in the analysis. A fully heteroscedastic
model was used, which estimates group-level residual variance in the intervention group and also permits
individual-level residual variance to differ between intervention and control groups.117,118 The assumptions for
the multilevel linear model were checked using diagnostic plots. The ICC coefficient in the intervention group
was estimated using the estimates of the group-level residual variance and individual-level residual variance in
the intervention group.
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Sensitivity analyses for the primary outcome
The following sensitivity analyses were conducted:
l Including all 12-month questionnaires – the analysis was repeated including participants whose
12-month questionnaires were returned after the 15-month post-randomisation window.
l Using different methods for missing baseline MSIS-Psy score – the analysis was repeated restricting the
analysis to participants with the MSIS-Psy completed at baseline and using the missing indicator method
for missing baseline MSIS-Psy values.
l Multiple imputation of missing primary outcome data – multiple imputation was performed using
multivariate multilevel linear regression using the pan procedure in R, under the assumption that
missing data were missing at random. Variables included in the imputation model were centre, age,
gender, MS type, MSIS-Psy score at baseline and at 6 months, MSNQ score, Doors and People overall
age-scaled score at baseline, Symbol Digit Modalities Test from the BRBN, whether or not the participant
had reported a MS relapse at 6 and 12 months, the number of cognitive rehabilitation sessions attended
and the following scores from baseline, 6 months and 12 months: GHQ-30 total score, EMQ-p score and
EuroQol-5 Dimensions visual analogue scale (EQ-5D VAS) score. Thirty data sets were imputed and the
results of the analyses on the imputed data sets were combined using Rubin’s rules.
l The complier average causal effect was estimated in a secondary analysis of the primary outcome.
Instrumental variable regression was used to estimate the effect of the intervention for participants
who would comply with the allocated treatment for whichever group they were randomised to.119,120
Participants in the intervention group were classified as adherent if they attended at least three
cognitive rehabilitation sessions. The instrumental variable regression model included baseline MSIS-Psy
score, gender, MS type and centre. The complier average causal effect was estimated using both the
observed data and the multiply imputed data.
Earlier effects on the primary outcome were investigated in a secondary analysis by comparing the
MSIS-Psy at 6 months after randomisation in the two groups using the same analysis model as for the
primary outcome.
Subgroup analyses for the primary outcome
Four exploratory subgroup analyses for the primary outcome were performed by including an interaction
term in the model for the primary analysis between allocated group and the following variables:
l MS type (progressive or relapsing–remitting)
l MSNQ score (i.e. according to cognitive problems at baseline)
l Doors and People score (overall score, i.e. according to memory function at baseline)
l Symbol Digit Modalities Test score from the BRBN (i.e. according to speed of processing of information).
The MSNQ score, the overall Doors and People score and Symbol Digit Modalities Test score were split into
three categories, according to the tertiles at baseline.
Secondary outcomes at 6 and 12 months
The difference in means between the two groups at 6 and 12 months was estimated, using the same
analysis model described for the primary outcome, for the following outcomes:
l memory problems in everyday life, measured using the EMQ-p and EMQ-r
l mood, measured using the GHQ-30
l fatigue, measured using the Rasch-transformed FSS
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l carer strain, measured using the MCSI
l quality of life, measured using the EQ-5D VAS (from the EQ-5D-5L), which asks participants to rate their
current health status
l attention and memory abilities, using the Selective Reminding total and delayed recall scores; 10/36
Spatial Recall Test total correct and delayed recall scores; the Symbol Digit Modalities total score; the
Paced Auditory Serial Addition Test, Easy and Hard total scores; and the Word Fluency total score from
the BRBN
l overall age-scaled score, verbal total score, non-verbal total score and forgetting score from the Doors
and People test
l the difference between the number of seconds to complete parts A and B of the Trail Making test
(derived as B – A)
l physical impact of MS on quality of life, measured using the MSIS-Phy.
The number of participants in any form of employment (full or part-time) was used for the analysis for
employment status. The odds ratio for any form of employment at 6 and 12 months in the two groups
was estimated using a generalised estimating equation with a logistic link function and robust standard
errors to account for potential clustering in the intervention group.121
The secondary outcomes for disability (as measured using GNDS) and the number of reported relapses in
the previous 6 months are reported descriptively.
The safety outcome, defined as an increase of ≥ 30 points on the GHQ-30 (using Likert scoring) between
baseline and 6 months, is also reported descriptively. All participants completing the 6-month questionnaire
were included in the analysis population for the safety outcome.
METHODS
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Chapter 3 Results
Recruitment
Participants were recruited between April 2015 and March 2017 (see Appendix 4, Figure 10). Of the
3556 people with MS who were invited to participate or expressed an interest in the trial, 818 had an
initial telephone eligibility screening and, of these, 579 consented. The majority of the patients screened
initially who did not consent were not eligible (n = 194; 81%). The breakdown of reasons for exclusion is
shown in Appendix 5, Table 28.
Of the 579 participants who gave consent, 449 were randomised (78%). Non-randomisation after consent
was mainly as a result of not being eligible (n = 68; 52%) or the trial being closed to recruitment (n = 40;
31%); the Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 1 and
reasons participants were not eligible are shown in Appendix 5, Table 29. The randomisation target was
exceeded because there was a pool of eligible participants who had been screened, consented and were
awaiting randomisation at the time the target was reached, as a result of the requirement to form groups
of 9–11 participants who could all attend for cognitive rehabilitation sessions at the same time and place
(if allocated).
Of the 449 participants randomised, 204 were randomised to usual care and 245 to cognitive
rehabilitation in addition to usual care (allocation ratio of 6 : 5 to the cognitive rehabilitation group, as
planned). There were 45 cognitive rehabilitation groups: two groups of four participants (4%), 21 groups
of five participants (47%) and 22 groups of six participants (49%).
Participants waited a median of 42 days between the baseline assessment and randomisation. However,
a few participants (n = 25; 6%) waited for ≥ 6 months to be randomised as a result of waiting for other
participants who could attend the intervention sessions at the same time or awaiting the availability of an
AP to deliver the intervention.
Baseline data
The mean age of participants was 49 years (SD 9.9 years), 326 (73%) were women and almost all were
white (96%) (Table 1). Approximately two-thirds of participants reported that they had relapsing–remitting
MS with a mean time since diagnosis of 11.7 years (SD 8.4 years). One-third of participants reported being
in employment, one-third reported being retired and one-third reported not being in either employment
or education.
The characteristics assessed at baseline were well balanced between groups, including the minimisation
stratification variables of gender and MS type. However, a slightly higher percentage of participants in
the cognitive rehabilitation group than in the usual-care group reported a relapse between baseline and
randomisation (10% vs. 6%, respectively). Attention and memory abilities, psychological and physical
impact of MS on quality of life, frequency of memory problems, and mood and fatigue were similar in the
two groups at baseline (Table 2).
The EMQ-r questionnaire was completed for 398 participants (89%) at baseline: 185 (91%) in the usual-care
group and 213 (87%) in the cognitive rehabilitation group.
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6-month follow-up 
• Questionnaire data, n = 187
• No questionnaire data, n = 17
Enrolment 
Randomisation
No response
(n = 2738)
Initial screening
(n = 818)
Excluded
(n = 239)
• Not eligible, n = 194
• Declined to participate, n = 27
• Recruitment closed, n = 9
• Deceased, n = 2
• Other, n = 7
Invited
(n = 3556)
• Postal invitation, n = 2517
• Face-to-face invitation, n = 561
• Self-referral, n = 198
• Unspecified, n = 45
• UK MS Register, n = 235
Not randomised
(n = 130)
• Not eligible, n = 68
• Recruitment closed, n = 40
• Withdrew consent, n = 11
• Lost to follow-up, n = 8
• Not known, n = 3
Consented
(n = 579)
Usual care
(n = 204)
Cognitive rehabilitation
(n = 245)
Randomised
(n = 449)
(45 groups)
12-month follow-up 
• Primary outcome data, n = 173 (85%)
• No primary outcome data, n = 31
6-month follow-up 
• Questionnaire data, n = 217
• No questionnaire data, n = 28
12-month follow-up 
• Primary outcome data, n = 214 (87%)
• No primary outcome data, n = 31
Follow-up
• Attended at least one session, n = 218
FIGURE 1 The CONSORT flow diagram. Reproduced with permission from Lincoln et al.122 This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/
licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).
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TABLE 1 Baseline characteristics
Characteristic Usual care (N= 204) Cognitive rehabilitation (N= 245)
Age at randomisation (years)
Mean (SD) 48.9 (10.0) 49.9 (9.8)
Minimum, maximum 25, 69 18, 69
Gender, n (%)
Men 56 (27) 67 (27)
Women 148 (73) 178 (73)
Ethnicity, n (%)
White 195 (96) 237 (97)
Black 3 (1) 3 (1)
Asian 2 (1) 3 (1)
Mixed 4 (2) 2 (1)
Marital status, n (%)
Single/divorced/widowed 66 (32) 81 (33)
Married/with partner 138 (68) 164 (67)
Participant-reported time since MS diagnosis (years)
Mean (SD) 11.1 (8.7) 12.1 (8.0)
Minimum, maximum 0, 40 0, 36
Type of MS (participant reported), n (%)
Relapsing–remitting 132 (65) 159 (65)
Primary progressive 24 (12) 22 (9)
Secondary progressive 48 (24) 64 (26)
Number of relapses in the previous 6 months, as assessed at screening (participant reported), n (%)
0 155 (76) 186 (76)
1 31 (15) 47 (19)
2 13 (6) 5 (2)
≥ 3 5 (2) 7 (3)
Relapse between baseline and randomisation (participant reported), n (%)
No 190 (93) 220 (90)
Yes 12 (6) 24 (10)
Not known 2 (1) 1 (< 0.5)
Years of education
Mean (SD) 13.9 (2.9) 14.2 (3.4)
Minimum, maximum 10, 30 10, 35
Employment status, n (%)
Retired 64 (31) 80 (33)
Not employed or in education 70 (34) 83 (34)
Employed part time 31 (15) 44 (18)
continued
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TABLE 1 Baseline characteristics (continued )
Characteristic Usual care (N= 204) Cognitive rehabilitation (N= 245)
Employed full time 38 (19) 31 (13)
In education full time 0 (0) 1 (< 0.5)
In education part time 0 (0) 6 (2)
Not knowna 1 (< 0.5) 0 (0)
Any employment (full or part time) 69 (34) 75 (31)
Living arrangements, n (%)
Lives alone 38 (19) 49 (20)
Lives with others 166 (81) 196 (80)
Living in care home 0 (0) 0 (0)
a Employment status was collected at the baseline visit, but was not completed for one participant.
Reproduced with permission from Lincoln et al.122 This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
TABLE 2 Scores on baseline assessments prior to randomisation
Assessment
Usual care, mean [SD] or
n (%) (N= 204)
Cognitive rehabilitation,
mean [SD] or n (%) (N= 245)
MSNQa 39.0 (7.4) 38.9 (7.1)
BRBNb
Selective Remindingc
Total recall 40.2 [10.5] 40.6 [11.0]
Long-term storage 30.9 [14.5] 31.2 [15.7]
Consistent long-term retrieval 18.7 [13.6] 19.0 [14.2]
Delayed recall 5.7 [2.8] 5.8 [2.8]
10/36 Spatial Recalld
Total correct 18.3 [4.9] 18.1 [4.5]
Total confabulations 11.3 [5.0] 11.5 [4.6]
Delayed recall 6.3 [2.1] 6 [2.2]
Symbol Digit Modalitiese 37.8 [12.1] 36.3 [11.5]
Paced Auditory Serial Additionf n = 199 n = 239
Easy total correct 31.1 [16.4] 31.6 [16.2]
Hard total correct 15.9 [15.8] 17.3 [16.5]
Word fluencyg n = 203 n = 244
Total score 25.1 [8.9] 24.8 [8.8]
GNDSh 20.0 [6.7] 19.9 [7.1]
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Baseline questionnaires should have been completed prior to randomisation; however, six participants (3%)
in the usual-care group and 12 (5%) in the cognitive rehabilitation group were randomised without the
questionnaires being completed.
Two randomised participants (one in each group) were found to not be eligible for the trial during checks
of the BRBN scoring as they did not have any test scores more than one SD below the mean of healthy
controls, corrected for age and years of education. These participants are included in all analyses.
TABLE 2 Scores on baseline assessments prior to randomisation (continued )
Assessment
Usual care, mean [SD] or
n (%) (N= 204)
Cognitive rehabilitation,
mean [SD] or n (%) (N= 245)
Doors and Peoplei n = 203 n = 245
Overall age-scaled score 7 [3.9] 7 [3.7]
Verbal total score 7.7 [3.9] 7.8 [3.7]
Non-verbal total score 7.7 [3.5] 7.5 [3.4]
Total forgetting score 8.8 [3.0] 8.8 [3.0]
Trail Making
j n = 200 n = 244
Part B – part A 69.6 [41.4] 71.7 [41.0]
EQ-5D VAS scorek 59.6 [20.3] 59.9 [21.2]
Baseline questionnaire booklet returned 198 (97) 233 (95)
MSIS-Psyl 24.7 [6.0] (n = 197) 23.3 [5.8] (n = 233)
MSIS-Phym 53.4 [13.1] (n = 197) 52 [13.6] (n = 232)
EMQ-pn 47.1 [23.2] (n = 194) 45.0 [22.8] (n = 229)
FSSo 1.3 [1.3] (n = 197) 1.4 [1.4] (n = 230)
GHQ-30
p
Total score (Likert scoring) 39.7 [15.8] (n = 197) 36.5 [14.2] (n = 230)
GHQ score of ≥ 5 (GHQ scoring) 136 (67) 150 (61)
EMQ-rn 38.2 [25.9] (n = 185) 34.7 [23.4] (n = 213)
a Scores range between 0 and 60 with higher scores indicating more cognitive problems. A score of ≥ 28 was required to
be eligible for the trial.
b Higher scores indicate better performance.
c Total recall: minimum 0, maximum 72; long-term storage: minimum 0, maximum 72; consistent long-term retrieval:
minimum 0, maximum 72; and delayed recall: minimum 0, maximum 12.
d Total correct: minimum 0, maximum 30; total confabulations: minimum 0, maximum 30; and delayed recall: minimum 0,
maximum 10.
e Minimum 0; maximum 110.
f Easy total correct – minimum 0, maximum 60; hard total correct – minimum 0, maximum 60.
g Minimum 0, maximum 150.
h Scores range between 0 and 55, with higher scores indicating increased disability.
i Scores range between 0 and 20, with higher scores indicating better performance.
j Maximum time to complete part A: 150 seconds; maximum time to complete part B: 240 seconds.
k Scores range from 0 (worst health participant can imagine) to 100 (best health participant can imagine).
l Scores range from 9 to 36. Higher scores indicate greater psychological impact of MS on everyday life.
m Scores range from 20 to 80. Higher scores indicate greater physical impact of MS on everyday life.
n Scores range from 0 to 112, with higher scores indicating more frequent memory problems.
o Scores range from –3.4 to 3.4, with higher scores indicating greater impact of fatigue.
p GHQ-30 scores range from 0 to 90, with higher scores indicating increased psychological distress.
Reproduced with permission from Lincoln et al.122 This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
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Cognitive rehabilitation sessions
Attendance at sessions
Participants attended a mean of 7 sessions (SD 3.4 sessions) not including catch-up sessions, and a mean
of 7.7 sessions (SD 3.5) when catch-up sessions were included (Table 3). Three or more sessions (including
catch-up sessions) were attended by 208 participants (85%). The reasons that participants did not attend
sessions are shown in Table 4. Twenty-four participants (10%) missed sessions as they did not want to
continue and six participants (2%) stopped attending as they withdrew from the trial (not mutually exclusive);
otherwise, sessions tended to be missed because of illness or other commitments.
TABLE 4 Reasons sessions were missed
Reason scheduled session missed Total number of sessions Total number of participants
Did not want to continue 162 24
Withdrew from trial 40 6
Unable to contact 92 26
Forgot to attend 14 13
Unwell – MS relapse 20 11
Unwell – other 119 66
Holiday 65 49
Work commitments 49 25
Travel problems 12 11
Othera 157 69
Not known 11 10
a Other reasons for missing sessions were mainly given as family commitments and other appointments.
TABLE 3 Summary of attendance at cognitive rehabilitation sessions
Sessions attended (N= 245)
Including catch-up sessions
Mean (SD) 7.7 (3.5)
Median (25th, 75th centile) 10 (7, 10)
Number of sessions attended, n (%)
0–2 37 (15)
3–7 32 (13)
8–10 176 (72)
Excluding catch-up sessions
Mean (SD) 7 (3.4)
Median (25th, 75th centile) 8 (6, 10)
RESULTS
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Follow-up
Participant follow-up was between November 2015 and April 2018. At the 6-month follow-up, 412 (92%)
participants completed the assessment visit and 405 (90%) completed the questionnaire booklet (Table 5).
Completion rates were similar in the two groups.
At the 12-month follow-up, 387 (86%) participants completed the assessment visit and 392 (87%) completed
the questionnaire booklet; completion rates were similar in the two groups (see Table 5). A total of 80% of
questionnaire booklets at both time points were completed on paper rather than electronically.
TABLE 5 Participant follow-up at 6 and 12 months
Follow-up completion
6-month follow-up 12-month follow-up
Usual care
(N= 204)
Cognitive
rehabilitation
(N= 245)
Usual care
(N= 204)
Cognitive
rehabilitation
(N= 245)
Face-to-face visit
Attended, n (%) 187 (92) 225 (92) 175 (86) 212 (87)
Not done,a n (%) 5 (2) 5 (2) 3 (1) 7 (3)
Discontinued with reasons, n (%) 12 (6) 15 (6) 26 (13) 26 (11)
Death (n) 0 0 0 0
Withdrawal of consent (n) 9 10 16 13
Lost to follow-up (n) 3 4 10 12
Other – not known (n) 0 1 0 1
Days to assessment visit from randomisation
Median (25th, 75th centile) 182 (178, 188) 184 (180, 188) 365 (359, 370) 364 (359.5, 370)
Minimum, maximum 166, 261 167, 288 343, 546 334, 479
Visit completed within 3 months of due date, n (%)
No – 1 (< 0.5) 2 (1) 3 (1)
Yes 187 (92) 224 (91) 173 (85) 209 (85)
Questionnaire booklet, n (%)
Returned 187 (92) 218 (89) 176 (86) 216 (88)
Not donea 5 (2) 12 (5) 2 (1) 3 (1)
Discontinued 12 (6) 15 (6) 26 (13) 26 (11)
Days to completion from randomisation
Median (25th, 75th centile) 177 (170, 187) 178 (170, 184) 357 (351, 366.5) 358 (350, 366)
Minimum, maximum 151, 260 152, 288 327, 532 313, 478
Questionnaire completed within 3 months of due date, n (%)
No – 1 (< 0.5) 3 (1) 1 (< 0.5)
Yesb 187 (92) 217 (89) 173 (85) 215 (88)
a ‘Not done’ for participant visit/questionnaire indicates that participant follow-up was carried out at a later time point or
that only one of the visits or questionnaires was completed at that follow-up time point.
b For the 6-month follow-up, the numbers of participants completing the questionnaire within 9 months of randomisation
are reported in the CONSORT flow diagram (see Figure 1), as this is the analysis population specified in the SAP.
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Almost all of the visits and questionnaires were completed within 3 months of the scheduled time point
(see Table 5).
Fifty-two participants did not complete the 12-month follow-up (12%; 26 participants in each group)
because they either withdrew consent or were lost to follow-up (see Table 5). The main reasons for
withdrawal (when given) were health problems or having too many other commitments.
Inclusion in primary analysis of the primary outcome
A total of 173 participants (85%) in the usual-care group and 214 (87%) participants in the cognitive
rehabilitation group were included in the primary analysis of the primary outcome at 12 months. Three
participants in the usual-care group and two participants in the cognitive rehabilitation group who
completed questionnaires at 12 months were not included in the primary analysis of the MSIS-Psy because
either they completed the questionnaire > 15 months after randomisation (n = 4) or there was more than
one item missing on the MSIS-Psy (n = 1).
Participants in both groups with no primary outcome were slightly younger, more likely to report having
relapsing–remitting MS and had poorer scores on cognitive assessments and questionnaires at baseline
(see Appendix 6, Tables 30 and 31).
Relative/friend questionnaire follow-up
At 6 months relative/friend questionnaires were completed for 158 participants (77%) in the usual-care
group and 185 participants (76%) in the cognitive rehabilitation group. All of the 6-month relative/friend
questionnaires were completed within 9 months of a participant’s randomisation.
At 12 months, relative/friend questionnaires were completed for 147 participants (72%) in the usual-care
group and 171 participants (70%) in the cognitive rehabilitation group. One relative/friend questionnaire
in the usual-care group and three relative/friend questionnaires in the cognitive rehabilitation group were
completed > 15 months after the participant’s randomisation.
Unblinding at follow-up visits
Research assistants reported being unblinded prior to the follow-up for 17 participants at 6 months (4% of
completed visits) and for six participants at 12 months (2% of completed visits). The percentage of RAs who
reported being unblinded prior to the visits were similar in the two groups at each follow-up time point.
Research assistants reported being unblinded during the visit more often in the cognitive rehabilitation
group than in the usual-care group. At 6 months, RAs reported being unblinded during the visit for
36 participants (16%) in the cognitive rehabilitation group and for 16 participants (9%) in the usual-care
group. At 12 months, RAs reported being unblinded during the visit for 17 participants (8%) in the
cognitive rehabilitation group and for six participants in the usual-care group (3%).
Overall, there was little agreement between the RA opinion of treatment allocation and the actual
treatment allocation as assessed using the kappa statistic. The kappa values were 0 at the start of the
6-month visit, 0.17 at the end of the 6-month visit, 0.02 at the start of the 12-month visit and 0.07 at
the end of the 12-month visit. Details of the RA opinion of treatment allocation at the start and end of the
visit are shown in Appendix 7, Table 32.
Primary outcome: MSIS-Psy at 12 months
Primary analysis
A total of 387 participants were included in the primary analysis at 12 months (86%); 376 of these
completed the MSIS-Psy at baseline. There was a mean of 4.8 participants per cognitive rehabilitation
group who had MSIS-Psy data at the 12-month follow-up.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
There was no evidence of a difference between the two groups in the MSIS-Psy score at 12 months (Table 6).
The adjusted difference in means was –0.6, with 95% confidence interval (CI) –1.5 to 0.3, which does not
include the 2-point difference assumed to be clinically important on version 2.0 of the MSIS-Psy.
There was no evidence that the assumptions for the model were not met. The estimated ICC coefficient
for the MSIS-Psy score from the model was 0 in the cognitive rehabilitation group.
Sensitivity analyses
The sensitivity analyses for the primary analysis were all consistent with the primary analysis, showing no
clinically important difference between the groups in MSIS-Psy score at 12 months (Table 7).
Secondary analysis
The complier average causal effect estimate of the adjusted difference in means using the observed
data was –0.7 (95% CI –1.7 to 0.4, n = 387), and using the multiply imputed data it was –0.6 (95% CI
–1.7 to 0.4, n = 449), based on attending three or more cognitive rehabilitation sessions.
Subgroup analysis for the primary outcome
There was no evidence of a difference in the effect of cognitive rehabilitation according to MS type (p-value
for interaction effect, 0.79), cognitive problems at baseline assessed on the MSNQ (p-value for interaction
effect, 0.71), memory function at baseline using the Doors and People overall age-scaled score (p-value for
interaction effect, 0.92) or speed of information processing at baseline using the Symbol Digit Modalities Test
from the BRBN (p-value for interaction effect, 0.38) (Figure 2; see also Appendix 8, Table 33).
TABLE 7 Sensitivity analysis for the MSIS-Psy score at 12 months
Sensitivity analysis n
Adjusted difference
in means (95% CI)
Including participants completing the 12-month questionnaire booklet > 15 months
after randomisation
391 –0.5 (–1.4 to 0.4)
According to method used for missing baseline MSIS-Psy score
Participants with observed baseline MSIS-Psy score 376 –0.7 (–1.6 to 0.2)
Using missing indicator method 387 –0.7 (–1.6 to 0.2)
Multiple imputation for missing MSIS-Psy score at 12 monthsa 449 –0.5 (–1.5 to 0.5)
a See Chapter 2, Sensitivity analyses for the primary outcome, for details of variables included in the imputation model.
TABLE 6 The MSIS-Psy at 12 months
Trial group
Time point, mean (SD); n
Adjusted difference in
means (95% CI) p-valueBaselinea 12 months
Usual care 24.2 (5.9); 170 23.4 (6.0); 173
Cognitive rehabilitation 23.0 (5.7); 206 22.2 (6.1); 214 –0.6 (–1.5 to 0.3) 0.20
CI, confidence interval.
a Baseline scores for participants are included in the primary analysis at 12 months; missing baseline MSIS-Psy scores were
imputed for the analysis using the mean baseline score at the relevant centre.
Note
MSIS: psychological subscale scores range from 9 to 36. Higher scores indicate greater psychological impact of MS on
everyday life. Difference in means at 12 months (cognitive rehabilitation compared with usual care) estimated using a
multilevel linear model with a random effect for group for participants allocated to the cognitive rehabilitation group,
allowing the participant-level variance to vary between allocated groups, with baseline MSIS-Psy score, gender, MS-type
and centre included as covariates.
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The MSIS-Psy score at 6 months
At 6 months, the adjusted difference in mean MSIS-Psy score and 95% CI favoured the cognitive
rehabilitation group (Table 8). However, the 95% CI does not include the 2-point difference that is
assumed to be clinically important.
Secondary outcomes
Secondary outcomes were considered to be supportive to the primary analysis. No formal adjustment
for multiple significance testing was applied so the number of tests conducted should be taken into
consideration when interpreting the results.
Secondary outcomes assessed on questionnaires
At 6 and 12 months, the differences between the two groups favouring the cognitive rehabilitation group
were observed for participant-reported frequency of memory problems assessed using the EMQ-p and
mood using the GHQ-30 (Table 9). The EMQ-r scores (relative/friend report of a participant’s frequency of
memory problems) were lower for the cognitive rehabilitation group, with an effect size for the difference
in means between the two groups of a similar magnitude to the participant report (see Table 9).
– 6 – 4 – 2 0 2 4 6
Difference in mean MSIS-Psy score at 12 months
SDMT score of 43 to 76 (n = 127)
SDMT score of 33 to 42 (n = 137)
SDMT score of 5 to 32 (n = 122)
DP score of 10 to 18 (n = 113)
DP score of 6 to 9 (n = 154)
DP score of 0 to 5 (n = 119)
MSNQ score of 43 to 60 (n = 121)
MSNQ score of 36 to 42 (n = 119)
MSNQ score of 28 to 35 (n = 147)
Progressive (n = 142)
Relapsing–remitting (n = 245)
Primary analysis (n = 387)
Speed of information processing
Memory function
Cognitive problems
MS type
FIGURE 2 Adjusted difference in mean MSIS-Psy score according to subgroup. DP, Doors and People; SDMT, Symbol
Digit Modalities Test.
TABLE 8 The MSIS-Psy score at 6 months
Trial group
Time point, mean (SD); n
Adjusted difference in
means (95% CI) p-valueBaselinea 6 months
Usual care 24.5 (6.0); 181 24.1 (5.9); 187
Cognitive rehabilitation 23.2 (5.8); 210 22.3 (6.2); 217 –0.9 (–1.7 to –0.1) 0.03
a Baseline scores for participants were included in the analysis of the MSIS-Psy score at 6 months; missing baseline
MSIS-Psy scores were imputed for the analysis using the mean baseline score at the relevant centre.
Reproduced with permission from Lincoln et al.122 This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
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TABLE 9 Secondary outcomes assessed on questionnaires
Questionnaire
Time point, mean (SD); n Adjusted difference
in means at 6 months
(95% CI); n
12 months,
mean (SD); n
Adjusted difference in
means at 12 months
(95% CI); nBaseline 6 months
EMQ-pa
Usual care 47.1 (23.2); 194 44.5 (23.5); 181 43.1 (24.0); 168
Cognitive
rehabilitation
45.0 (22.8); 229 37.6 (23.4); 214 –5.3 (–8.7 to –1.9); 395 37.9 (22.7); 210 –4.4 (–7.8 to –0.9); 378
EMQ-ra
Usual care 38.2 (25.9); 185 38.6 (25.7); 152 38.5 (26.4); 142
Cognitive
rehabilitation
34.7 (23.4); 213 31.3 (22.9); 184 –5.4 (–9.1 to –1.7); 336 30.5 (23.3); 164 –5.5 (–9.6 to –1.5); 306
GHQ-30b (Likert scoring)
Usual care 39.7 (15.8); 197 37.8 (14.8); 183 38.3 (16.2); 167
Cognitive
rehabilitation
36.5 (14.2); 230 32.9 (15.1); 212 –3.4 (–5.9 to –0.8); 395 33.9 (16.1); 209 –3.4 (–6.2 to –0.6); 376
FSSc (Rasch-transformed score)
Usual care 1.3 (1.3); 197 1.1 (1.4); 185 1.2 (1.4); 168
Cognitive
rehabilitation
1.4 (1.4); 230 1.1 (1.4); 214 –0.1 (–0.3 to 0.2); 399 1.0 (1.4); 210 –0.3 (–0.5 to 0.0); 378
EQ-5D VASd score
Usual care 59.6 (20.3); 203 59.2 (20.2); 187 59.7 (20.0); 173
Cognitive
rehabilitation
59.9 (21.2); 245 61.7 (19.5); 224 2.6 (–0.9 to 6.0); 411 61.6 (19.3); 209 2.6 (–0.9 to 6.0); 382
MSIS-Phye
Usual care 53.4 (13.1); 197 53.0 (13.9); 187 52.5 (13.6); 173
Cognitive
rehabilitation
52.0 (13.6); 232 51.4 (13.3); 215 –0.6 (–2.2 to 0.9); 402 51.8 (14.0); 214 –0.1 (–1.8 to 1.5); 387
MCSIf score (relative/friend)
Usual care – 6.8 (6.2); 154 6.2 (6.0); 141
Cognitive
rehabilitation
– 5.9 (5.6); 173 –0.9 (–2.2 to 0.4); 327 5.8 (5.2); 159 –0.4 (–1.6 to 0.8); 300
GNDSg
Usual care 20.0 (6.7); 204 20.5 (7.3); 183 – 20.5 (7.4); 166 –
Cognitive
rehabilitation
19.9 (7.1); 245 20.6 (7.2); 211 – 20.1 (7.4); 202 –
a EMQ scores range from 0 to 112; higher scores indicate more frequent memory problems.
b GHQ scores ranges from 0 to 90; higher scores indicate increased psychological distress.
c FSS scores range from –3.4 to 3.4; higher scores indicate a greater impact of fatigue.
d EQ-5D VAS scores range from 0 (worst health imaginable) to 100 (best health imaginable).
e MSIS-Phy scores range from 20 to 80; higher scores indicate a greater physical impact of MS on everyday life.
f MCSI scores range from 0 to 26; higher scores indicate greater carer strain.
g GNDS scores range between 0 and 55; higher scores indicate increased disability. Note that no formal comparison
between groups was conducted for GNDS.
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There was no evidence of a difference between the groups in fatigue, health status (based on the EQ-5D
VAS score), physical impact of MS on quality of life, or carer strain at 6 or 12 months (see Table 9).
The percentage of participants in employment (full or part time) was ≈30% at baseline and at 6 and
12 months in each group (Table 10). Further details on employment status can be seen in Appendix 9,
Tables 34 and 35.
The mean scores on the GNDS, to assess disability due to MS, at 6 and 12 months were similar to baseline
in both groups (see Table 9). The percentage of participants reporting that they had had a relapse in the
previous 6 months was also similar in the two groups at follow-up (see Table 10). Details on the number
of reported relapses can be seen in Appendix 10, Table 36.
Cognitive abilities
Scores from the BRBN, Doors and People, and Trail Making tests are shown in Table 11. There was no
evidence of a difference between groups at 6 or 12 months for six of the eights tests compared on the
BRBN. On the selective reminding test, there was evidence of higher total recall scores at 6 months and
higher delayed recall scores at 12 months in the cognitive rehabilitation group. However, there was no
evidence of a difference between groups in the selective reminding test total recall score at 12 months or
the selective reminding test delayed recall scores at 6 months.
On the Doors and People test, there was evidence that the combined verbal scores were better for the
cognitive rehabilitation group than for the usual-care group at 6 and 12 months. However, there was no
evidence of a difference between the groups for the combined visual score or total forgetting score at
either time point.
There was no evidence of a difference between the two groups in the Trail Making Test.
Safety outcome
At 6 months, four participants (2%) in the usual care group and three participants (1%) in the cognitive
rehabilitation group had an increase of ≥ 30 points in GHQ-30 score from baseline (see Appendix 11,
Table 37).
TABLE 10 Employment status and participant-reported relapse in the previous 6 months
Employment
and relapse
Screening/baseline,
n (%); N
6 months,
n (%); N
Adjusted odds
ratio (95% CI); n
12 months,
n (%); N
Adjusted odds
ratio (95% CI); n
Any employment (full or part time)
Usual care 69 (34); 203 57 (30); 187 50 (29); 173
Cognitive
rehabilitation
75 (31); 245 62 (28); 224 0.88 (0.55 to 1.39);
411
60 (29); 209 0.99 (0.60 to 1.63);
382
Relapse in the previous 6 months
Usual care 49 (24); 204 39 (21); 187 34 (20); 173
Cognitive
rehabilitation
59 (24); 245 37 (17); 217 – 41 (19); 215 –
Notes
Employment status was collected at the baseline visit and the follow-up visits. The odds ratio for any form of employment
was estimated using generalised estimating equation with a logistic link function and robust standard errors with gender,
MS-type and centre included as covariates.
Relapse in the previous 6 months was collected at the screening visit and on the follow-up questionnaires. Note that no
formal comparison between groups was conducted for participant-reported relapse.
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TABLE 11 Cognitive abilities at 6 and 12 months
Test
Baseline,
mean (SD); n
6 months,
mean (SD); n
Adjusted difference
in means at 6 months
(95% CI); n
12 months,
mean (SD); n
Adjusted difference in
means at 12 months
(95% CI); n
BRBNa
Selective reminding testb
Total recall
Usual care 40.2 (10.5); 204 43.5 (10.4); 182 46.5 (11.3); 170
Cognitive
rehabilitation
40.6 (11.0); 245 45.6 (10.5); 220 1.6 (0.1 to 3.0); 402 47.5 (10.9); 206 0.6 (–0.9 to 2.1); 376
Delayed recall
Usual care 5.7 (2.8); 204 6.5 (2.9); 182 7.1 (2.9); 170
Cognitive
rehabilitation
5.8 (2.8); 245 6.7 (2.9); 220 0.2 (–0.2 to 0.6); 402 7.5 (2.8); 206 0.4 (0.1 to 0.8); 376
10/36 Spatial recallc
Total recall
Usual care 18.3 (4.9); 204 19.8 (5.4); 182 20.4 (5.4); 170
Cognitive
rehabilitation
18.1 (4.5); 245 19.1 (5.3); 217 –0.6 (–1.5 to 0.3); 399 20.1 (4.9); 206 –0.1 (–1.0 to 0.8); 376
Delayed recall
Usual care 6.3 (2.1); 204 6.6 (2.3); 182 7.0 (2.3); 170
Cognitive
rehabilitation
6.0 (2.2); 245 6.6 (2.3); 217 0.0 (–0.4 to 0.4); 399 6.8 (2.2); 206 –0.1 (–0.5 to 0.2); 376
Symbol Digit Modalitiesd
Usual care 37.8 (12.1); 204 40.7 (12.7); 181 39.9 (12.8); 170
Cognitive
rehabilitation
36.3 (11.5); 244 41.4 (12.1); 220 1.3 (–0.6 to 3.2); 401 39.9 (11.9); 205 0.4 (–1.7 to 2.5); 375
Paced Auditory Serial Additione
Easy total
Usual care 31.1 (16.4); 199 35.7 (17.6); 178 36.5 (17.7); 169
Cognitive
rehabilitation
31.6 (16.2); 239 36.6 (16.1); 217 0.0 (–2.4 to 2.5); 395 36.4 (17.8); 205 –0.6 (–3.1 to 1.9); 374
Hard total
Usual care 15.9 (15.8); 199 19.3 (17.7); 178 19.2 (18.9); 169
Cognitive
rehabilitation
17.3 (16.5); 239 20.7 (17.5); 217 –0.3 (–2.9 to 2.2); 395 18.5 (19.2); 205 –1.9 (–4.8 to 1.0); 374
Word fluencyf total score
Usual care 25.1 (8.9); 203 27.2 (9.3); 182 28.3 (10.2); 169
Cognitive
rehabilitation
24.8 (8.8); 244 27.4 (9.4); 219 0.0 (–1.3 to 1.3); 401 28.0 (10.3); 206 –0.2 (–1.5 to 1.2); 375
continued
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TABLE 11 Cognitive abilities at 6 and 12 months (continued )
Test
Baseline,
mean (SD); n
6 months,
mean (SD); n
Adjusted difference
in means at 6 months
(95% CI); n
12 months,
mean (SD); n
Adjusted difference in
means at 12 months
(95% CI); n
Doors and Peopleg
Overall age-scaled score
Usual care 7.0 (3.9); 203 9.1 (4.4); 181 9.9 (4.4); 168
Cognitive
rehabilitation
7.0 (3.7); 245 9.5 (4.2); 221 0.4 (–0.1 to 0.9); 402 10.5 (4.1); 206 0.6 (0.0 to 1.1); 374
Combined visual score
Usual care 7.7 (3.5); 203 9.1 (3.7); 181 9.4 (3.8); 169
Cognitive
rehabilitation
7.5 (3.4); 245 9.2 (3.4); 221 0.2 (–0.2 to 0.7); 402 9.7 (3.6); 207 0.4 (–0.1 to 1.0); 376
Combined verbal score
Usual care 7.7 (3.9); 203 9.5 (3.9); 183 10.5 (4.0); 168
Cognitive
rehabilitation
7.8 (3.7); 245 10.1 (4.2); 221 0.6 (0.0 to 1.2); 404 11.5 (4.0); 206 0.8 (0.2 to 1.5); 374
Total forgetting score
Usual care 8.8 (3.0); 203 9.2 (2.9); 181 9.9 (2.7); 168
Cognitive
rehabilitation
8.8 (3.0); 245 9.5 (2.8); 221 0.2 (–0.3 to 0.8); 402 10.0 (2.6); 207 0.1 (–0.4 to 0.6); 375
Trail Makingh (part B – part A)
Usual care 69.6 (41.4); 200 62.3 (38.3); 179 63.0 (40.3); 165
Cognitive
rehabilitation
71.7 (41.0); 244 63.0 (39.1); 218 –0.3 (–6.8 to 6.2); 397 61.3 (39.7); 205 –3.2 (–10.0 to 3.6); 370
a Higher scores indicate better performance.
b Total recall: minimum, 0; maximum, 72. Delayed recall: minimum, 0; maximum 12.
c Total correct: minimum, 0; maximum, 30. Delayed recall: minimum, 0; maximum 10.
d Minimum, 0; maximum, 110.
e Easy total correct: minimum, 0; maximum, 60. Hard total correct: minimum, 0; maximum 60.
f Minimum, 0; maximum, 150.
g Scores range between 0 and 20; higher scores indicate better performance.
h Maximum time to complete part A: 150 seconds; maximum time to complete part B: 240 seconds.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
Chapter 4 Assessing intervention fidelity in the
CRAMMS trial
Background
In evaluations of complex interventions, it is important to know the content of the treatment that was
delivered in a trial. This is so that the results obtained can be attributed to what was actually delivered,
and to allow replication of the interventions across studies. An accurate description of what was delivered
may also help in implementing the intervention in health-care settings. Treatment fidelity is the degree
to which a treatment is implemented as intended (treatment integrity) and whether or not the treatment
being evaluated differs from other treatments or the control condition (treatment differentiation).123 Dumas
et al.124 distinguished between content fidelity, what was done, and process fidelity, the way it was done.
Treatment fidelity requires not only that the treatment is delivered, but also that participants engage with
the treatment.125 This requires participants to understand the intervention, be able to perform the skills
required by the intervention (‘intervention receipt’), and to use these skills in daily life (‘intervention
enactment’).126
There are useful recommendations on methods to ensure the integrity of the intervention in the design and
conduct of the study. Bellg et al.127 produced best-practice guidelines for ensuring the fidelity of intervention in
randomised trials. The recommendations at the design stage included documenting the ‘dose’ of therapy to be
delivered and identifying methods to ensure that the intervention is the same for all participants, documenting
the delivery of both intervention and control conditions and planning for setbacks in the provision of treatment.
They also recommended standardisation of training for treatment providers, followed by observation of
treatment sessions, conducting booster sessions to ensure that there is no ‘drift’ in treatment delivery and
monitoring drop-outs from treatment across those providing treatment. Strategies to maintain fidelity during
the conduct of the trial included having treatment manuals and monitoring the delivery of treatment using
audio- or video-recordings.
There are also methods to check the fidelity of the intervention after the trial has been completed.
Walton et al.125 conducted a review of measures of fidelity of treatment delivery and treatment engagement.
They identified that, in 66 studies, the most common single method of recording fidelity of delivery was
observation, used by 39% of those studies reviewed, although 25% of studies used multiple methods
including observation, self-report and interviews. The main methods to assess fidelity of engagement was
self-report (18%), although some studies (17%) also used multiple methods. The authors highlighted a lack
of information on the psychometric and implementation qualities of the measures used.125
In the CRAMMS trial, the aims of the treatment integrity evaluation were to:
l report the training received by AP delivering the intervention
l describe the therapists’ reported dose of therapy delivered across sites
l check whether or not the content of the delivery corresponded with the treatment manual using
video-recordings of treatment sessions
l check the consistency in the content of therapy delivered across sites.
Methods
The initial three AP (from sites 1, 2 and 3) delivering the intervention attended a 1-day workshop, facilitated
by a qualified clinical psychologist, to introduce them to the trial and the content of the intervention in the
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manual. Subsequent APs who joined the trial later (sites 4 and 5) and additional APs in sites 1, 2 and 3
covered this in individual 2-hour meetings about the intervention as described in the manual, delivered by a
qualified clinical psychologist.
Once an AP had started delivering the intervention, they received weekly supervision from a clinical
psychologist, based at their site, on issues related to dealing with participants. These tended to focus on
site-specific issues that affected intervention delivery. Monthly individual telephone supervision with a
clinical psychologist co-applicant allowed for discussion of specific challenges relating to the delivery of the
intervention. This person offered supervision for all the APs. In addition, monthly teleconferences provided
an opportunity for peer group supervision, with all APs participating, and to facilitate consistency in the
delivery of intervention across sites. Furthermore, when staff changes occurred, former staff completed a
handover document for new staff.
Treatment sessions were video-recorded by the AP, unless the session was the first run by an AP or a
participant in the group did not consent to being recorded. Practices for video-recording drew on guidance
on minimising intrusiveness of the recording.128,129 The camera was set up at the beginning of the session
to show the AP delivering the intervention, and then was left to run for the entire session.
A coding schedule, as shown in Appendix 12, Tables 38 and 39, was based on the components of
treatment described in the manual and previous work on the content of rehabilitation contexts.130,131
The schedule listed activities that were expected in each session for both the APs (e.g. facilitating
discussion or providing feedback) and participants (e.g. asking for information about the intervention
content or describing problems).
A distinction was made between content that was applicable in all sessions (e.g. describing strategies,
discussing take-home activities and reflecting on personal experiences) and content that was specific to a
session (e.g. learning about rhyming mnemonics in session 6 and discussing the use of diaries in session 9).
Non-rehabilitation activities (e.g. social chat, information about sessions, and preparing tasks or materials)
were coded as ‘other’ content. The primary activity of the therapist or participant was also recorded at
each time point.
An independent researcher, not involved in the delivery of the intervention, coded the videos using a
time-sampling procedure. Coding took place on the minute, every minute, throughout the video-recording.
On each observation, the content of the treatment and the activity of the AP or participant were given the
appropriate activity codes. A 10% sample of sessions was randomly selected by group number, using an
online random number generator. These sessions were checked by another observer. The inter-rater reliability
was determined using Cohen’s kappa. The discrepancies were then resolved by discussion and the coding for
all sessions amended on the basis of this discussion. Data from the coding sheets were entered into IBM SPSS
Statistics version 23 (IBM Corporation, Armonk, NY, USA) for analysis. The frequencies of each code were
reported. Discrepancies of > 5% between the frequency of a specific observation at a site and the overall
average across all sites were described.
After each session, the AP recorded the number of people who had attended and reasons for non-attendance.
Results
The breakdown of attendance according to site is shown in Table 12.
The results show that the mean number of sessions attended at all sites was between 7.1 and 8.2 when
catch-up sessions were included and between 6.3 and 7.5 when catch-up sessions were excluded.
The pattern of attendance was similar between sites. The main reasons for non-attendance were that
the participant did not want to continue with treatment (24 participants, 162 sessions), being unable to
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contact the participants (26 participants, 92 sessions), illness (66 participants, 119 sessions) and holidays
(48 participants, 64 sessions).
There were 45 treatment groups delivered by 10 APs. Of these, 35 treatment groups (78%) had at least
two sessions recorded. The reason for non-recording of a treatment group was that for four groups (9%)
it was the first conducted by an AP and for two groups (4%) a participant did not consent. Both these
reasons were part of the exclusion criteria for recording. Of the remaining four groups, for two (4%), the
group was not recorded in error and for two (4%) the reason was unknown. Of those groups recorded,
all sessions were recorded for two (6%) groups. The main reasons for some sessions not being recorded
were as follows: there were camera problems for 26 groups (74%), there was a misunderstanding of the
requirements for recording for 3 groups (9%), there was resistance from participants even though they
had initially agreed to the recordings for 3 groups (9%) and the reason is unknown for 1 group (3%).
The number of recordings per session is shown in Appendix 12, Table 40. Of the 450 sessions held, 252
(56%) were fully recorded and 39 (9%) were partially recorded. The inter-rater reliabilities of the coding
categories were very good according to criteria reported by Altman132 (manual content applicable to all
sessions, κ = 0.98; session-specific manual content, κ = 0.99; other content not related to cognitive
rehabilitation, κ = 0.89; AP activities, κ = 0.83; participant activities, κ = 0.91).
The distribution of manual content applicable to all sessions and according to site is shown in Table 13.
This showed that about one-quarter of the time was spent on discussing strategies to help people remember
and pay attention. Just under one-fifth of the time was spent reviewing and explaining take-home activities.
Less than 10% of time was spent on content that was not related directly to cognitive rehabilitation, such
as social chat and making arrangements for future sessions. Therefore, the focus of the intervention was on
content directly related to delivering cognitive rehabilitation. This pattern of delivery was consistent between
sites. The only notable variation was that the sessions at site 2 included less learning about attention and
memory than the other four sites.
The distribution of manual content applicable to all sessions in each session is shown in Table 14. The distribution
of time was consistent with expectations based on the manual. The discussion of take-home activities occurred a
similar proportion of times in all sessions apart from session 1, which was lower as no take-home activity would
have been completed. Learning about attention and memory occurred predominantly in session 2, in which
the focus was on explaining memory and the processes involved. The summary of previous sessions gradually
increased over time, from 3% in session 2 to 6% in session 8. This indicates that, as more material was covered,
there was more review of previous material. Reflections on personal experiences occurred mainly in the final
few sessions.
TABLE 12 Attendance at intervention sessions by site
Attendance Site 1 Site 2 Site 3 Site 4 Site 5 Total
Including catch-up sessions
Mean 8.0 7.6 7.1 7.8 8.2 7.7
SD 2.9 3.7 3.8 3.8 3.5 3.5
Excluding catch-up sessions
Mean 7.1 7.1 6.3 7.3 7.5 7.0
SD 2.9 3.5 3.7 3.7 3.4 3.4
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The distribution of content that was specific to individual sessions, as described in the manual, is
summarised in Table 15. This showed that all expected components of the manual occurred and no
components of the manual were missed. The distribution of time reflects the main theme of the session.
Session 1 covered things people forgot (e.g. where they parked their car) and the strategies they used to
overcome this. Site 4 spent a relatively high proportion of time discussing strategies that people used to
overcome problems (28.7% compared with just less than 20% in the other sites). In session 2, the focus
was on memory storage and the processes involved in memory. Site 1 spent a relatively high proportion
of time on memory storage and site 4 spent time on the processes involved in memory. In session 3,
the session-specific content was distributed approximately equally between different types of attention,
the attention exercise and techniques to improve attention. In site 2, more time was spent on techniques
to improve attention and less on discussing types of attention and types of distractors, compared to the
other four sites. Most session-specific time in session 4 was spent on story recall using the five Ws and
the H (who, what, when, where, why and how). In session 5, one-third of session-specific content was
on categorisation. Session 5 also included material from session 6 from one group at site 3. In session 6,
just under one-third of time was spent on the levels of processing exercise, with about one-fifth of time
spent on visual imagery. Little time was spent on first-letter cues or rhyming. The main focus of session 7
was on the PQRST (preview, question, read, state, test) technique and then the ‘little-and-often’ strategy.
Session 8 was mainly focused on diary use, which accounted for almost 40% of the time. Site 4 included
more discussion of memory aids in general and site 5 included more on pacing, relative to the other sites.
The problems with the use of external memory aids were the most frequent component of session 9.
TABLE 13 The distribution of categories of manual content applicable to all sessions by site
Content
Site 1 Site 2 Site 3 Site 4 Site 5 Total
n % n % n % n % n % N %
Manual content applicable to all sessions
Summarise previous session 416 5.3 18 3.3 103 2.1 107 3.6 72 4 716 4
Reflect on personal
experience
879 11.2 70 12.9 593 12.3 280 9.3 295 16.4 2117 11.7
Discuss take-home activities 1354 17.2 85 15.7 920 19 482 16.1 319 17.7 3160 17.5
Learn about attention and
memory
634 8.1 24 4.4 365 7.5 394 13.1 189 10.5 1606 8.9
Learn about strategies to
address problems
1949 24.8 159 29.3 1108 22.9 699 23.3 390 21.6 4305 23.9
Other content
Social chat 367 4.7 28 5.2 278 5..7 82 2.7 42 2.3 797 4.4
Discussing the CRAMMS
trial research activities
72 0.9 0 0 21 0.4 31 1 8 0.4 132 0.7
Discuss living with MS 158 2.0 2 0.4 130 2.7 29 1 36 2 355 2
Administration, for example
reimbursing travel expenses
28 0.4 2 0.4 15 0.3 4 0.1 3 0.2 52 0.3
Hospital visits, and other
MS services
20 0.3 0 0 9 0.2 2 0.1 1 0.1 32 0.2
Providing information about
sessions; housekeeping
158 2.0 1 0.2 83 1.7 48 1.6 14 0.8 305 1.7
Missing values
(session specific)
1819 23.2 152 28 1214 25.1 843 28.1 433 24 4461 24.7
Total 18,038 100
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TABLE 14 The distribution of categories of manual content applicable to all sessions by session
Content
Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total
n % n % n % n % n % n % n % n % n % n % N %
Manual content applicable to all sessions
Summarise previous session 0 0 49 2.8 70 3.7 89 3.8 73 4 57 3.2 75 4.7 111 6.2 73 4.3 119 6 716 4.0
Reflect on personal experience 150 11 117 6.6 218 11.6 200 8.6 167 9.1 195 10.9 121 7.6 354 19.9 266 15.5 329 16.6 2117 11.7
Discuss take-home activities 53 8.9 389 22 433 23.1 428 18.3 358 19.4 243 13.6 346 21.7 242 13.6 328 19.1 340 17.2 3160 17.5
Learn about attention and memory 49 3.6 809 45.8 368 19.6 64 2.7 35 1.9 115 6.5 75 4.7 3 0.2 3 0.2 85 4.3 1606 8.9
Learn about strategies to address
problems
119 8.8 56 3.2 231 12.3 814 34.8 735 39.9 692 38.9 519 32.5 461 25.9 432 25.3 246 12.4 4305 23.9
Other content
Social chat 78 5.7 72 4.1 88 4.7 89 3.8 73 4 67 3.8 54 3.4 92 5.2 83 4.8 101 5.1 769 4.3
Discussing the CRAMMS trial research
activities
17 1.3 4 0.2 0 0 1 0 2 0.1 1 0.1 6 0.4 2 0.1 1 0.1 98 4.9 132 0.7
Discuss living with MS 67 4.9 50 2.8 35 1.9 19 0.8 23 1.2 13 0.7 20 1.3 38 2.1 30 1.8 60 3 355 2
Administration, for example travel
expenses
10 0.7 6 0.3 5 0.3 7 0.3 2 0.1 9 0.5 3 0.3 4 0.2 2 0.1 4 0.2 39 0.2
Hospital visits, and other MS services 8 0.6 2 0.1 1 0.1 0 0 2 0.1 1 0.1 2 0.1 3 0.2 6 0.4 7 0.4 32 0.2
Providing information about sessions,
venue, group, etc.; housekeeping
100 7.4 47 2.7 20 1.1 28 1.2 19 1.0 16 0.9 19 1.2 20 1.1 19 1.1 17 0.9 197 1.1
Missing values (session specific) 709 52.1 166 9.4 404 21.6 600 25.7 355 19.3 372 20.9 357 22.4 451 25.3 471 27.5 576 29.1 4461 24.7
Total 18,038 100
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TABLE 15 Percentage of time spent on session-specific activities by site
Session-specific activity
Site 1 Site 2 Site 3 Site 4 Site 5 Total
n % n % n % n % n % N %
Session 1
Introduction to others 66 11.3 0 0 45 9.0 19 7.0 0 0 130 9.6
Discuss format of programme 64 10.9 0 0 44 8.8 28 10.3 0 0 136 10.0
Establish group rules 21 3.6 0 0 18 3.6 19 7.0 0 0 58 4.3
Explore attention and memory 14 2.4 0 0 16 3.2 8 0.2.9 0 0 38 2.8
Things that we forget 102 17.4 0 0 102 20.3 50 18.4 0 0 254 18.7
How do you feel? 32 5.5 0 0 21 4.2 26 9.6 0 0 79 5.8
Own techniques to help 110 18.8 0 0 100 19.8 78 28.7 0 0 288 21.2
What else do you want to know? 11 0.1 0 0 3 0.1 6 0.2 0 0 20 1.5
Session 2
What is memory? 92 12.7 0 0 47 10.3 50 13.9 29 12.6 218 12.3
Processes involved in memory 87 12.0 0 0 50 11.0 72 20.1 36 15.7 245 13.9
Memory storage 126 17.4 0 0 44 9.7 49 13.6 26 11.3 245 13.9
Memory retrieval 35 4.8 0 0 42 9.2 57 15.9 29 12.6 163 9.2
Memory systems 57 7.9 0 0 40 8.8 21 5.8 18 7.8 136 7.7
Session 3
Different types of attention 118 14.8 6 8.6 74 15.1 84 32.2 42 16.3 324 17.3
Different types of distractors 66 8.3 4 5.7 47 9.6 21 8.0 18 7.0 156 8.3
Attention exercise 160 20.1 15 21.4 104 21.3 55 21.1 47 18.2 381 20.3
Techniques to improve attention 144 18.1 21 30.0 78 16.0 21 8.0 66 25.6 330 17.6
Session 4
Story-recall exercise 118 12.6 22 15.2 78 12.8 61 15.3 40 16.3 319 13.6
5Ws and the H 74 7.9 7 4.8 30 4.9 33 8.3 13 5.3 157 6.7
Story-recall with 5Ws and the H 134 14.3 32 22.1 115 18.8 54 13.5 38 15.4 373 15.9
When difficult to attend 58 6.2 8 5.5 41 06.7 20 5.0 18 7.3 145 6.2
How attention improved 55 5.9 9 6.2 21 3.4 20 5.0 14 5.7 119 5.1
Strategies to remember 59 6.3 6 4.1 57 9.3 2 0.5 2 0.8 126 5.4
Case study handout 99 10.6 25 17.2 90 14.7 66 21.6 34 22.8 356 15.2
Session 5
Use of internal memory aids 81 9.6 0 0 28 5.7 36 12.9 27 12.0 172 9.3
Rehearsal 66 7.8 0 0 39 7.9 23 8.2 21 9.3 149 8.1
Chunking/telephone number
exercise
131 15.5 0 0 102 20.6 41 14.6 40 17.8 314 17.0
Categorisation 240 28.4 0 0 140 28.3 91 32.5 77 34.2 548 29.7
Session 6 content (associations and
visual imagery)
0 0 0 0 15 3.0 0 0 0 0 15 0.8
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Site 4 included a relatively high proportion of time on problems with external memory aids and sites 2
and 4 both included a relatively high proportion of time on the case study on making life easier by using
external memory aids. Session 10 was mainly an overview of the material covered in the manual and
reflecting back on problems discussed in session1. Site 4 spent a relatively high proportion of time on
group feedback. Overall, some material from earlier sessions was repeated in subsequent sessions, but only
one group included material that was designated for later sessions.
The distribution of AP and participant activities is shown in Table 16. The APs were engaged in activities
on 49% of observations and participants were engaged in activities on 51% of observations. The main
activity for APs was presenting and discussing strategies (19%); this was consistent across sites. The second
TABLE 15 Percentage of time spent on session-specific activities by site (continued )
Session-specific activity
Site 1 Site 2 Site 3 Site 4 Site 5 Total
n % n % n % n % n % N %
Session 6
Levels of processing 242 32.1 29 33.7 91 20.1 99 27.6 36 27.7 497 27.9
Visual imagery 139 18.5 17 19.8 72 15.9 65 23.7 20 15.4 333 18.7
Associations 58 7.7 9 10.5 22 4.9 25 7.0 16 12.3 130 7.3
Story method 76 10.1 9 10.5 79 17.4 54 15.0 29 22.3 247 13.9
First-letter cues 17 2.3 1 1.2 15 3.3 11 3.1 3 2.3 47 2.6
Rhymes 15 2.0 1 1.2 11 2.4 6 1.7 1 0.8 34 1.9
Session 7
Little-and-often strategy 124 14.9 16 19.3 97 19.4 21 17.9 9 14.1 267 16.7
PQRST method 217 26.1 18 21.7 151 30.2 41 35.0 21 32.8 448 28.1
Learning strategies 124 14.9 11 13.3 35 7.0 5 4.3 15 23.4 190 11.9
Relaxation 53 6.4 12 14.5 35 7.0 7 6.0 2 3.1 109 6.8
Session 8
Memory aids 56 7.0 8 10.0 43 10.0 38 15.3 11 5.0 156 8.8
Diary use 328 40.8 30 37.5 179 41.7 91 36.5 83 37.9 711 39.9
Pacing 102 12.7 18 22.5 68 15.9 54 21.7 54 24.7 296 16.6
Positive attitude 46 5.7 7 8.8 16 3.7 5 2.0 5 2.3 79 4.4
Session 9
Problems with external aids 287 38.3 36 46.2 165 39.8 143 53.4 77 39.3 711 41.5
Memory aids use in future 30 4.0 2 2.6 12 2.8 15 5.6 6 3.1 65 03.8
Case studies: Making Life Easier 93 12.4 20 25.6 79 18.7 38 14.2 49 25.0 279 16.3
Useful tips 13 1.7 1 1.3 11 2.6 2 0.7 9 4.6 36 2.1
Session 10
Overview of sessions 170 20.5 0 0 126 26.1 113 25.9 43 18.4 452 22.8
Favourite strategies 78 9.4 0 0 56 11.6 64 14.6 35 15.0 233 11.7
Reflecting on memory problems 132 15.9 0 0 91 18.8 71 16.2 50 21.4 344 17.4
Group feedback 92 11.1 0 0 36 7.5 33 7.6 49 20.9 210 10.6
5Ws, who, what, when, where, why; H, how; PQRST, preview, question, read, state, test.
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most frequent activity was presenting and discussing educational material (12%), which was also consistent
across sites. The only difference between sites was that APs at site 2 had a lower proportion of providing an
explanation of attention and memory (0.9%) than at other sites (overall average, 7%). The main activities
observed in participants were discussing and filling in educational material (17%), followed by discussing
strategies (16%). These were consistent across sites. The distribution of AP and participant activities across
sessions is shown in Appendix 12, Table 41.
TABLE 16 The distribution of AP and participant activities by site
Activity
Site 1 Site 2 Site 3 Site 4 Site 5 Total
n % n % n % n % n % N %
AP activity
Discussing/conducting
administrative aspects
179 2.3 5 0.9 70 1.4 58 1.9 19 1.1 331 1.8
Presenting/discussing
educational material
967 12.3 63 11.6 557 11.5 330 11.0 157 8.7 2074 11.5
Presenting/discussing strategies 1483 18.9 114 21.0 713 14.7 513 17.1 231 12.8 3054 16.9
Providing explanation 521 6.6 5 0.9 311 6.4 317 10.6 110 6.1 1264 7.0
Facilitating discussion 360 4.6 21 3.9 251 5.2 190 6.3 64 3.6 886 4.9
Providing feedback 239 3.0 15 2.8 185 3.8 146 4.9 54 3.0 639 3.5
Summarising 134 1.7 4 0.7 48 1.0 30 1.0 14 0.8 230 1.3
Paraphrasing 83 1.1 12 2.2 66 1.4 56 1.9 10 0.6 227 1.3
Discussing the CRAMMS trial
research process
58 0.7 0 0 8 0.2 19 0.6 6 0.3 91 0.5
Discussing diagnosis/living
with MS
2 0 0 0 0 0 0 0 1 0.1 3 0
Social chat 39 0.5 2 0.4 20 0.4 10 0.3 1 0.1 72 0.4
Participant activities
Discussing/conducting
administrative aspects
13 0.2 0 0 11 0.2 8 0.3 1 0.1 33 0.2
Discussing/filling in
educational material
1294 16.5 143 26.4 897 18.5 521 17.4 512 28.4 3367 18.7
Discussing strategies 1230 15.7 86 15.9 759 15.7 454 15.1 310 17.2 2839 15.7
Asking for information related
to intervention content
41 0.5 1 0.2 33 0.7 30 1 8 0.4 113 0.6
Asking for information not
related to intervention content
6 0.1 0 0 4 0.1 3 0.1 0 0 13 0.1
Describing problems 577 7.3 40 7.4 426 8.8 167 5.6 167 9.3 1377 7.6
Describing emotions and
coping strategies
93 1.2 5 0.9 45 0.9 16 0.5 22 1.2 181 1.0
Discussing MS diagnosis/
hospital visit
196 2.5 4 0.7 165 3.4 45 1.5 68 3.8 478 2.6
Discussing the CRAMMS trial
research process
6 0.1 0 0 8 0.2 6 0.1 6 0.3 13 0.1
Social chat 328 4.2 21 3.9 262 5.4 80 2.7 43 2.4 734 4.1
Missing 5 0.1 1 0.2 8 0.2 4 0.1 1 0.1 19 0.1
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Discussion
The APs were trained to deliver the intervention and received supervision from clinical psychologists and peer
supervision to ensure the integrity of the intervention. Most participants received the treatment as intended
and the number of sessions delivered was consistent between sites. The reasons for non-attendance related
to unavoidable constraints on time, such as conflicting appointments, and were similar across sites.
The video-recordings indicated that, generally, most time was spent on the content of the manual; the
distribution of time was consistent with what was expected. All components of treatment were observed.
There was also overall consistency between sites in the content of the intervention that was delivered.
The slight differences in proportions observed in site 2 recordings may be because fewer sessions were
recorded here. This was partly because three APs covered the site and so there were three first groups
to be run by an AP and partly because of a misunderstanding about the recording requirements. Other
variations between sites were minor and are likely to reflect issues raised by participants and a response
to the requirements of the group.
The limitation of the video analysis was that not all sites recorded all the sessions that were expected to be
recorded, especially site 2. This may have masked minor discrepancies between sites. However, based on
feedback obtained during monthly peer and supervisor meetings with the APs, there was no indication
that the unrecorded sessions would be markedly different from the recorded ones. Some sessions were
incomplete due to the camera battery running out or having no charging point at the group venue. These
incomplete sessions could not be analysed as the end of the session was missing in each case; therefore,
the proportions of time allocated to content could not be ascertained. However, these partial recordings
occurred at all sites and across sessions so it is improbable that their omission has influenced the results.
There is a possibility that the presence of the camera may have influenced the way the APs delivered the
intervention, but, as most sessions were recorded, this effect was minimised. The coding was done by one
observer, but supported by good evidence of inter-rater reliability. In addition, in one of the pilot studies,
there was good inter-rater reliability of a similar coding system (97% agreement).130 In addition, using only
one observer may have increased the consistency in the interpretation of the codes used. All analyses were
completed after all treatments were completed. This meant that omissions in recording were not identified
until it was too late to rectify the problem. In addition, had any major discrepancies occurred between
sites, it was too late to conduct further training with the APs to ensure greater consistency between sites.
Observing the videos of the intervention at each site, as each group was completed, would have helped
to ensure that recordings were more complete and could have minimised any discrepancies between sites.
Attendance at groups was comparable to the pilot study60 (7.9 sessions) and slightly better than a comparable
study for people with traumatic brain injury95 (6.3 sessions). The higher attendance rates for people with MS
may reflect that fewer had had any previous cognitive rehabilitation compared with those with traumatic
brain injury, who may also have had behavioural problems that may lead to worse attendance.
A similar assessment of treatment fidelity using video-recordings was conducted for the ReMemBrin
(Rehabilitation of Memory following traumatic Brain Injury) trial95 and the pilot study,131 but different
coding systems were used. Therefore, direct comparisons are not possible. However, the pilot study
seemed to have less emphasis on take-home activities than in the CRAMMS trial (3% vs. 17% of time).
Overall, these studies also established that APs were able to deliver the intervention according to the
manual.
The results support confidence that the cognitive rehabilitation delivered in the CRAMMS trial was consistent
with that described in the treatment manual. Therefore, the results reflect the effectiveness of treatment as
described in the treatment manual.
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Chapter 5 Qualitative feedback interviews
Rationale
The CRAMMS trial was a mixed-methods RCT, so that, although the primary outcomes of the trial
were quantitative, there was a nested qualitative study to unpack some of the subtle experiential and
phenomenological aspects of participating in a cognitive rehabilitation trial. The use of such qualitative
studies in RCT designs is becoming more commonplace,133 particularly when the RCT is designed to
evaluate the effectiveness of a complex intervention.
Aims
The aims were to examine and compare feedback from participants who took part in the CRAMMS trial.
Participants’ perceptions of the RCT and overall outcomes were examined and compared between those
who were in the intervention group and those who were in the control group. Specifically, from both
groups, we wanted to:
l understand the care participants received in relation to their cognitive problems prior to enrolling in
the trial
l assess whether or not they perceived any changes to their cognitive problems after joining the trial.
For those in the intervention group, we also wanted to:
l explore participants’ views on the perceived mechanism of change (if any) of their cognitive problems.
Methods
Epistemological position
Participant perspectives provide us with unique access to understand their thoughts, feelings and experiences
about the services they received and the impact this had on their daily life. With respect to the provision of
cognitive rehabilitation services (or lack thereof), we assumed that a ‘truth’ about its effectiveness could be
approximated through the investigation of patient feedback. This is in line with a critical realist epistemological
position. This position allows for the acceptance of the existence of a reality independent of human conception;
human experience can know aspects of this reality, but it is fallible.134 Thus, we acknowledge that the
self-reports collected as part of this qualitative study are fallible; however, they can be viewed as an
approximation of reality until better information is available.
Sampling
We aimed to recruit participants from all participating sites to obtain a wide range of views and experiences.
We recruited eight participants (four from the intervention group and four from the control group) each
from four of the sites to interview, as planned. However, as an additional site was added part way through
recruitment, we included four interviews from this site: two from the intervention and two from the
control group.
Participants were selected based on the maximum variation sampling technique135 to recruit individuals
with different self-reported cognitive impairment levels (based on the EMQ) and self-reported demographic
characteristics. Once an initial group of participants was recruited, subsequent participants were selected
on the basis of how ‘different’ they were from the initial group, in order to have a diverse sample.
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Sample size
There is no agreed sample size calculation for qualitative studies, so we adopted a pragmatic approach
to interview as many participants as we could over a defined time frame, and based on our available
resources. However, in deciding what was ‘pragmatic’, we took account of the sample sizes reported in
other similar studies. For a similar trial of memory rehabilitation in people with traumatic brain injuries,95
we interviewed 32 participants (16 from the control group and 16 from the intervention group), and
this provided us with sufficient data to answer our research questions (which were similar to our current
research questions). We also sought information from two meta-syntheses: (1) of cognitive rehabilitation
for people with MS,136 which had sample sizes of between 31 and 98 participants (it must be noted that
some of the larger studies used focus groups and content analyses of written texts) and (2) of group-based
memory rehabilitation,137 which had sample sizes of 10 to 38 participants. Therefore, we were confident
that with 36 participants we would have rich data to allow us to explore with sufficient depth the areas
we were interested in. We did have the facility to recruit a few more participants if we were not satisfied
with the richness of the data from the 36 interviews. We did not look for data saturation, but our
conceptual depth criterion was one of sufficiency.138 We operationalised conceptual depth based on work
by Nelson138 in terms of (1) the range of evidence (or quotations from different respondents), (2) a complex
network of connection between themes, (3) subtlety in concepts, (4) resonance with extant literature and
(5) external validity.138 We aimed to obtain sufficient data within each cell of our framework matrix that
related to each of our domains (or ‘conceptual categories’).
Procedure
Participants who had consented to be contacted about the qualitative study from the CRAMMS trial were
considered for inclusion. We conducted one-to-one feedback interviews with participants enrolled in the
trial within 2 months of completion of the 6-month follow-up assessment. To reduce social desirability
bias, the feedback interviews were conducted by two individuals who were not involved with the
assessments or intervention aspects of the trial.
The interviewers were a PhD student (Olga Klein) who was researching cognitive rehabilitation
implementation in MS, and a carer of a person with MS. We decided to include a patient and public
involvement (PPI) member as an interviewer based on our PPI group’s feedback to consider more ambitious
ways to include PPI in our research. We also wanted to determine how the interviews conducted by both
parties differed. Both the PhD student and the PPI interviewer were trained to conduct the interviews and
use the interview schedule by one of the co-applicants (RdN).
Two semistructured interview schedules were developed based on extant literature and in relation to the
content of the groups that participants attended. The interview schedules focused on the following
domains:
l general experienced cognitive problems
l advice received about managing cognitive problems (before and during the trial, but not as part
of the trial)
l treatments received to manage cognitive problems from the point participants were recruited to the
point of the interview
l strategy use before the trial
l changes of cognitive abilities in the past 6 months (if any)
l what would have made the participants’ experience of being involved in the trial better.
The interview schedule for the control group included two additional specific aspects:
1. whether or not the participants had received any form of cognitive rehabilitation during the trial
2. participants’ experience and thoughts on being part of the control group.
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The interview schedule for the intervention group focused on some specific aspects:
l most and least useful aspects of the cognitive rehabilitation programme
l strategy use after the trial, and impact on daily life activities
l participants’ experience and thoughts on being part of the intervention group
l overall experience of the cognitive rehabilitation programme.
The interviews were conducted over the telephone. Before the interview began, the interviewers reminded
the participants of the purpose of the interviews, reassured them about confidentiality and told them that
they could pause the interview or choose not to answer questions if they did not wish to. They were also told
that the interview was going to be audio-recorded and transcribed verbatim. Transcription was conducted
by a professional transcribing service. Transcripts were checked against the original audio-recording and any
errors were corrected.
Analysis
Framework analysis, an atheoretical form of thematic analysis, was used to analyse the data. This method
has become an increasingly popular approach in medical and health research.139 In framework analysis,
the data from the transcripts are mapped onto a predefined framework. To establish the analytic framework,
four transcripts were chosen, two from the intervention and two from the control group, for initial coding by
two independent researchers. They read and re-read the transcripts a few times to form initial impressions of
the data. The left-hand margin was used to describe each segment of data (which was underlined) with a
code or codes, and the right-hand margin was used to record more detailed notes and ideas about that
segment of data. We underlined and annotated key words, parts of sentences or whole paragraphs. We
followed Gale et al.’s139 guide to framework analysis.
Following the initial coding of the first four transcripts, the PhD student met with one of the co-applicants
(RdN) to discuss the codes and to check whether or not the coding was consistent and comprehensive.
Disagreements were resolved through discussion. The remainder of the interview transcripts were then
analysed in the same vein.
Once all the coding was completed, Olga Klein and Roshan das Nair met again to confirm the thematic
structuring of the data. Again, any disagreements were resolved through re-examining the data and its fit
in the framework matrix and through discussion. Finally, Olga Klein and Roshan das Nair met with our PPI
co-applicant (and co-interviewer) to share the coding and thematic structure and to have a general ‘sense
check’ of our interpretation and structuring of the data. Some minor modifications were made as a result
of this consultation.
Quality considerations
We followed published criteria in relation to ensuring rigour in our analysis and the quality of our
presentation.140 We have fully described our approach and methods for replicability, we have considered all
aspects of every transcript and included ‘negative’ cases where we have found them, and we used multiple
coders and checks to ensure that the coding was consistent and did not privilege any one point of view.
Results
Details of interview participants are given in Table 17.
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TABLE 17 Interview participant demographic characteristics
Interview
ID Interviewer Site Group Gender Ethnicity
Years of
education
(n)
Year
diagnosed Type of MS
2 SE 1 Intervention Female White 11 2007 Secondary progressive
3 OK 1 Intervention Male White 18 1992 Relapsing–remitting
4 OK 1 Intervention Female White 14 2015 Relapsing–remitting
5 OK 1 Intervention Female White 11 2008 Relapsing–remitting
6 SE 2 Intervention Female White 13 2003 Relapsing–remitting
7 SE 2 Intervention Female White 13 1986 Secondary progressive
8 OK 2 Intervention Female White 14 2003 Relapsing–remitting
9 SE 2 Intervention Female White 13 2007 Relapsing–remitting
10 SE 3 Intervention Female White 17 2003 Secondary progressive
11 SE 3 Intervention Female White 17 1987 Relapsing–remitting
12 SE 3 Intervention Female White 18 1996 Relapsing–remitting
13 SE 3 Intervention Female White 35 2010 Relapsing–remitting
14 OK 4 Intervention Female White 10 1987 Secondary progressive
15 OK 4 Intervention Male White 20 1990 Relapsing–remitting
16 OK 4 Intervention Male White 16 2013 Relapsing–remitting
17 OK 4 Intervention Female White 16 2010 Relapsing–remitting
18 OK 5 Intervention Female White 11 1998 Secondary progressive
19 OK 5 Intervention Male White 12 2000 Relapsing–remitting
21 SE 1 Control Male White 11 2012 Primary progressive
22 SE 1 Control Female White 12 2009 Secondary progressive
23 SE 1 Control Female White 16 2011 Relapsing–remitting
24 OK 1 Control Male White 17 2015 Relapsing–remitting
25 SE 2 Control Male White 12 2012 Relapsing–remitting
26 SE 2 Control Male White 12 1985 Relapsing–remitting
27 OK 2 Control Female White 15 1992 Secondary progressive
28 SE 2 Control Female White 17 2013 Relapsing–remitting
29 SE 3 Control Female White 10 1986 Relapsing–remitting
30 OK 3 Control Female White 11 2014 Primary progressive
31 OK 3 Control Male White 11 2009 Relapsing–remitting
32 OK 3 Control Female White 13 2011 Relapsing–remitting
33 OK 4 Control Female White 13 2011 Secondary progressive
34 OK 4 Control Male White 16 2004 Relapsing–remitting
35 OK 4 Control Female white 11 1999 Relapsing–remitting
36 OK 4 Control Female white 11 2008 Secondary progressive
37 OK 5 Control Male white 12 2011 Relapsing–remitting
38 OK 5 Control Female white 12 2012 Secondary progressive
ID, identification; OK, Olga Klein; SE, Susan Evans.
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Thirty-six participants, 24 women and 12 men (18 from the intervention and 18 from the control groups),
were interviewed. All self-identified as being of white British ethnicity. The mean age of the participants was
50 years (SD 9.13 years, range 26–70 years). They had an average of 14 years of education (SD 4.55 years,
range 10–35 years). Two-thirds of participants had relapsing–remitting MS [n = 23 (64%)], just under
one-third had secondary progressive MS [n = 10 (28%)] and three (8%) had primary progressive MS. In
terms of time since MS diagnosis, this varied from 3 to 32 years. Interviews lasted between 6 and 59
minutes, with most interviews lasting ≈30 minutes.
In the following sections, we outline the various themes elicited from the data, and offer illustrative quotations
from the interviews. Each quotation is followed by a unique participant identification (ID) number. When
relevant, we have provided a segment of the conversation between the participant (P) and the interviewer (I).
As per our methods, the themes map onto the initial framework that relate to the specific foci of our research,
but additional themes were added when we felt that there were substantial data to support these themes.
Each theme has a number of subthemes. These subthemes relate to various aspects of the theme, and some
subthemes are broken down further into subtheme categories (when data were available) to provide further
nuance to the subtheme. Table 18 lists these themes, subthemes and subtheme categories.
TABLE 18 Themes
Theme Subtheme Subtheme categories
1. Management of cognition before
the CRAMMS trial
1.1 Advice received 1.1.1 None
1.1.2 External memory aids
1.1.3 Information about MS on websites/
leaflets/booklets
1.2 No cognitive rehabilitation
1.3 Self-generated strategy use
2. Perceived cognitive changes 2.1 Improved
2.2 Stayed the same
2.3 Worsened
3. Perceived mechanism of change
of cognitive function for
intervention group
3.1 Increased strategy use 3.1.1 Repetition and habit formation
3.1.2 Improved confidence and mood
3.1.3 Selective and adapted strategy use
3.1.4 Increased activity in daily life
3.2 Psychoeducation 3.2.1 Acceptance of cognitive problems
3.2.2 Theoretical understanding of cognition
3.3 Effect of group format 3.3.1 Being understood
3.3.2 Sharing of experiences and ideas
3.3.3 Social aspect
3.3.4 Altering perspectives
3.4 Workbook 3.4.1 Enabling homework activities
3.4.2 Useful in combination with group sessions
3.4.3 Useful for notes and reminder of contents
3.4.4 Used as reference after intervention
continued
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Management of cognition before the CRAMMS trial
Advice received
None
The majority of participants had not received any advice about managing attention and memory problems:
No I haven’t really only – the only time I’ve ever talked to anybody about it was when I went to
the meetings.
ID 02
No, not really. I’ve just been carrying on with my day-to-day way I deal with things.
ID 03
One interviewee mentioned that they had seen a neuropsychologist about 10 years ago for cognitive tests,
but not rehabilitation:
Just a test, yep, to say you’ve not imagined it.
ID 10
Participants believed that they did not receive cognitive rehabilitation for a few reasons. One reason was
that they did not initially see cognitive problems as being directly associated with MS; therefore, they did
not bring it up in consultation with health-care practitioners:
I just always thought I had a bad memory. From when I was younger I just always thought I had a
bad memory.
ID 36
Another reason was that other symptoms, such as fatigue and mobility limitations, were the focus of
annual reviews and these symptoms were managed first, whereas cognitive problems were ignored.
Mh, I am going to the hospital quite regularly, but it’s looking at my lung functioning not my memory.
ID 23
TABLE 18 Themes (continued )
Theme Subtheme Subtheme categories
4. Additional reasons for adherence
to intervention and trial
4.1 Improvements seen in daily
life activities
4.2 Positive appraisal of therapist
skills
4.3 Suitability of venues
4.4 Having cognitive assessments
4.5 Possibility of receiving
cognitive rehabilitation
4.6 Altruism
5. Possible improvements 5.1 Refresher/booster sessions
5.2 Option to download
workbook
5.3 Adding mindfulness to help
focus?
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External memory aids
Some participants who brought up the issue of having cognitive problems at annual clinical reviews or
hospital visits did receive advice on managing their cognitive problems, such as keeping a diary/calendar
and using Post-it® notes (3M, Cynthiana, KY, USA). This advice was mostly focused on external memory
aids rather than internal memory aids:
. . . very, very little [advice on cognitive rehabilitation]. I know that I have been given advice,
that was all, erm just advice that says keep a diary, a to-do list and take notes from your fridge
[tape notes to your fridge]. It was just, you know, er A4 side of what things might help with memory.
ID 10
One participant stated that she had received advice from a MS nurse specialist and an information pack
from day 1 when she was diagnosed (ID 09).
Information about cognitive problems in multiple sclerosis on websites/leaflets/booklets
Some participants said that they were signposted to relevant information in the form of leaflets, booklets
or online resources:
P (ID 22): Erm, just a booklet really, erm, from the MS nurse on memory and, erm, concentration.
One of the m – m – is it MS society?
I: Yeah.
P: Like leaflet things.
I: Yes, yes and, erm, have you – have you managed to look through that and follow any of it? Has any
of it been useful?
P: Erm, it is when I can read properly ‘cause [. . .] You know when I’m reading to you [. . .] I tend to
either read the same lines or soon as I’ve read it, it’s like, ‘what’ve I just read?’
I: Yeah, yeah.
P: So you – you’re constantly going back on yourself. So things don’t tend to sink in.
However, as this interaction suggests, merely providing workbooks or information about memory aids
without additional support is unlikely to be helpful for people with MS, particularly because of their
cognitive problems.
No cognitive rehabilitation
Besides the information given about external memory aids, no participants received any other form
of cognitive rehabilitation:
Well no, b– but, er, apart from that, my – my usual care is just my annual review . . . Where the doctor
sort of talks to me about how I’m feeling and sort of has a bit of a look at my sort of, um, motor function,
if you like. Watch me walk, look you know . . . Checks my reflexes and what have you. And – and that,
that’s the only sort of usual care apart from – from going to the – on the CRAMMS [. . .] that I received.
ID 02
No, not a single thing.
ID 16
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Self-generated strategy use
Generally, the majority of participants used external memory aids before they were recruited to the trial.
These strategies included writing lists, keeping a calendar with appointments, and asking family members or
friends to remind them of appointments or tasks they needed to complete. These tasks were self-generated,
in that participants decided to try them out themselves:
Well, as I said, I did already, um, have – use lists for everything [. . .] And, erm, just to not get upset by
it really [. . .] (and look after) myself.
ID 02
You know, erm, yeah. I write on my hand, if there’s some emergency, if an appointment I have to
keep physically.
ID 10
Participants changed tack when they found that some of the strategies they were accustomed to were no
longer providing them with the results they expected:
So, ‘cause that [writing lists] was sort of starting to not work, erm, I’ll say to my friend I’m like,
‘Can you remind me?’
ID 22
Perceived cognitive changes
Improved
All six interviewees who stated that their cognitive abilities had improved over the previous 6 months were
from the intervention group:
I think I’ve improved.
ID 12
I say that the CRAMMS has helped.
ID 07
I think that actually since I’ve been on – on the CRAMMS sort of meetings, they’ve [cognitive
problems] improved.
ID 02
Stayed the same
Some participants from both the control and intervention groups stated that their cognitive abilities had stayed
the same over the previous 6 months. However, the numbers of those in the intervention and control groups
endorsing this view differed: 11 participants from the intervention group and six participants from the control
group. Furthermore, although participants in the intervention group reported that their cognitive abilities had
stayed the same, they did feel that they managed better (using strategies) as a result of the intervention:
No, I don’t think so. I don’t think they’ve [cognitive problems] got any better or any worse, about the
same. It’s just that I’ve put strategies in place to help me with those things.
ID 04
No. I don’t know. I don’t know [whether cognitive problems have got better or worse]. Since I’ve been
able to do, since being on the course thing, . . . I’m able to remember . . . that I just could not before
. . . so that’s really good.
ID 14
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I think I’m remembering a bit more than I was before. But a lot of it is just writing things down, doing
different things.
ID 16
What is interesting about these quotations, all from participants from the intervention group, is that
although they reported not knowing or not thinking that their cognitive problems had reduced, they do
report improvements in daily life (‘I’m able to remember’, ‘I’m remembering a bit more than I was before’).
However, they minimise the impact of these changes because they are using cognitive strategies to
compensate for their deficits (‘It’s just that I’ve put strategies in place’, ‘But a lot of it is just writing things
down’). Thus, they do not see this as improvement.
However, by contrast, those in the control group only reported not seeing any change over time:
I don’t think so, no. It might be slightly worse but nothing major. I’ve not noticed anything major.
ID 32
No, about the same.
ID 35
Actually, they probably stayed the same, to be honest.
ID 28
Worsened
Thirteen participants stated that they thought that their attention and memory had worsened; of these,
all but one were in the control group:
. . . I’m forgetting more and more.
ID 31
Yes, it’s definitely got worse, yeah.
ID 36
Er, yeah, erm, my memory is getting worse definitely. I forget things within, within moments really.
ID 25
Many of these participants used words like ‘definitely’ to indicate that they had no doubt that their
cognitive abilities had deteriorated. One person from the intervention group reported a worsening of their
cognitive abilities:
I think they [cognitive problems] have got worse. [. . .] I am struggling with things, like I said, at work.
And I am being now – I’m being performance managed because I am struggling because of my memory.
ID 08
Perceived mechanism of change of cognitive function for
intervention group
For those who felt that there was an improvement in their cognitive ability or reduction in their cognitive
problems, we were interested to know what could have caused these changes. All these participants were
in the intervention group. Participants referred to increased strategy use; improved awareness of their
cognitive problems (psychoeducation) and, thereby, improved acceptance; the positive effects of the group;
and the workbook as potential causes of the positive changes they observed. We outline each of these
perceived mechanisms.
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Increased strategy use
All participants in the intervention group reported that they were using significantly more strategies as a
result of the cognitive rehabilitation programme. Although several were using external memory aids prior
to joining the programme, the majority reported that they were using considerably more internal memory
aids after the intervention, to help them to memorise things and forget less. Some of the strategies that
participants adopted were putting things in the same place (e.g. keys, mobile phone, wallet), using
descriptions when they could not recall the name of an object, using pictures to recall events or things,
grouping items on a grocery list (vegetables, fruits) and making little stories about things they wanted to
remember.
We investigated further why they were using more strategies after having attended the intervention groups.
Repetition and habit formation
Participants highlighted that the repetition of using different strategies helped them to keep the strategies
‘in their head’, resulting in a behaviour change:
To try and help myself ‘cause they’re sort of in your head, you don’t forget them. Because we did –
we did them for so long – we did them week after week for 10 weeks. And – and once you’ve done
things so often you sort of use the same – or –or similar technique and – and new ones. You add to
them and – and then you go back and review them. But – but by the time you’re done with it – it –
it’s set into your long-term memory so you don’t forget it so it – you – it – it’s just there in your head;
well, this is the way my mind works [. . .].
ID 02
I think it’s some of the techniques, repeating things over or going over things over and over again and
making stories. I just tend to go over it in my head so after a while it tends to sink in a lot more. It’s
just through techniques I am using a lot more. That’s helping a lot.
ID 16
Behaviour change was also attributed to habit formation:
Yeah, I try and put things in the same place when I, so when I go to bed at night, I put my phone
in one place, my wallet in a different place. But they’re always in the same place so in the morning
I know where I’m supposed to be looking for them and picking them up. Things like that I think are
helping me.
ID 15
Improved confidence and mood
Some participants attributed their increase in strategy use to improved confidence and mood. Participants
reported having an increase in confidence to tackle different tasks in daily life. One participant stated that
she was nervous when she found out that she was assigned to the intervention group because she was
never a ‘very confident person’. However, when she felt that she was among the best in the intervention
group at performing certain tests (as part of the intervention) and she felt that she was improving,
her self-confidence developed:
Yeah, it did boost my self-esteem so much and it made me feel a lot more positive about;
it did help me. Yeah, I’ve got memory problems, but that does not mean, you know, yeah I’m
(almost forget) people, yes I’m useless. It just means, yeah, erm, I can say, er, I have psoriasis
on my scalp [. . .] You know, it’s just another little hiccup in my life. My confidence has increased
so much.
ID 10
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Yes, definitely. That’s [memory exercises and using different strategies] helped me a lot, yeah.
I feel a lot more confident in a lot of things now trying to solve things and stuff like this
[participant talking about feeling more confident to approach other problems he comes across
in daily life].
ID 16
For some participants, the improved confidence was not directly attributed to attending the intervention,
but because of changes they had made to their lifestyle, such as exercising:
I feel I am more confident because I didn’t used to be very active before. But I do go to the gym once
a week. Even though I’m not very mobile, they’ve set me up with a session because I’ve improved in
certain areas in my session at the gym. I’ve actually asked them if there’s something else I can try out.
So I’m trying to better myself all the time going to the gym. Now that the weather is better, I do tend
to just have a little walk round . . . but I tend to use my walker and just walk round once a day, just a
bit of exercise, and that helps me gain confidence as well.
ID 05
Participants not only stated that they felt more confident, but they also experienced fewer negative
feelings as a result of forgetting, as the strategies they learned helped them to remember more:
Yeah, I found it [the intervention] really, really useful. To make me feel less worried about th– I’m –
I’m not saying that I worried unduly, but I did have some concerns. I think it really eased my concerns.
[. . .] I’ve been better really because I’ve been less sort of anxious, if you like.
ID 02
Selective and adapted strategy use
Participants noted that they adapted some of the strategies they learnt to make these strategies work for
them. In addition, some participants noted that some of the strategies were not as useful as others, and
they would only use the strategies that suited them:
And I have taught myself, different la– erm, language strategies of remembering words and when I
don’t have the precise words, huge vocabulary, I can carry on talking and come up with some of it
that I can in moderate enough to be and . . .
ID 10
Participant talking about the group sessions: [. . .] It’s about putting things in boxes and trying to
remember them in a list. So, which is about learning the different techniques – or the best techniques
that work for yourself. I mean not everybody, I don’t suppose everybody using the same techniques
when we have left the class. I just used the ones that I have found that were really good for me like,
you know, chunking and the diary and you know, putting stuff on my phone and then doing the
same things with the keys and the bags and then if I have got something, you know when the phone
rings and I have got to remember to give someone a message then I write it down and obviously pass
the message on.
ID 18
Some strategies were not considered useful for some participants:
Some of the techniques that we were talking about for me didn’t work. So I put those on the
side burner.
ID 03
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No, there was nothing I didn’t like about them [group sessions], they were all fine and, although I may
not do some of the things, it’s probably I discarded them at the time because I didn’t think they would
help me or I didn’t see them being useful for me.
ID 17
Psychoeducation
Participants commented that the intervention provided them and their families with information and
support to accept, better understand and cope with their cognitive problems.
Acceptance of cognitive problems
Some participants reported feeling that they were ‘going mad’ because they noticed their cognitive
problems but were not certain what caused them, and others reported that their family did not take them
seriously when they shared their concerns about their cognitive problems:
Erm, because I have accepted it [cognitive problems] so I don’t get frustrated, so I don’t use the energy
for frustration. And to be able to accept it, I think you need to be able to go through a process which
we know. But if I know what’s wrong, I can then accept, I can treat and then I can sort of move on
with my life; where[as], other people, they don’t want to know; out of sight, out of mind. I don’t
really want to know, but I need to know so I can address my issues and problems.
ID 13
This participant highlighted the importance of knowing what the problems were so that she could accept
them, and then take the necessary action.
One participant reported that only his wife knew about his cognitive problems and that he had tried to
hide these problems from his family and friends, prior to receiving the intervention:
No, it’s not the case no more. I’m quite open with it [cognitive problems] now and my wife said I’m
getting better anyway with remembering things.
ID 16
Another participant talked about how her husband’s behaviour had changed after he found out that she
really did have cognitive problems:
Erm, the action if you like, he [husband] was sort of like more, ‘mm, yeah we do have a problem, do
you?’ . . . So they [family] think you’re either making it up or you’re going over the top or to, to be
invited to CRAMMS was very significant for me because then that showed my family I had a problem.
ID 7
Theoretical understanding of cognition
Participants stated that the theoretical session of the intervention was useful to them because it helped
them to understand and visualise what was happening:
. . . I understand a bit more now why it’s [cognitive problems] happening and where it’s happening
and stuff, yeah. It’s great to learn.
ID 16
[. . .] and also having theoretical background for the workbook. So, you know, for somebody, I think
that’s what I’s trying to say, so the theoretical background was really interesting to me. Look at how
we are actually, erm, are made and why we forget, why, erm, you know, why we need to practice,
erm, and just reinforcing [. . .]
ID 13
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Effect of group format
All participants reported that the group format was a very useful aspect of the intervention. Participants
commented that sharing experiences and giving advice in a group setting was very helpful to them. In
addition, learning about other people’s issues made participants feel relieved that they were not the only
ones who experienced these problems, and they felt comfortable to share their experiences because they
felt understood by the others in the group.
Sharing of experiences and ideas
Participants reported that the most valued aspect of being part of a group was that of being able to
share experiences with others who were in a similar situation. Some such sharing related to the general
experience of having cognitive problems, but, in some instances, participants also spoke about the value of
sharing ‘ideas’ and offering and receiving ‘advice’ from the others:
The most useful thing to me was the opportunity to actually share experiences with other people.
And other people, they would give a little bit of advice, you know, what they’ve come across themselves
and share that experience with other people. And I think it was good for other people to be able to
share their experiences with us. So it was just communicating with other people in the group, which I
thought was really good. But that was one of the best things, being able to speak with other people.
ID 05
And it’s just nice to have people who have got the same disability just talking about their issues,
talking about some things they have to go through. Often it was very humorous, very funny.
ID 03
Can’t tell you how helpful it was [being in a group], just to meet other people going through similar
things, that we, we’ve all been there and we could all say to each other, ‘yeah I felt stupid but I found
this way’, and, and, just sharing our ideas and stories was wonderful.
ID 10
And, um. . .but it was just sort of, you felt as though you’d got somebody there that you could talk
to anything about, you know, somebody to call on and um [. . .] and help really. [. . .] Because I yeah
– I – I would recommend it to anybody, I really would. I thought it [joining the group] was absolutely
the best thing I could’ve done.
ID 02
Being understood
Being understood by others was a very important aspect for the participants, who sometimes felt that
others who did not share their condition or problems did not understand how it felt to forget and not
remember in specific situations:
As – as I say so that you don’t feel like you’re all on your own and you’ve got these problems and
nobody understands.
ID 02
I think, in terms of the sessions themselves, it’s being with other people who are suffering from the
same condition and being able to talk to them about the problem you have, particularly on the
memory side, and the likeness that we all had in terms of our ability to remember things was
quite marked.
ID 03
And hearing other people’s problems as well, it wasn’t just me.
ID 16
DOI: 10.3310/hta24040 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 4
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Lincoln et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Social aspect
For some participants, the groups offered them a social space to connect with people and make new friends:
Yeah, I’ve met one of the ladies from the group. We’ve met for lunch and we’re trying to get the
others [in the group] together as well, but I feel like we all know each other, to a limited extent, and it
would be nice now to get to know the others better.
ID 04
And you can sort of relate to them and even pick up a phone now and we made good friends, erm
[. . .] Also that has been good.
ID 06
Altering perspectives
A few participants voiced initial concerns over being with other people with MS who had more severe
visible symptoms, because it worried them about their own future:
It was [useful to be with other people with MS], but it was distressing because they were different
various, erm [. . .] So seeing other people which might have got tremors, it was, it’s new sort of
experience to see people and thinking ‘oh, gosh, is that something that might come to myself?’ and
people with more walk, err, difficult – walking difficulties.
ID 13
However, this participant also found a positive aspect to being with a more disabled group of people:
On the other side of the coin, you can look and think, ‘well, I am fortunate’ and so I suppose it’s
double-edged really [. . .] So . . . it’s not a disadvantage, it’s, it’s, – it’s an eye opener and it, – it’s also,
erm, don’t know, it’s, it’s rationalising and sort of thinking ‘well, you know that doesn’t necessarily
have to be yourself’, and just so I suppose, do I isolate myself from the symptoms that could be, erm,
but it’s useful to see how people manage when they have got worse symptoms, so it is, it is a positive
really, in a way.
ID 13
Another participant also found this shift in perspective by recognising how well they were in comparison
to others, but also recognising that, even with severe disabilities, people had learnt to cope:
I suppose there were a couple of people who were more disabled than I was (and so I hadn’t realised
there was one gentleman who wasn’t able to write very well. But he was able to use his smartphone
to remind himself about things, appointments he had to go to, so that really worked well for him.)
Yeah, so it made me appreciate how well I am compared to a lot of people.
ID 04
Workbook
We enquired about how participants made use of the workbooks they were provided with as part of the
intervention. Participants made use of the workbook in different ways.
Enabling homework activities
Overall, most participants found that the workbook enabled them to complete their homework activities:
It [workbook] was really helpful and obviously I came away with my little booklet which we did the
little tests [homework activities] every week.
ID 02
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[. . .] it was the workbook, it was ex, – sort of experimenting with workbooks, coming back with the
homework, and also having theoretical background for the workbook.
ID 13
Useful in combination with group sessions
Although participants stated that the workbook was useful for the take-home activities, they felt that
the workbook alone, in the absence of the group sessions, may not have been as useful. During the
intervention, the workbook was useful as a reference point and served as a reminder of the content
of the sessions:
It was good with the combination of the intervention as well, because you can see what you’re
talking about.
ID 17
I think you need both the workbook and the intervention.
ID 04
Useful for notes and reminder of contents
While still in the intervention programme, participants also stated that they used the workbook to make
notes about the session, and to refer back to what they had learned in each session, or to use it to
prepare for upcoming sessions. They appreciated its simplicity:
[. . .] and, you know, sort of our answers and notes and what have you, and I’ve got that, you know,
that I can to refer back to and – and I just, you know, even though it was quite simple things,
I mean you need, you need simple things, you don’t want it to be too complex do you otherwise . . .
You know, some people might, er, not understand it or they might find it difficult. But it was just
really – I thought it was just really useful. Really, really useful.
ID 02
Yeah, at the time, I found it [workbook] particularly useful. Yes, because after the weekly session,
I could get back and think about what we’d done over a couple of days and try and remember
what we’ve been doing.
ID 15
So it was really good for something to refer to and know what you’re going to be talking about.
ID 05
Used as reference after intervention
Some participants reported that they had used the workbook as a refresher following completion of the
intervention. Others had not used the booklet since the intervention ended, but reported that it felt good
knowing that they had it with them in case they needed to refer to it:
[. . .] And since then [after the intervention], I’ve had another look over it [workbook] a few times
just to remind me of what we were doing. So, yeah, it was good.
ID 15
Yes, I still refer to it [workbook] now and look over things and stuff now, so yeah, it was
very helpful.
ID 16
Yes, and, – and I can refer back to that [workbook], err, and oh and that really, erm, so I think
that’s really useful [. . .].
ID 13
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Additional reasons for adherence to intervention and trial
Participants in the intervention group felt that they benefited from the cognitive rehabilitation sessions;
therefore, they adhered to the intervention. This was particularly in terms of improvements seen in
daily life activities. However, participants in both the intervention and control groups mentioned
additional reasons for adherence to the intervention and the trial. For those in the intervention group,
participants appraised the therapists’ skills as well as the venues where the cognitive rehabilitation
sessions took place.
Improvements seen in daily life activities
Participants in the intervention group reported that they had increased the level and types of activities they
were involved in:
Yes, I think, remembering, erm, much more detail about things, and attacking, – attacking things,
if that makes sense.
ID 10
Rather than me just sitting and thinking about things, it’s [the intervention] made me more active.
Rather than thinking about something, it’s a case of rather than thinking I’ll do that later, I now think
I’ll do that now. [. . .] So it’s made me get up and go really.
ID 05
I’ve started doing things myself more [. . .] I play games. It tends to helps me, certain games, trying to
remember things and I’m writing things down more and I’ve got diaries and tend to use my phone
a lot more now. My social life, I tend to spend a lot more time going to places now than my wife.
I’ve just joined up as a member of the Man[chester] United fan club so I tend to go to a lot of football
matches every other week. I tend to go to Liverpool to see my family and different things like that.
And just spending time with the kids really, doing things with the kids.
ID 16
Positive appraisal of therapist skills
Many participants commented on the skill with which the therapists facilitated the group:
But I think the ladies [therapists], there were two of them over the 10 weeks who did it, who work for
the CRAMMS units, were very good. They really were good at what they did, and they put the whole
idea of the process to us very clearly and very succinctly, so I was very happy with that.
ID 03
No, I mean, no, the whole – as I said to you – the whole experience, I don’t think you could have
done it any better. [. . .] And it was made really interesting [by the therapists] by having flip charts and
you know things – there were little exercises that we could do that really were interesting. So, I think
the whole experience was quite enjoyable.
ID 18
Suitability of venues
Although the venue was dependent on the site the participant was recruited from, most participants
stated that the venue was easy to get to and that it was appropriate for them:
Lovely premises, oh thank you very much. For the rented room, oh yeah. They’ve got a balls room and
oh, it was just beautiful. Erm, we were all these professionals, sat round this big posh table with these
lovely chairs.
ID 10
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Although some participants who used wheelchairs found that some venues were not easy to access,
most participants found them easy to find and get to by public transport:
. . . there’s a taxi company that I use all the time. And they took me all the time and picked me up.
Because I’ve got quite a good rapport with the taxi company, they’re always there to support me
anyway. So I didn’t have any problems getting there [venue] at all.
ID 05
Having cognitive assessments
Participants in both the intervention and control groups mentioned that it was good to have the cognitive
assessments completed both at baseline and at follow-up assessments. This allowed them to get an accurate
idea of their cognitive abilities and profile:
I think it [cognitive assessment] highlighted certain issues I was not quite happy with in the first place,
so it was good to actually do that, to do the study [. . .] With neurological things, you need to test
yourself and see what your capabilities are with certain things. So it’s always good to test you. I quite
enjoyed that, not enjoyed as such, because certain things I think I don’t like doing that but you have
to do it. It was good to try them.
ID 34
It was just me and one other – she came to my house and did tests on me. Yeah that, yeah, and that
took about – she came twice. [. . .] Yes, they [cognitive assessments] were very helpful, yes.
ID 38, talking about being in the control group
Possibility of receiving cognitive rehabilitation
Participants joined the trial with the expectation that, if they were allocated to the intervention group, this
might be of benefit to them:
I was rather pleased I was in that [intervention group], because I thought, if you’re in a control group,
there’s nothing going to make you improve. If you’re in the intervention group, there’s a chance that
you’ll improve through the intervention.
ID 15
Actually, I was really looking forward to it, because I felt it was a chance to meet up with other people
and for us to actually share our experiences together. So it was one of those times where you could
actually speak to other people as well. So I was really looking forward to it. And I was really pleased
when I was nominated to be on it.
ID 05
I was happy that I was going to get help [. . .] talking to different people that have got the problems
I have. I think being there [in the intervention] helped a lot. I learned quite a lot from there so it’s not
like, even though I wasn’t expecting much from it, but it helped in a way that I knew people out there
were trying to do stuff and it, like, encouraged me to try and do more there as well. It made me feel a
lot better.
ID 16
Altruism
Participants reported that, although they preferred to be part of the intervention group, they recognised
the need for some people to be in the control group. For such participants, it was a sense of altruism that
motivated them to join the trial and remain in it even when they were allocated to the control group:
I understand that [there had to be a control group]. That [being part of the intervention group] was the
only thing I would say that would have helped me. I’m fine being in either group just to try and help
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and everything, but, yeah that [not being part of the intervention group] was the only thing really. That
[finding out that he was part of the control group] was fine. I don’t mind because as long as I can help
in some way, that’s why I do these trials, to help further with MS and help whatever way I can.
ID 24
Possible improvements
Although most participants did not feel that the intervention needed further improvements, a few
participants did suggest some improvements that could be made.
Refresher/booster sessions
Some participants felt that a refresher/booster session would have been useful at a later point because
they felt that the 10 weeks went by quite quickly. A few such sessions, they felt, would enable them to
sustain what they had learnt:
But I’m just trying to think whether there could be anything else just to keep it going for a short, not
another 10-week course or anything like that, just something that could have followed it up. Perhaps
another meeting or another two meetings just to go through it again and even think of anything new
that might come up in terms of techniques.
ID 03
Option to download workbook
Some participants also suggested that it would be useful to have access to the workbook online, but also
reiterated the importance of having someone to go through the workbook with them:
I think it would [be a good idea to have a downloadable workbook], but I think it would have made a
lot more sense for someone to explain it when you couldn’t understand certain things.
ID 16
But we ask, erm, that if there is a workbook that could be printed on the web, on the NHS, you know on
the website, that will be able to help people, the research programme. It will be useful for people to dip
in and look at memory issues and how they can be addressed and how they can probably manage them,
yeah so that would be useful [. . .] Yes, I don’t know whether its licensed or not, but it would be really
useful, erm, yeah. No I think it, I think, – I think it would be a shame to lose that effort of compiling it and
the knowledge that was used to do it, and the fact that I felt that, for me personally, I really benefited
from it and, – and use it on a daily basis, and now its hardwired with myself and equally for any others,
erm, you can. ‘Cause, er, lots of people have memory problems, you don’t just have to have MS.
ID 13
Adding mindfulness to help focus
Two participants highlighted the importance of mindfulness and how it could help participants to be more
in the ‘here and now’ and focus on the things they are doing. They felt that it would help to incorporate
this aspect into the intervention programme:
Having mindfulness to call is really useful to keep focus on what your aim is to do, so that’s where I
come with that really . . . ‘cause, I think, I think that if we all, well I don’t mean that I’m like a Buddha,
but if we [are] all calm and serene and the, we not on edge or we not all frustrated, we, we just
accept, erm where we are, a bit like acceptance and commitment therapy really, where we accepting
what is happening to us, err, or, yeah, we accept what’s happening to us and then the different stage
down the line, we know how to accept that second stage, we know and it continues, and so I think
that, errm, part of that is having all the tools if you want to use in your tool bag.
ID 13
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I don’t really utilise them [strategies to compensate for cognitive problems] as I should do really. I know
deep down I should literally pause and think about it and just clear my mind and use mindfulness and
stuff like that, but in the grand scheme of things I don’t as such. I’m fully aware I can do more.
ID 34
Discussion
Cognitive rehabilitation does not appear to be provided as part of routine care for people with cognitive
problems associated with MS. Although some participants received some ‘advice’ to help them with their
cognitive problems, this was limited to providing them with some suggestions of external memory aids to
use and signposting to other resources. This cannot be considered cognitive rehabilitation. Indeed, none of
the participants had received any cognitive rehabilitation and, for all of those who received the intervention,
it was the first time that they were systematically taught about cognition, why they were experiencing
problems and what they could do to address and manage the cognitive problems.
Some participants had developed their own strategies for coping with the cognitive problems they faced;
this was limited to using a few external memory aids, such as lists, using a calendar and requesting others
to remind them to do things. There was no suggestion that participants spontaneously used any internal
strategies or ways to improve their concentration or reduce distractions.
Participants in the control group did not report any reductions to their cognitive problems, and, in fact, were
certain (using words such as ‘definitely’) that their cognitive problems had got worse. Most participants in the
intervention group, however, reported benefiting from having attended the cognitive rehabilitation groups.
Even when participants felt that their cognitive abilities had remained the same since they were enrolled in
the trial, they did acknowledge that their cognitive problems in daily life had reduced. The significance of
this, however, was somewhat minimised in participants’ accounts because they were using strategies to
compensate for these cognitive deficits. This was clearly highlighted in their talk, in which they justified their
talk using phrases such as ‘it’s just that I’ve put strategies in place’ or ‘it is just writing things down’.
The majority of participants who had received the intervention did feel that their cognitive problems had
reduced. Their attributions for this change are similar to those found in extant cognitive rehabilitation
literature in MS136 and other acquired brain injuries.61,137 Participants had a sense that one reason that they
saw this change was because of an increase in their use of strategies to compensate for their cognitive
deficits. Increased use of these strategies was as a result of these strategies having become habitual to
individuals, participants’ improved confidence and mood and the selective use of the strategies with
necessary adaptations to suit individuals’ daily lives.
Participants recognised the role of psychoeducation in providing them with better knowledge and
understanding of their problems, and associated with it an acceptance of their problems and a desire to
act or change things. They therefore saw strategy use as a way to make these necessary changes.
Most participants also commented on the role the group format of the intervention had to play, in terms
of the positive changes that they had observed in themselves. The group served as an arena where they
could share their experiences of having MS and cognitive problems, and share ideas about how to manage
these problems. Participants felt that the group understood them, when others, including family members
and friends, could not. The groups also offered them an opportunity to connect socially with others and
make new friends. Some people were initially concerned about being part of a group of people with
different stages of MS and severity of MS symptoms, where they felt that they would be distressed by
what their own futures may look like. However, these concerns abated over time; in fact, the diversity
in the group allowed those who had less severe problems to reconsider the impact of their symptoms,
recognising that they were better off than some others. For this group of people, it was also beneficial for
them to see that people, despite their severe symptoms, were coping well.
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Most participants found the workbook useful. It helped them during the cognitive rehabilitation sessions
because they could annotate it with additional notes; it helped them to complete their homework activities
and to review and prepare for the next session. The workbook was also found to be beneficial after the
rehabilitation programme had ended, because it served as a useful reference for people to return to at a
later date. However, all participants were certain that the workbook was useful only if used or if provided
as part of the whole package of cognitive rehabilitation, including the group work.
Participants in the intervention group remained in the group sessions and the trial because they felt that
they benefited from the intervention. However, another reason why this group remained in the trial was
because of the therapists who facilitated the group sessions, who were seen to be highly skilled to deliver
the cognitive rehabilitation. Most also found the venues easy to get to and accessible; however, this was
not the case with some wheelchair users.
For both participants in the intervention and control groups, having the cognitive assessments at baseline
and follow-up was a motivator to remain in the trial. They felt that such assessments allowed them to
understand and monitor their cognitive deficits better.
Finally, although most participants did not find anything that they would like to change about the
intervention, some participants had some suggestions to improve the intervention. They felt that refresher
or booster sessions would be useful to help them maintain the gains they made from the cognitive
rehabilitation. Some participants wanted the option of downloading or viewing the working book online.
They felt that this would reach a wider audience. Two participants also felt that adding a ‘mindfulness’
component to the intervention would help people to focus on the ‘here and now’.
The interviews were conducted by two people: a PhD student and a PPI partner, who is the mother of a
person with MS. Although there were some differences between the interviews and how participants
responded to the interviewers, there were no major differences in how much participants disclosed with
either interviewer. We also did not feel that there was any difference in participants’ willingness to share
information with either interviewer. Some participants disclosed more than others, but this was the same
for both interviewers. The interviews were of similar length. There were no differences in the quality of
the data that were generated. Participants did ask different types of questions depending on who the
interviewer was. The PPI partner was asked about her daughter by a few participants and how she was
doing, whereas participants interviewed by the PhD student asked more research and treatment-related
questions towards the end of the interview, when participants were asked whether or not they had any
additional comments. The themes elicited were, therefore, consistent across interviewers.
The findings from this trial must be viewed in light of its methodological limitations. It is probable that the
overwhelmingly positive response participants had to the trial and the intervention could be attributed
mainly to a sampling bias, in that, only those who had a positive experience agreed to be interviewed.
However, the data do suggest that participants were willing and able to be open about their experiences,
with some clearly mentioning that their memory problems had stayed the same or got worse. Participants
also made comments on potential improvements that could be made to the trial and the intervention.
All participants were white British; therefore, the sample was not heterogenous in terms of gender. We
were limited in terms of seeking out non-white participants, because the sample for the interview study
was drawn from the wider RCT in which only 4% of participants were non-white, reflecting the low
incidence of MS in those from some non-white communities.141 We did, however, attempt to vary the
selection as much as we could by seeking individuals with different self-reported cognitive impairment
levels and other demographic characteristics (such as gender, age, time since diagnosis and type of MS).
Participant accounts of their experiences were retrospective, so some details may have been forgotten or
misremembered. This is particularly relevant for this patient group who have memory problems. However,
the depth of the interview data and the lack of inconsistencies in the talk (even when probed) would
suggest that participants were able to recall their experiences relatively well.
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The interviews were conducted over the telephone, as opposed to being face to face. Therefore, the visual
nuances associated with participants’ talk were not available to the interviewers. These cues may have
been useful in exploring aspects of the talk in which a discrepancy was seen between the words and the
manner in which they were articulated. However, the analysts did pay attention to intonation and phrasing
of the interviewees’ talk, and made note of this, when relevant, to aid interpretations. Furthermore,
telephone interviews also have their advantages over face-to-face interviews, over and above the practical
aspects of conducting such interviews (e.g. reduced costs, increased geographical reach and ability to
make notes unobtrusively). For instance, a review of the use of telephone interviews in qualitative
research142 noted other benefits including allowing participants to be in their own space (which is
particularly important for people with MS who may have mobility issues), decreased social pressure and
allowing greater anonymity.
Given that cognitive rehabilitation is a complex intervention and includes several components with various
interconnecting parts,143 it is difficult to define with precision the active ingredients and how these relate to
each other.144 However, the outcomes of the feedback interviews indicate that it is likely to be an interplay
between the factors that were identified.
DOI: 10.3310/hta24040 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 4
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Lincoln et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63

Chapter 6 Economic evaluation
Parts of this chapter have been reproduced from the CRAMMS trial protocol.65 This article is distributedunder the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Study question
The aim of the economic evaluation was to assess the cost-effectiveness of cognitive rehabilitation for
attention and memory problems in addition to usual care when compared with usual care alone in people
with MS.
Selection of alternatives
The economic evaluation used the cognitive rehabilitation intervention in addition to usual care versus
usual care alone as the competing alternatives. These are described in Chapter 2.
Evaluation methods
An economic evaluation was undertaken alongside the clinical trial. A cost–utility analysis (incremental
cost per QALY gained) was conducted using the EQ-5D-5L results at 12 months as the primary outcome
for the economic analysis. A cost-effectiveness analysis was undertaken using the primary clinical outcome
(incremental cost per point improvement in the MSIS-Psy score) at 12 months. Decision-analytic modelling
was not undertaken to extrapolate the trial results to a longer-term horizon to explore longer-term
cost-effectiveness (see Results of model-based analysis for longer-term cost-effectiveness).
The trial methodology is described in detail in Chapter 2; only the methods and results specific to the
economic analysis are described in this chapter. A health economic analysis plan was produced alongside
the SAP and finalised with the trial team before completion of data collection. Table 19 summarises the
methods used for the base-case analysis and subsequent sensitivity analyses, which are discussed in more
detail in the following sections.
Effectiveness data
The economic analysis used the primary clinical outcome (MSIS-Psy score), as summarised in Chapter 2,
in a cost-effectiveness analysis. The EQ-5D-5L and MSIS-8D (Multiple Sclerosis Impact Scale – 8 Dimensions;
derived from the MSIS, as described in Benefit measurement and evaluation) were used for cost–utility
analyses. Cost-effectiveness was evaluated at the primary end point of 12 months and at 6 months to
evaluate any short-term effects of cognitive rehabilitation.
Benefit measurement and evaluation
Quality-adjusted life-years were generated using utility scores derived from the EQ-5D-5L index. The
EuroQol-5 Dimensions (EQ-5D) is a standardised instrument for use as a measure of HRQoL.106 The study
employed the five-level version of the questionnaire (EQ-5D-5L). Individual-level utility scores were obtained
at each assessment point using the EQ-5D-5L questionnaire. In August 2017, NICE issued a position
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statement advising that the five-level valuation set for England is not recommended for use in deriving
utility values and instead advise that the validated mapping function to the three-level version be used
for reference-case analysis.145 The utility scores derived from the direct valuation set for the five-level
version were used in a sensitivity analysis. Utilities were summarised and QALYs for each participant in
the intervention and control groups were calculated over 6 and 12 months using the area under the curve
approach (assuming linear interpolation). The mean difference per participant in QALY gain/loss between
the cognitive rehabilitation and usual-care groups is presented over 6 and 12 months.
The Multiple Sclerosis Impact Scale (MSIS-29) was used to derive the MSIS-8D using published methods.146
MSIS-8D is an 8-dimensional (general physical function, mobility, employment, social function, fatigue,
cognition, depression and general emotional well-being) HRQoL measure used to produce a MSIS-8D utility
score. Each item of the MSIS-8D has four levels, describing 65,536 health states. A descriptive analysis of
MSIS-8D responses was undertaken; the responses were summarised and used to generate QALYs at 6
and 12 months.
The primary outcome for the CRAMMS trial was the psychological impact of MS on everyday life,
as a reflection of HRQoL measured using the MSIS-Psy, version 2.0. As higher scores indicate greater
psychological impact of MS on everyday life; an improvement would be represented by a negative
difference in the MSIS-Psy score.
TABLE 19 Summary of methods used in the health economic analysis
Aspect of methodology Strategy for base-case analysis
Alternative strategy for sensitivity
analysis
Data set All randomised participants, analysed on an
intention-to-treat basis
ACA
Health outcome measurement EQ-5D-5L (administered at baseline, 6 months
and 12 months), mapping to three-level
valuation set
l EQ-5D-5L (administered at baseline,
6 months and 12 months),
mapping to five-level valuation set
l MSIS-8D
Clinical outcome measurement l Primary trial outcome at 12 months
l Secondary trial outcomes presented in a
cost–consequences analysis
l 6 months
l Not applicable
Costs included in analysis l Intervention cost (excluding cognitive
assessment)
l Health and personal social services costs
including primary care, secondary care and
medication costs
l Inclusion of cognitive assessment
l Medication costs amended to
exclude those that are classified as
disease modifying
Missing data Multiple imputation ACA
Adjustment for baseline
covariates
Regression used to adjust outcomes for
differences at baseline. Adjusting for baseline
covariates should also improve the precision
of the between group estimate
No adjustment for baseline covariates
Base-case analysis l Incremental cost per QALY gain at
12 months
l Incremental cost per improvement in
MSIS-Psy score at 12 months
l At 6 months
l At 6 months
ACA, available-case analysis.
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Costing
The perspectives taken were the UK NHS and Personal Social Services. Individual-level resource use was
collected from the UHSSQ, summarised in Chapter 2.
The data collected were the costs of:
l the CRAMMS trial intervention (including training, implementation and delivery costs)
l health-care resource use (primary and secondary care) and personal social services
l medications.
All resource use data were valued in Great British pounds using published unit costs147–149 at 2017 prices.
When current unit costs were unavailable, the most recently available costs were used and inflated to
2017 prices using the Hospital and Community Health Service index.149
Intervention costs
Resource use resulting from the implementation of the CRAMMS trial intervention (including materials,
consumables, staff time and training) was estimated through interviews and direct communications with
clinical staff involved in the trial and the trial team, and by using data collected during the trial (e.g. supervision
records). No travel costs were included for training or delivery of the CRAMMS trial intervention because,
in routine clinical practice, cognitive rehabilitation training would be delivered at the base site of the clinical
psychology team.
The resource use and costs associated with the delivery of the CRAMMS trial intervention were estimated
from published sources and discussion with the trial team. Unit costs of materials and consumables were
obtained directly from financial records collected by the trial team. Staff costs were obtained from published
unit costs.147 The costs of additional catch-up sessions delivered to participants who missed one or more
previous sessions were based on the assumption that these required 30 minutes and were delivered as a
group, rather than on an individual basis.
The assumptions were made from consulting with clinical experts on the trial team and the impact on the
results was tested as part of the sensitivity analysis. For the base-case analysis, the costs of the cognitive
assessment to determine eligibility for the CRAMMS trial were excluded as these were assumed to be part
of usual care. The impact of including the cognitive assessment as part of the CRAMMS trial intervention
was tested in a sensitivity analysis.
Costs of health-care and Personal Social Services resource use
Health-care resource use [including primary care consultations, accident and emergency (A&E) visits,
outpatient appointments and inpatient stays] and Personal Social Services use (e.g. home adaptations)
were collected using data from a health and social services questionnaire that had been developed and
used in a previous MS trial.107 Information was collected at baseline, and at 6 and 12 months’ follow-up to
assess the difference in profile of health-care resource use in the intervention group compared with the
usual-care group.
Costs were assigned using published unit costs.147–149 Outpatient visits and inpatient stays were costed
individually according to the reasons for health-care contact, length of stay and specialty/department
visited recorded in the UHSSQ.
A description of unit costs associated with health and personal and social care resource use are presented
in Appendix 13, Table 42.
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Costs of medications
Participants were asked to recall the medications (including drug name, dosage and frequency) they had
used over the previous 3 months at baseline and at follow-up assessments. The UHSSQ did not specify
when medication was started or stopped, or how long the medication had been taken for. It was assumed
that the medication was taken or used for the whole 3-month period [or, when applicable, the prescribed
length from the British National Formulary (BNF)149]. This may have overestimated the cost of medications
for some participants, but accounts for non-compliance to the length of prescription in both the usual care
and the cognitive rehabilitation groups. For medications with multiple indications from the BNF,149 an
assumption was made regarding the most probable indication applicable to the patient group or most
common indication for the general population. Clinical members of the trial team checked all medication
data and assumptions made before analysis.
The health-care costs in both the intervention and control groups were summated and presented for each
of the time points with differences in resource utilisation between the CRAMMS trial intervention at 6 and
12 months calculated, using methods consistent with the statistical analysis of outcomes (as described in
Chapter 2). The difference per participant in costs (including 95% CIs) was calculated, using non-parametric
bootstrapping.
Missing data
Issues concerning missing data are particularly prevalent to health economic analyses. Missing items
relating to health-care resource use may undervalue costs, whereas missing outcome data may be
intrinsically linked to effects. Missing data may relate to item non-response, where a questionnaire is
partially incomplete, or unit non-response, where all information is missing.150
Missing questionnaire items in outcome measures
Partially completed questionnaires for the health outcomes used in the economic analysis were handled
and the total score was calculated using the same approach as in the statistical analysis (see Chapter 2).
If the number of missing items exceeded that for which total scores were calculable, the questionnaire was
treated in accordance with unit non-response procedures. Any missing items in the EQ-5D-5L descriptive
questionnaire were not individually imputed; utility values were instead imputed in accordance with unit
non-response procedures.
Missing baseline data
If baseline scores for the outcome measures remained missing (e.g. the questionnaire was not usable, even
taking into account the above rule for missing data), data were imputed using the mean baseline score at
each study site. This enabled all participants to be included in the regression analyses of the outcome
score, ensuring consistency with the statistical analysis. These simple imputation methods are superior to
more complicated imputation methods when baseline variables are included in an adjusted analysis to
improve the precision of the treatment effect.116
Missing outcome data at follow-up
For the base-case health economic analysis, data were assumed to be missing at random (MAR). Multiple
imputation using chained equations was undertaken to impute missing items. Imputations were combined
following Rubin’s rules.151 Owing to the predefined range of outcome scores, including utility derived from
the EQ-5D-5L, truncated regression methods were used to ensure that imputed values were consistent
with the valid range. Predictive mean matching (PMM) was used to impute missing cost data, ensuring
that imputed values were consistent with observed data.
An available-case analysis (ACA) was conducted on both outcomes and costs as part of a sensitivity
analysis. ACA is generally biased under MAR or missing not at random assumptions, with the ACA mean
unbiased only if missingness in the parameter of interest is independent of its value. ACA examined the
robustness of conclusions from the imputed data compared with those from the observed data, after
conducting the procedures outlined in handling missing questionnaire items.
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Missing service use data
The UHSSQ was used to estimate the resources used and costs of health service usage by participants
because of MS. Participants were asked to complete the relevant boxes with the number of contacts
received over the previous 3 months for each item, or to place a ‘00’ in the relevant box should no usage
of this item have occurred. Item non-response may, however, represent either the individual failing to
record the non-zero number of contacts or no contact. Missing UHSSQ data were thus treated according
to the following rules:
l If one or more items were completed (values of ‘0’ or greater) on the UHSSQ, then the questionnaire
was assumed to be fully completed and any missing items were imputed with zeros.
l If the UHSSQ was marked as ‘not done’ or otherwise fully incomplete, appropriate imputation methods
were used. At baseline, data were imputed using the site mean akin to the process outlined above. At
the 6-month and 12-month follow-ups, data were imputed using multiple imputation or ACA methods,
with imputation conducted on the total for each contact type (e.g. general practice and community
services, social services, medications).
Because of the typically skewed distribution of cost data, in which the UHSSQ was marked ‘not done’,
PMM was used to impute missing costs under multiple imputation using the methodology outlined in
Missing service use data.
Adjustments for timing of costs and benefits
As the trial period did not exceed 12 months, discounting was not applied to the within-trial analysis of
either costs or outcomes.
Cost-effectiveness analyses
Cost–utility and cost-effectiveness analyses were undertaken to estimate the incremental cost per QALY
gained and the incremental cost per improvement in MSIS-Psy score based on the primary clinical end
point at 12 months. The multiple imputation approach to missing data for costs and QALYs was used for
the primary cost–utility analysis. For the cost-effectiveness analysis, a similar methodological approach to
the statistical analysis outlined in Chapter 3 was conducted to ensure consistency with the analysis and
reporting of the primary outcome.
Results of the comparative analysis of incremental costs and effects can be summarised in terms of ICERs.
An ICER can be represented as:
ICER =
C1−C0
E1− E0
=
ΔC
ΔE
, (1)
where C1 and E1 are the costs and effects of the intervention arm, C0 and E0 are the cost and effects
of the control arm and ΔC and ΔE are the incremental costs and effects of the intervention compared with
the control. For the cost–utility analysis using QALYs, ΔE > 0 would represent an improvement favouring
the intervention group. For the cost-effectiveness analysis on the MSIS-Psy, higher scores represent a
greater psychological impact of MS on everyday life; therefore, ΔE < 0 would represent an improvement
favouring the intervention group.
If the intervention is less costly and more effective than usual care, then the intervention is classified as
dominant and no ICER would be calculated. Conversely, if the intervention is more expensive and less
effective than usual care, the intervention is considered to be dominated by usual care. ICERs are
calculated when a trade-off between cost and effect is evident, for example when the intervention is more
costly but generates an improved health effect (QALY gain) compared with usual care.
The ICER is reported to determine the cost-effectiveness of cognitive rehabilitation compared with usual
care and to aid decision-making. NICE reports a base cost-effectiveness threshold of £20,000 per QALY,
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but cost-effectiveness is a spectrum rather than a dichotomy, with the threshold changing according to the
circumstances. The ICERs are presented to assist with the decision-making process and are not an absolute
statement on whether or not the intervention can be deemed cost-effective. No established willingness-
to-pay (WTP) threshold for the MSIS-Psy or other secondary outcomes is available.
Net monetary benefit (NMB) was also calculated. NMB is a summary statistic that represents the value of
the intervention in monetary terms when a WTP threshold for a unit of benefit is known.152 NMB for the
cognitive rehabilitation and control groups is based on the following equation:
NMB = ΔEλ − ΔC, (2)
where ΔE and ΔC represent the change in effects and costs and λ represents the WTP threshold.
Incremental NMB was calculated as the difference in NMB between the intervention and usual care
groups. If the incremental NMB is positive, the intervention can be identified as cost-effective at the given
WTP threshold relative to usual care.
Allowance for uncertainty
Sensitivity analyses were undertaken to account for the uncertainty in the parameters used in the cost-
effectiveness analyses. Deterministic one-way sensitivity analyses (OWSAs) were undertaken to examine the
impact of changes in key parameters on ICERs by modifying the value of one parameter at a time within a
plausible range (e.g. upper/lower 95% CIs, ±30% to key parameters). A threshold analysis was conducted
to determine the required changes to affect base-case findings (e.g. changes in QALY gains to provide a
cost-effective result).
Bootstrap resampling was undertaken to analyse the joint uncertainty of parameter estimates. A minimum
of 1000 resamples was used. The results of the probabilistic sensitivity analysis are illustrated using
cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs). The probability that the
intervention is cost-effective at various WTP thresholds was examined and expressed as a percentage.
Where dominance is observed, the probability of dominance is presented.
Subgroup analysis
In the health economics plan, subgroup analysis was to be conducted only with sufficient evidence
obtained from the exploratory analyses of interaction for the primary outcome (see Chapter 3) to justify
further investigation on the cost-effectiveness findings. The trial team concluded that no subgroup analysis
was required.
Longer-term cost-effectiveness
It was originally proposed to construct a decision-analytical model to extrapolate the findings from the trial
to estimate the cost-effectiveness of cognitive rehabilitation compared with usual care beyond the trial
horizon of 12 months. The modelling exercise was based on extrapolating the results from the within-trial
analysis to longer-term cost per QALY estimates supplemented with data sources from the literature and,
when necessary, clinical opinion from the trial team. A model plan is presented in Appendix 14, Figure 11.
Results
The costs for the economic evaluation consisted of two broad categories:
1. the implementation and delivery of the group-based cognitive rehabilitation programme
2. health and personal and social care resource use.
Intervention costs
The resource use and associated costs of delivering the intervention are summarised in Table 20;
a detailed account of each component is presented in Appendix 15, Table 43. The primary analysis was
conducted excluding costs associated with cognitive assessment, which the trial team agreed to be
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incurred by both usual care and cognitive rehabilitation groups. The total cost of cognitive rehabilitation
was calculated at £209.
The main cost drivers of the intervention cost were training, the delivery of the sessions, supervision and
administration. One clinical psychologist (band 8a, £62 per hour) delivered the training across all sites to APs
(band 5, £33 per hour, one per site) on a one-to-one basis. Training was assumed to require 4 hours. No
provision was included for travel costs and room hire associated with training as, in standard practice, this
would take place on NHS premises. As detailed in Chapter 2, an AP delivered 10 cognitive rehabilitation
sessions to each group individually. Each session lasted for approximately 1 hour and 30 minutes. An additional
30 minutes was required for both set-up and close-down; provision for 30-minute catch-up sessions was
included for 137 of 450 sessions for those participants who missed one or more sessions previously.
To ensure that cognitive rehabilitation was delivered appropriately, provision for supervision is included in
the cost of the intervention. Each AP routinely received supervision sessions with a clinical psychologist
lasting 1 hour on a weekly basis, of which it was assumed that 30 minutes was attributable to the delivery
of cognitive rehabilitation.
The delivery of cognitive rehabilitation required one administrator to set up each group, send invitations to
participants and send reminders of upcoming sessions. It was assumed that an administrator (band 3, £25
per hour) would be required for 30 minutes per session. Additional costs of stationery, refreshments and
providing an intervention manual to each participant were included.
Cognitive assessment is used to determine patient eligibility for cognitive rehabilitation and was a key cost
driver in providing the intervention. From discussions with the TMG and clinicians, it was determined that
cognitive assessment would form part of usual care and was not exclusive to the intervention group. This
may differ on a site-by-site basis. It was decided that cognitive assessment would not be included in the
primary analyses, but would be included in the sensitivity analyses.
TABLE 20 Resources and costs associated with the delivery of cognitive rehabilitation
Resource area Resource
Intervention
total (£)
Training Training in cognitive rehabilitation provided by clinical psychologist
to AP
1900.00
Delivery of cognitive
rehabilitation
Sessions delivered by AP 39,385.50a
Supervision conducted by clinical psychologist 2375.00
Administration 5625.00
Intervention manual 500.00
Stationery 245.00
Refreshments 1225.00
Total cost of cognitive rehabilitation (excluding cognitive
assessment)
51,255.50
Total cost of cognitive rehabilitation per participant
(excluding cognitive assessment)
209.21
a Inclusive of 30-minute catch-up sessions for 137 of 450 sessions.
Notes
Based on 245 participants, across 45 groups, receiving 10 cognitive rehabilitation sessions across five sites.
A total of 450 sessions were delivered.
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Resource use and costs
The resource use for available cases is presented in Appendix 16, Tables 44–46. Resource use costs were
summarised by:
l general practice and community nursing services
l hospital and community services
l therapy services
l social services
l A&E services
l other hospital services
l medications.
The key cost drivers for this group of participants were medications, and social services; however, for each
component of the resource use questionnaire, outliers had a substantial impact on the mean value, with a
few high-cost users increasing the average cost, resulting in high SDs. t-tests on differences between
groups for each component of resource use were typically not statistically significant.
At 12 months, the cognitive rehabilitation group had medication costs that were £320.45 cheaper (95% CI
–£928.61 to £287.71) than the medication costs of the usual-care group; however, the usual-care group had
a much larger SD and a maximum medication cost of £34,929, compared with a maximum of £7395 for the
cognitive rehabilitation group. Similarly, at 6 months, the cognitive rehabilitation group had medication costs
that were £313.55 cheaper (95% CI –£860.86 to £233.77) than those of the usual-care group. However,
the usual-care group had a much larger SD and a maximum medication cost of £26,516, which was over
three times larger than the maximum medication cost for the cognitive rehabilitation group.
Excluding the costs of disease-modifying therapies resulted in a small increase in the difference in medication
costs to –£332.33 (95% CI –£812.80 to £148.14) at 12 months, and a reduction at 6 months to –£181.13
(95% CI –£522.38 to £160.12); at both follow-ups the difference was not statistically significant.
Multiple imputation was used to impute missing costs. Imputation was performed on total costs for unit
non-response after the procedures outlined in Chapter 2 regarding item non-response were performed.
The multiple imputation results in Table 21 show that, at 6 months, cognitive rehabilitation had total
costs of £3144 and was about £20 cheaper than usual care. However, the difference was not statistically
TABLE 21 Multiply imputed total cumulative costs
Trial group Baseline, mean (SD), n 12 months, mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: total cumulative costs at 12 months
Usual care 3068.32 (224.48), 204 6092.01 (630.07), 204 –574.93 (–1878.93 to 729.07) 0.39
Cognitive rehabilitation 3271.68 (327.76), 245 5623.67 (391.38), 245)
Panel B: total cumulative costs at 6 months
6 months, mean (SD), n
Usual care 3068.32 (224.48), 204 3115.49 (313.36), 204 –19.91 (–777.13 to 737.31) 0.96
Cognitive rehabilitation 3271.68 (327.76), 245 3144.40 (251.12), 245
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline costs, gender, MS type and site as covariates.
Reproduced with permission from Lincoln et al.122 This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
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significant, with wide CIs observed. At 12 months, the mean total costs associated with cognitive
rehabilitation were £5623; the difference between the two groups increased at 12 months, with cognitive
rehabilitation about £575 cheaper than usual care. This indicates that cognitive rehabilitation was
cost-saving compared with usual care; however, the differences in costs were not statistically significant
at either 6 months or 12 months, with wide CIs at both follow-ups.
Further analysis was conducted to explore the drivers of costs in the two groups. Figure 3 presents a
histogram of cumulative total costs for available cases at 12 months by intervention group.
Figure 3 shows that at 12 months approximately 40% of participants in both the cognitive rehabilitation and
usual care groups incurred total costs of ≤ £2500. Similarly, > 75% of participants in both groups incurred
costs of ≤ £10,000. A few participants incurred costs in excess of £20,000, of whom nine were in the usual-
care group and five were in the cognitive rehabilitation group. No participants in the cognitive rehabilitation
group had costs in excess of £30,000, whereas there were two notable outliers in the usual-care group,
with costs of £53,784, and £81,074. These outliers were investigated further. The participant with total costs
of £53,784 incurred £24,809 in medication costs at both 6 months and 12 months, attributable to daily
administration of teriparatide (Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA). The participant with
total costs of £81,074 incurred £77,250 of costs due to 30 nights spent on a hospital ward as a planned
admission (based on NHS reference costs148 for elective inpatient medical care of patients with MS). Two
further participants in the usual-care group had total costs at 12 months in excess of £30,000. Excluding
these two outliers from the ACA (see Appendix 17, Table 47) reduces mean total costs for the usual-care
group to £5849.49 (SD 6190.98) and the adjusted difference in total costs is –£38.85 (95% CI –£1162.14 to
£1084.45) (i.e. cognitive rehabilitation was slightly cheaper than usual care).
Outcomes
Utility values derived from EQ-5D-5L and MSIS-8D scores were converted into QALYs using linear
interpolation and the area-under-the-curve method, with adjustment for baseline covariates including
baseline utility, gender, MS type and site. In accordance with the methods for total costs, multiple
imputation was used to impute missing outcome data for utility scores derived from both the EQ-5D-5L
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FIGURE 3 Histogram of cumulative total costs at 12 months. (a) Usual care; and (b) cognitive rehabilitation.
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and the MSIS-8D. Multiple imputation was performed on items for which utility scores could not be
calculated after the item non-response procedures detailed in Chapter 2 were performed. Results are
presented in Table 22.
Table 22 shows the EQ-5D-5L scores at baseline and at 12 months. The mean utility value was slightly
higher in both groups at 12 months than at baseline; however, there was no evidence of an observable
QALY gain as a result of cognitive rehabilitation compared with usual care. The CIs ranged from –0.02 to
0.02, with no statistically significant difference between the two groups. Similar results were observed for
EQ-5D-5L scores at 6 months.
We also examined HRQoL derived from the MS-specific MSIS-8D instrument using the modelling
methodology presented by Goodwin et al.146 Results are presented in Table 23.
TABLE 22 The QALYs derived from the EQ-5D-5L at 12 months
Trial group Baseline, mean (SD), n 12 months, mean (SD), n
Adjusted difference
in means (95% CI)a p-value
Panel A: EQ-5D-5L QALYs at 12 months
Usual care 0.57 (0.02), 204 0.58 (0.02), 204
Cognitive rehabilitation 0.60 (0.02), 245 0.60 (0.02), 245 0.00 (–0.04 to 0.05) 0.91
QALY gain 0.00 (–0.02 to 0.02) 0.91
Panel B: EQ-5D QALYs at 6 months
6 months, mean (SD), n
Usual care 0.57 (0.02), 204 0.57 (0.02), 204
Cognitive rehabilitation 0.60 (0.02), 245 0.60 (0.02), 245 0.01 (–0.03 to 0.05) 0.59
QALY gain 0.00 (–0.01 to 0.01) 0.59
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline EQ-5D-5L utility, gender, MS type and site as covariates.
TABLE 23 The QALYs derived from the MSIS-8D at 12 months and 6 months
Trial group Baseline, mean (SD), n 12 months, mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: MSIS-8D QALYs at 12 months
Usual care 0.51 (0.01), 204 0.52 (0.01), 204
Cognitive rehabilitation 0.53 (0.01), 245 0.56 (0.01), 245 0.02 (–0.01 to 0.05) 0.19
QALY gain 0.01 (–0.01 to 0.03) 0.19
Panel B: MSIS-8D QALYs at 6 months
6 months, mean (SD), n
Usual care 0.51 (0.01), 204 0.54 (0.01), 204
Cognitive rehabilitation 0.53 (0.01), 245 0.57 (0.01), 245 0.03 (–0.00 to 0.06) 0.06
QALY gain 0.01 (–0.00 to 0.01) 0.06
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline MSIS-8D utility, gender, MS type, and site as covariates.
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Table 23 shows the MSIS-8D scores at baseline and at 12 months. The mean utility value was slightly
higher in both groups at 12 months than at baseline. There was a numerically small QALY gain of 0.01
(95% CI –0.01 to 0.03) in the cognitive rehabilitation group compared with the usual-care group. A small
baseline imbalance in MSIS-8D scores was noted, with the cognitive rehabilitation group having a slightly
higher utility score than the usual-care group, and was included as a covariate in the analysis model.
There was no statistical difference in QALY gains between the two groups. At 6 months, utility values in
both groups were higher than at baseline, with a larger increase observed for the cognitive rehabilitation
group than for the usual-care group. The adjusted difference in means for MSIS-8D and QALY gains,
favouring the intervention group, was nearly statistically significant. This corresponds with the results for
the MSIS-Psy in Chapter 3, with statistical significance observed at 6 months but not at 12 months.
The cost–utility analysis required the calculation of ICERs using the total costs and outcomes presented in
Tables 21–23. The results for the cost–utility analysis are presented in Table 24.
Table 24 requires careful explanation. Cognitive rehabilitation shows numerical differences in costs at 6
and 12 months compared with usual care. With no evidence of any incremental effect on QALY gain
between the groups (when the EQ-5D-5L is used), cognitive rehabilitation could be considered to be less
expensive against no difference in effect (QALY gain) than usual care. When the MISIS-8D was used to
generate QALYs, there was a numerically small QALY gain in cognitive rehabilitation compared with usual
care, which (technically) presents cognitive rehabilitation as dominant over usual care (i.e. cognitive
rehabilitation is less expensive and has a greater effect). A similar picture is presented when available cases
are used to generate QALYs (EQ-5D-5L or MSIS-8D; see Appendix 17). For the MSIS-Psy, the negative
effect is representative of an improvement for the cognitive rehabilitation group. This would, again,
present cognitive rehabilitation as dominant over usual care for the primary outcome. However, across all
scenarios, the CIs for both incremental costs and incremental effects span zero, and for the costs, CIs are
wide. Given this, caution should be applied in interpreting these results.
Cost-effectiveness planes and associated CEACs were constructed using non-parametric bootstrapping
(5000 replications with replacement) for the primary and secondary cost–utility analyses (cost per QALY)
derived from the EQ-5D-5L and MSIS-8D, respectively.
TABLE 24 Multiply imputed ICERs (cost per QALY gain)
Outcome measure Incremental cost (95% CI) (£)
Incremental effect
(95% CI) ICER
EQ-5D-5L QALY
6 months –19.91 (–777.13 to 737.31) 0.00 (–0.01 to 0.01) Intervention dominant.
No ICER calculated
12 months –574.93 (–1878.93 to 729.07) 0.00 (–0.02 to 0.02) Intervention dominant.
No ICER calculated
MSIS-8D QALY
6 months –19.91 (–777.13 to 737.31) 0.01 (–0.00 to 0.01) Intervention dominant.
No ICER calculated
12 months –574.93 (–1878.93 to 729.07) 0.01 (–0.01 to 0.03) Intervention dominant.
No ICER calculated
MSIS-Psy
12 months –574.93 (–1878.93 to 729.07) –0.5 (–1.5 to 0.5) Intervention dominant.
No ICER calculated
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Cost-effectiveness planes and CEACs were also constructed for the multiple imputation analysis on EQ-5D-5L
and MSIS-8D QALY gains, and for the change in the MSIS-Psy. These are presented in Figures 4–6.
At 12 months, the cost-effectiveness planes (see Figures 4 and 5) show that cognitive rehabilitation was
less costly and more effective than usual care; the distribution of bootstrapped estimates are centred in
the south-east quadrant, which is consistent with the intervention dominating usual care. The estimates
for MSIS-8D are centred further eastwards than those for the EQ-5D-5L. As higher scores on the MSIS-Psy
indicate a greater psychological impact of MS on everyday life, a negative incremental effect represents an
improvement in favour of cognitive rehabilitation, with the interpretation of the cost-effectiveness plane
reversed on the x-axis compared with the analysis of QALY gains. The cost-effectiveness plane in Figure 6
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FIGURE 4 Total costs and EQ-5D-5L QALYs at 12 months (multiply imputed analysis). (a) Cost-effectiveness plane;
and (b) CEAC. Reproduced with permission from Lincoln et al.122 This article is distributed under the terms of the
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has the largest proportion of estimates in the south-west quadrant; this is, again, consistent with the
intervention being more effective and less costly than usual care.
The CEACs in Figures 4–6 show a high probability that cognitive rehabilitation was cost-effective compared
with usual care at WTP thresholds of between £0 and £100,000 per QALY gain. For QALYs derived from the
EQ-5D-5L, cognitive rehabilitation has an 84.8% probability of being cost-effective at a WTP threshold of
£20,000 per QALY gain, and an 85.7% probability of being cost-effective at a WTP threshold of £30,000 per
QALY gain. In comparison, for QALYs derived from the MSIS-8D, cognitive rehabilitation has an 86.7%
probability of being cost-effective at a WTP threshold of £20,000 per QALY gain, and an 88.8% probability of
being cost-effective at a WTP threshold of £30,000 per QALY gain. For both HRQoL measures, the probability
that cognitive rehabilitation was cost-effective is very high at all WTP thresholds. For the MSIS-Psy, at a WTP
threshold of £20,000 per point improvement, cognitive rehabilitation had a 60.6% probability of being
cost-effective, and a 59.8% probability of being cost-effective at a WTP threshold of £30,000. However,
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FIGURE 5 Total costs and MSIS-8D QALYs at 12 months (multiply imputed analysis). (a) Cost-effectiveness plane;
and (b) CEAC.
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caution should be given to interpreting these thresholds for the cost-effectiveness analysis as no established
threshold exists for improvement in MSIS-Psy score.
Cost-effectiveness planes and CEACs were also constructed on multiply imputed data at 6 months to
investigate earlier effects of the intervention on HRQoL; results are presented in Figures 7–9.
At 6 months, the cost-effectiveness plane estimates in Figures 7 and 8 for the EQ-5D-5L and MSIS-8D are,
again, primarily clustered on the x-axis, and to the east of the y-axis. The distribution of bootstrapped
estimates for the MSIS-8D was slightly further east of the y-axis than for the EQ-5D-5L, consistent with the
greater level of effectiveness observed for the disease-specific measure of HRQoL. The CEACs show that,
at WTP thresholds of ≥ £20,000, a high probability of cost-effectiveness of cognitive rehabilitation is
observed. For the MSIS-Psy, (see Figure 9) the distribution of bootstrapped estimates is located mainly to
the west of the x-axis, consistent with the intervention being more effective than usual care. At a WTP
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FIGURE 6 Total costs and change in MSIS-Psy at 12 months (multiply imputed analysis). (a) Cost-effectiveness plane;
and (b) CEAC.
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threshold of £20,000, the intervention has an 83.9% probability of being cost-effective, which rises to
84.1% at a WTP threshold of £30,000.
Sensitivity analyses
To assess the impact of the base-case findings to both methodological and parameter uncertainty, a series
of sensitivity analyses were conducted, including an ACA and a multitude of OWSAs.
The base-case analysis used multiple imputation to address missing data for both costs and outcomes.
To examine the impact that imputation had on the findings, an ACA was conducted on the data directly
observable from the questionnaire responses. Tables summarising cumulative costs, and QALYs derived
from the EQ-5D-5L and MSIS-8D are presented in Appendix 17, Tables 47–49.
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FIGURE 7 Total costs and EQ-5D-5L QALYs at 6 months (multiply imputed analysis). (a) Cost-effectiveness plane;
and (b) CEAC.
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For available cases, Appendix 17, Table 47, shows that, at 12 months, the mean total costs associated with
cognitive rehabilitation [£5885 (n = 208)] were over £800 lower than those of usual care [£6574 (n = 170)].
Consistent with the primary multiple imputation analysis (see Table 21), this indicates that cognitive
rehabilitation was less costly than usual care. Again, the difference was not statistically significant, with
wide CIs observed.
The incremental cost-effectiveness analysis for the ACA is presented in Appendix 17, Table 50. For the
primary cost–utility analysis (incremental cost per QALY on EQ-5D-5L at 12 months) and all secondary
cost–utility analyses, negative incremental costs and positive incremental QALYs are observed.
0
– 0.10 – 0.08 – 0.06 – 0.04 – 0.02
(a)
0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16
In
cr
em
en
ta
l c
o
st
 (
£0
00
)
Incremental effect
– 4
– 3
– 2
– 1
1
2
3
0.0
0 10 20 30 40 50 60 70 80 90 100
0.1
0.2
0.3
0.4
0.5
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0.6
0.7
0.8
0.9
1.0
(b)
Value of ceiling ratio (£000)
FIGURE 8 Total costs and MSIS-8D QALYs at 6 months (multiply imputed analysis). (a) Cost-effectiveness plane; and
(b) CEAC.
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This is consistent with the multiple imputation analysis and represents dominance of the intervention, with
cognitive rehabilitation being less costly and more effective than usual care. As CIs for both costs and
QALYs span zero and are not statistically significant, the interpretation of cognitive rehabilitation as
cost-effective requires some caution. For the MSIS-Psy, negative incremental effects observed at 6 and
12 months are representative of an improvement in favour of the intervention group. The intervention
can therefore be considered dominant at both 6 months and 12 months; however, as noted in Chapter 3,
the difference at both follow-ups is not considered to be of clinical significance.
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FIGURE 9 Total costs and MSIS-Psy at 6 months (multiply imputed analysis). (a) Cost-effectiveness plane; and
(b) CEAC.
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Cost-effectiveness planes and CEACs were also constructed for the ACA on EQ-5D-5L and MSIS-8D QALY
gains. These are presented in Appendix 17, Figures 12–15. As observed for the multiple imputation analysis,
at 12 months, the cost-effectiveness planes (Figures 12 and 13) show that the distribution of bootstrapped
estimates were centred in the south-east quadrant, which is consistent with the intervention dominating
usual care. The estimates for MSIS-8D are centred further eastwards than those for the EQ-5D-5L.
Figures 12 and 13 show a high probability that cognitive rehabilitation was cost-effective compared
with usual care at WTP thresholds of between £0 and £100,000 per QALY gain.
Cost-effectiveness planes and CEACs were also constructed at 6 months to investigate earlier effects of
the intervention on HRQoL; the results are presented in Appendix 17, Figures 14 and 15. At 6 months,
the cost-effectiveness plane estimates in Figures 14 and 15 for the EQ-5D-5L and MSIS-8D are, again,
primarily centred in the south-east quadrant. Points are clustered closer to zero, with smaller incremental
costs and QALY gains than in the 12-month analysis. In addition, all four quadrants of Figures 14 and 15
are populated, indicating greater uncertainty regarding the cost-effectiveness of cognitive rehabilitation at
6 months. In accordance with the CEACs at 12 months, Figures 14 and 15 show a high probability that
cognitive rehabilitation was cost-effective at all WTP thresholds up to £100,000.
A series of OWSAs were undertaken to assess the impact of parameter uncertainty on the estimations of
cost-effectiveness. These sensitivity analyses were conducted on the multiple imputation data set, providing
an objective approach in handling uncertainty regarding missing data. The results are presented in
Appendix 18, Tables 51 and 52.
As the 95% CIs for both incremental costs and incremental effects span zero, the OWSAs for the EQ-5D-5L
QALY gains using a combination of these bounds provide four separate conclusions regarding the
cost-effectiveness of cognitive rehabilitation. At 12 months, using the lower bound for cost and the upper
bound for effect, intervention dominance is observed to be consistent with the base-case analysis, whereas
when using the upper bound for cost and the lower bound for effects, usual care is dominant. Using the
upper bound for both incremental costs and incremental effects produces an ICER of £31,055 per QALY
gained, whereas using the lower bound for both incremental costs and incremental effects produces an
ICER of £89,306 per QALY lost. Similar results are observed at 6 months and for the MSIS-8D at both 6 and
12 months. These sensitivity analyses emphasise that, despite the base-case analysis suggesting dominance
of the intervention, these results are subject to uncertainty and are not conclusive.
Including the cost of cognitive assessment increased the intervention cost from £209, used in the primary
analyses, to £333 (see Appendix 19, Table 53). At 12 months, the calculated ICERs for the QALYs derived
from both the EQ-5D-5L and the MSIS-8D continued to be representative of intervention dominance.
At 6 months, the inclusion of cognitive assessment resulted in an incremental cost of £104.09 (95% CI
–£653.13 to £861.31). When cognitive assessment was included as a component of the intervention and
used to estimate the incremental cost per QALY gain at 12 months using the EQ-5D-5L, an ICER of
£39,826 was calculated. The ICER for the QALYs derived from the MSIS-8D would be £14,559.
As noted in Resource use and costs, two notable outliers with total costs in excess of £40,000 at 12 months
were identified. Removing these two outliers from the ACA at 12 months reduced the incremental cost from
–£808.33 to –£38.85 (95% CI –£1162.14 to £1084.45). This illustrates that the two outliers have a large
effect on mean costs, despite not resulting in statistical significance. As cognitive rehabilitation continued to
be less costly than usual care, albeit this cost difference was considerably reduced, there is no change in the
interpretation in the ICER of intervention dominance.
Chapter 2 detailed the use of upper and lower 95% CIs for incremental costs and effects; we assessed the
impact of changes in key parameters to the ICERs.
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Results of model-based analysis for longer-term cost-effectiveness
The original trial protocol65 and health economics plan proposed a model-based analysis to evaluate the
longer-term cost-effectiveness of cognitive rehabilitation at horizons > 1 year. In the proposal, criteria were
determined to ensure that any model-based analysis would be rigorously undertaken and produce reliable
and informative estimates of the longer-term cost-effectiveness of cognitive rehabilitation. Given the results
of the within-trial analysis the conclusions are as follows:
l Cognitive rehabilitation does not show sufficient evidence of clinical effectiveness. Neither a statistically
significant nor clinically important difference was observed between the cognitive rehabilitation and
usual-care groups in the MSIS-Psy score at 12 months.
l Although the primary cost–utility analysis indicated that cognitive rehabilitation was dominant
compared with usual care, differences in costs and QALY gains were not statistically significant.
l There was a lack of available evidence for the longer-term effects of cognitive rehabilitation. Clinical
opinion deemed that, in the absence of any observed effect in the short term, no effect would be
observed in the long term, during which patients no longer received the intervention; therefore,
the decision was taken not to proceed with the model-based analysis.
l Although a robust mathematical model could be constructed, the data inputs would yield an
extrapolation of the within-trial results and not produce plausible, reliable or informative estimates
of the longer-term costs and consequences of cognitive rehabilitation.
One potential area of future consideration would be to re-examine the evidence in the light of extending
the meta-analysis reported in the Cochrane Review29,31 to include the CRAMMS trial findings. This would
provide more robust and reliable data to inform a model-based analysis in the future.
Discussion
A comprehensive economic evaluation was undertaken of cognitive rehabilitation for attention and
memory problems in people with MS. The analysis was designed and reported following recognised
standards.153 The economic evaluation was conducted alongside the main trial, which had high
methodological quality and rigour. This allowed for the economic analysis to benefit from the collection
of a range of resource use, clinical effectiveness and health utility information to inform future economic
evaluations in this area. A particular strength of the design is the use of the EQ-5D-5L and MSIS-8D
to assess the impact of using a generic-based HRQoL compared with deriving utilities from a
condition-specific measure for people with MS.
The results of the economic analysis are complex. Overall, cognitive rehabilitation was found to have
non-significantly lower costs at 12 months (–£575) than usual care, with no gain in QALYs (based on the
EQ-5D-5L) as a result of cognitive rehabilitation compared with usual care, that is the treatment groups did
not differ significantly in either costs or benefits. When the MSIS-8D was used as an alternative method for
deriving utilities, there was a numerically small, significant incremental QALY gain. In this scenario, this small
QALY gain (0.01) was not statistically significant. These results indicate that the intervention dominates
usual care; however, although cognitive rehabilitation is technically cost-effective, QALY gains were very
small and differences in incremental costs and incremental effects are not statistically significant. These
results are consistent with the analysis of the primary outcome, which also failed to observe a clinically
significant impact in the MSIS-Psy.
The probability of cognitive rehabilitation being cost-effective at 12 months at a societal WTP threshold of
< £20,000 per QALY was 84.8% and 85.7% (utilities derived from the EQ-5D-5L and MSIS-8D, respectively).
In the light of the results, further scrutiny is needed to ensure that such findings are appropriately interpreted
in the context of the main trial findings. Sensitivity analyses were undertaken to assess the impact of varying
the methods and parameters used in the evaluation. As the 95% CIs used to calculate the OWSAs span
zero, the incremental costs and effects resulted in varying interpretation of the cost-effectiveness of the
DOI: 10.3310/hta24040 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 4
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Lincoln et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
intervention, including scenarios of intervention dominance and usual care dominance. This further
highlights the uncertainty in the health economic results and the inability to draw decisive conclusions
regarding the cost-effectiveness of cognitive rehabilitation.
As previously reported, the MSIS-8D produced a slight, but statistically non-significant, QALY gain at
12 months (0.01, 95% CI 0.01 to 0.03; p = 0.19) for cognitive rehabilitation compared with usual care,
whereas the EQ-5D-5L produced no numerical change in QALYs at 12 months for cognitive rehabilitation
compared with usual care (0.00, 95% CI –0.02 to 0.02; p = 0.91). For both measures, the 95% CIs include
zero, indicating no difference in QALY gain between cognitive rehabilitation and usual care at 12 months.
A similar picture was shown for the multiply imputed and available-cases scenarios, suggesting that the
analysis was relatively robust to the methodological uncertainty utilised to derive utilities in the economic
analysis, with regard to QALY outcomes. Overall, cognitive rehabilitation made little or no impact on
QALYs gained as a result of the intervention compared with usual care. This is commensurate with the
main clinical findings, which found that cognitive rehabilitation did not confer a clinical benefit in
improving HRQoL for this group of people with MS.
The impact of cost presents a mixed picture, particularly in accounting for the impact of key cost drivers in
the overall results. As reported in the results, the largest health resource use and costs were incurred in the
last 6 months of follow-up. In the first 6 months of follow-up, cognitive rehabilitation was £20 (95% CI
–£777.13 to 737.31; p = 0.96) cheaper than usual care, whereas, at 12 months, cognitive rehabilitation
was £575 (95% CI –1878.93 to 729.07; p = 0.39) cheaper than usual care. When available cases were
examined, these differences in costs at follow-up showed a similar but greater pattern, with cognitive
rehabilitation £13 cheaper at 6 months, increasing to £808 cheaper at 12 months, than usual care. It is
important that further post hoc analysis does not violate or undermine the principles applied to the health
economic methods, particularly with respect to missing data. However, when the available cases were
examined in more detail to explore potential factors driving this cost difference, the impact of two extreme
outliers in the usual-care group was identified: one due to medication use to treat osteoporosis and one
due to an extended hospital stay. When these two outliers were removed from the analysis, the cost
difference was £39 (95% CI –£1162 to £1084) in favour of cognitive rehabilitation over usual care.
Although the finding that cognitive rehabilitation was less expensive than usual care remained robust,
there was uncertainty, introduced by wide variances in the figures, ranging from cognitive rehabilitation
being £39 cheaper than usual care on removal of two outliers in usual care who incurred large health-care
costs, to cognitive rehabilitation being £808 cheaper than usual care when all available cases were
examined. The variation in findings could result in different interpretations of the impact and magnitude of
the conclusion on any potential for cost savings as a result of cognitive rehabilitation compared with usual
care. The plausibility of cognitive rehabilitation having an impact on reducing resource use and costs over
the longer term should also be placed in the context that, although there was some evidence from the trial
that the programme improved HRQoL over the short term, these effects were not maintained over time.
In the light of the clinical findings, the lack of evidence of whether or not such a programme of cognitive
rehabilitation would result in longer-term clinical benefits and the conclusion from the trial team and TSC that
any longer-term modelling would not produce plausible, reliable or informative estimates of the longer-term
costs, further modelling would not add value to the analysis. This is a departure from the trial protocol and
was endorsed by the Health Technology Assessment (HTA) programme following a detailed explanation.
There are important limitations that are acknowledged. A health and Personal Social Services perspective
was employed that excluded wider costs, such as costs borne by other sectors, patients and family and
employers. Although employment status was captured in the trial, this was not further considered in the
economic analysis. However, changes in employment status and the MCSI score were not statistically
significant between groups (see Tables 9 and 10).
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Although the resource use measure had been developed and used in a trial of a similar population,107
a number of caveats must be recognised. The costing methodology considered service use over the
previous 3 months. As follow-up visits took place at 6 months and 12 months, any differences in costs
arising between 0–3 months and 6–9 months are unlikely to be adequately captured. A notable issue,
which has affected the explanation of the findings, is that the questionnaire did not consider medication
costs specific to the management of MS, other than being able to extract the impact of disease-modifying
therapies on health-care costs. Although the questionnaire tailored other health-care use to ‘as a result
of your MS’, data were not collected on the reasons for hospital stay, which, as shown in the analysis,
was high; thus, a unit cost specific to MS was applied. Although the resource use measure provided a
good basis given its use in a previous trial,95 further work to enable the collection of as accurate and
comprehensive resource use as possible balanced against the costs and burden of doing so should be
undertaken for similar trials in the future.154
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Chapter 7 Discussion
Context
This pragmatic trial was designed and conducted in response to a commissioned call for proposals
concerning cognitive rehabilitation for people with MS from the HTA programme (HTA number 12/190).
This call highlighted both the lack of research evidence to support the provision of cognitive rehabilitation
for people with MS and the potential to provide evidence to improve clinical practice in rehabilitation for
people with MS. The important outcomes to be addressed were the impact of cognitive rehabilitation on
functional performance and HRQoL. Additional outcomes suggested by the commissioning brief included
objective measures of cognitive function, subjective scores of cognitive functions, adherence to the
intervention, depression scores, fatigue, employment status and impact on family members and carers.
The minimum period of follow-up was stipulated as 1 year.
Summary of findings
Clinical effectiveness
The results indicate that there was no benefit of this cognitive rehabilitation programme for this group of
people with MS on their quality of life, with no clinically important difference in MSIS-Psy score (i.e. the
primary outcome) between the two groups at the 12-month follow-up. However, there was a small difference
in MSIS-Psy score at 6 months follow-up, favouring the intervention group. There was a difference between
the cognitive rehabilitation and the usual-care groups in terms of subjective participant and relative reports
of memory problems, as assessed on the EMQ, favouring the cognitive rehabilitation group at both 6 and
12 months. A similar finding was observed on mood outcomes, indicating that the cognitive rehabilitation
group showed less psychological distress than the usual-care group at both 6 and 12 months. There were,
however, no important differences between the groups on objectively assessed cognitive abilities, fatigue,
employment status or carer strain at the 6- or 12-month follow-ups. No safety concerns were raised and no
deaths were reported. The evaluation of treatment fidelity indicated that cognitive rehabilitation was delivered
as intended. Interviews with a subset of participants found that the treatment was well received and was
different from usual care. During interviews, the majority of participants reported that they found the
intervention helpful in reducing cognitive problems and improving confidence in daily life.
Cost-effectiveness
The health economic analysis illustrates that cognitive rehabilitation had lower costs and higher QALY gain
than usual care; however, incremental differences in both these measures were small. Although this represents
dominance of the intervention, at 12 months differences were not statistically significant and sensitivity analyses
demonstrated uncertainty concerning the base-case analysis. Therefore, definitive conclusions cannot be drawn
regarding the cost-effectiveness of cognitive rehabilitation compared with usual care.
Interpretation
This cognitive rehabilitation programme did not reduce the psychological impact of MS at 12 months,
but it may have reduced the psychological impact of MS at 6 months, reduced the frequency of subjective
complaints of cognitive problems and improved mood at the 6- and 12-month follow-ups. In the following
sections, the possible reasons for this pattern of results are considered.
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Choice of primary outcome measure
The commissioning brief indicated that quality of life was an important outcome; therefore, a quality-of-life
measure was used as the primary outcome. The MSIS was chosen as it was developed specifically for
people with MS, provides a patient’s perspective on the impact of their disease on daily life and Rasch
Analysis has confirmed the validity of two separate subscales: physical and psychological.84,85 The MSIS-Psy
subscale includes items on mood, and coping and cognition, has good psychometric properties and has
been shown to be sensitive to the effects of rehabilitation interventions (see Chapter 2). Most of the
MS-specific quality-of-life scales include many items that reflect the MS disease process, such as balance,
stiffness and spasms. However, cognitive rehabilitation does not alter the disease process; therefore,
the physical symptoms of MS are not expected to change. The aim is to enable people to cope with
their symptoms better. Although the MSIS-Psy subscale does include items related to cognition, such as
problems concentrating, it also includes items not likely to be influenced by cognitive rehabilitation, such
as feeling unwell and having problems sleeping.
Another option was one of two modified versions of the Short Form questionnaire-36 items (SF-36), which
has been amended to use as outcomes for pharmacological trials in people with MS: the Multiple Sclerosis
Quality of Life-54 (MSQOL-54),155 and the Multiple Sclerosis Quality of Life Inventory (MSQLI).156 However,
both are very long157 and include a large proportion of items that are unlikely to be influenced by cognitive
rehabilitation. A shorter version, the Multiple Sclerosis International Quality of Life questionnaire (MusiQoL),158
may have been appropriate but, as noted by Bandari et al.,157 there is a lack of information on the
responsiveness of the instrument compared with other clinical end points. In addition, Baumstarck et al.159
found that the MusiQoL was not responsive to changes in disability as recorded on other measures.
There are two outcome measures that have been developed to assess the outcome of cognitive rehabilitation.
The Adaptation to Memory Difficulties Outcome questionnaire (AMEDO)160 was developed to assess the
effects of memory rehabilitation, and the validation studies included people with MS. Patchick et al.161
developed an outcome measure for cognitive rehabilitation after stroke. Although these measures seem
appropriate, their responsiveness to the effects of intervention and their psychometric properties had not
been fully evaluated at the time of starting the trial. However, they might be considered in future evaluations
of cognitive rehabilitation.
Therefore, the MSIS-Psy subscale was probably the most appropriate quality-of-life measure. However, even
on the MSIS-Psy subscale, many of the items are unlikely to be directly influenced by cognitive rehabilitation.
Quality of life is, of necessity, a multidomain construct, and changing quality of life, although desirable, may
be unrealistic for interventions that focus on specific symptoms of MS. Future triallists may also consider a
more direct measure of cognitive abilities in daily life as a co-primary outcome for cognitive rehabilitation
trials. Co-primary outcomes are useful to provide a more ‘comprehensive picture of the intervention’s
effects’,162 but have implications for the trial design.
Long-term versus short-term effects of the intervention
The aim of the cognitive rehabilitation programme was to change the long-term effects of cognitive
impairment and, therefore, the primary outcome at the 12-month follow-up. Although this time frame is
useful to determine the longevity of treatment effects, not having interim assessment time points more
proximal to the end of the intervention risks missing the immediate impact of the intervention. As with
most other behaviour change interventions, it is probable that the impact of the intervention is greatest
immediately after the intervention, with gains diminishing over time. There was some evidence in this trial
to suggest that the programme improved quality of life in the short term (i.e. at the 6-month follow-up),
but the effects were not maintained over time. This is consistent with previous memory rehabilitation
research that shows that there are short-term benefits in quality of life, which are not maintained.29
Therefore, future research should consider having more outcome time points. However, the addition of
further assessment time points has the potential to add to participant burden, risking lower numbers
consenting to participate in the trial and increasing the likelihood of practice effects on some measures.
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Future research should also focus on ways in which the effects of cognitive rehabilitation can be
maintained. This might include booster sessions, telephone calls to review progress or online support; an
evaluation of booster sessions in a previous trial of improving learning in people with MS52 indicated little
benefit from these, but the sample sizes were small.
Subjective cognitive impairment and mood
There were effects of cognitive rehabilitation on the reported frequency of everyday memory problems and
mood. This could be because cognitive rehabilitation improved participants’ everyday memory, which had
a beneficial effect on mood, or it could be that the intervention improved mood, which led to a decreased
frequency of reporting cognitive problems.
Previous research has shown that there is a strong relationship between subjective cognitive problems and
mood in people with MS.102,103,163–166 Therefore, some of those recruited may have reported cognitive
problems associated with low mood, and this is consistent with the improvement in mood that also
occurred.
These effects may be partly attributable to the social contact afforded by attending for cognitive rehabilitation
rather than the cognitive strategy training aspects of the intervention per se. The group component was
reported to be a very useful aspect of the intervention by all participants in the intervention group who
were interviewed. Future research on this type of cognitive rehabilitation programme should control for the
therapeutic effect of the group interaction itself. However, creating an acceptable attention placebo control
for such programmes is difficult:59 they run the risk of disproportionate attrition from the control group
and there is no established gold standard for implementing an attention placebo control in psychosocial
intervention trials.167
It seems more probable that the change in mood was in response to changes in everyday memory, rather
than the cause of the changes in everyday memory. The reason is that relatives’ reports of the frequency of
everyday memory problems also showed a difference between groups, and relatives’ reports would be
unlikely to be influenced by the participants’ mood.102
One of the reasons that the EMQ was included as an outcome measure was to provide comparison with
other studies of the same intervention.59,60,95 The difference in EMQ scores at 6 and 12 months was about
5 points. The differences in the participant-reported EMQ are slightly smaller than those observed in
previous studies of the intervention in people with MS,60,62 but consistent with the difference observed in
people with traumatic brain injury.95 The smaller difference in relation to previous studies of people with
MS may be due to the broader recruitment strategies used and the difference may be comparable to the
study of people with traumatic brain injury because similar recruitment strategies were used.
It is, therefore, also probable that teaching people with MS the cognitive strategies improved their
confidence to use these in daily life. Improved confidence was also reported during the interviews by those
who had received the intervention. Increased strategy use, the benefits of the group environment and
improved confidence have all been reported in other qualitative studies of perceived effects of cognitive
rehabilitation among people with MS.136
Effect on cognitive impairment
The results, overall, indicated that the intervention had no effect on cognitive impairment. Scores in both
the intervention and the usual-care groups tended to improve over time, which is probably as a result of
practice effects and familiarity with the tasks. This finding is consistent with some studies of interventions
to improve strategy use,58,168 whereas change in cognitive abilities tends to be observed in studies that
provide specific training on cognitive tasks through computerised activities that are closely linked to the
cognitive outcomes.32,35,36,43,45,169
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Other outcomes
Fatigue was assessed to determine whether or not the intervention exacerbated fatigue-related problems,
but there was no indication of any negative effect on fatigue. Several previous trials of cognitive rehabilitation
have included fatigue as an outcome measure and none has shown any effects of cognitive rehabilitation
on general levels of fatigue.35,38,40,42,46,58,170 Two studies have shown positive effects on cognitive fatigue,35,170
but in both these studies the intervention was computerised retraining of cognitive abilities. Therefore,
it is improbable that cognitive rehabilitation has any effect on levels of general fatigue.
Guy’s Neurological Disability Scale and the number of relapses were recorded to determine whether or not
any differences between the two groups could be attributed to relapses or increasing disability. There were
no differences in the MSIS-Phy subscale score or the GNDS between the groups, so there is no suggestion
that the findings were due to differences in the physical effects of MS.
High levels of unemployment are common among adults with MS.171 In this trial, employment status was
no different between the groups at baseline or at the follow-ups. The majority (97%) of those who were
not employed at baseline were not employed at follow-up. Only a few participants gained employment
during the trial and this was equally balanced between the groups. Therefore, the intervention did not
facilitate return to work. This finding is likely to be partly due to the low rate of employment at baseline,
and because the sample had relatively severe cognitive problems at the time of recruitment. There was also
no evidence that the intervention enabled people to continue to work. This finding, however, needs to be
considered with caution. The questions around employment and education did not consider whether or
not participants had taken up voluntary positions. Although, to our knowledge, there is no research on the
effect of volunteering on people with MS, there is good evidence that volunteering has a positive effect
on psychological well-being and mood and slows self-reported decline in health and functioning levels
among older adults.172,173 Furthermore, absenteeism or presenteeism were not investigated. Research has
demonstrated that there is a link between cognitive impairment and levels of absenteeism.174 Future
research could consider more nuanced ways of collecting information about employment status.
There was also no indication of an effect of the intervention on carers and relatives. Previous studies of
people with MS have not examined the effects of cognitive rehabilitation on carers. However, one study
with patients with acquired brain injuries found that holistic neuropsychological rehabilitation did reduce
carer strain.175 This study, however, used a pre–post repeated-measures design, and is therefore susceptible
to bias.
Consistency with previous research
There are relatively few trials that have been conducted using a similar intervention with people with MS.
The results support the pilot study,60 which demonstrated a beneficial effect on mood. A similar finding
was observed in the ReMIND trial,62 which used a similar treatment approach, whereby people with MS
who were taught the use of compensation strategies had better mood outcomes than those who had
only restitution approaches. The finding that perceived cognitive deficits improved in response to group
treatment is consistent with two studies with people with MS.58,168 However, comparison of the present
trial with the ReMemBrIn trial,95 which evaluated the same intervention in people with traumatic brain
injury, suggested that those with MS responded better than those with traumatic brain injury. The most
probable reason for this discrepancy is that usual care for people with traumatic brain injury often includes
cognitive rehabilitation whereas it does not for people with MS. Those with traumatic brain injury may
have been taught many of the strategies in the intervention before they were recruited and so they
responded less well to the intervention.
The cost of providing cognitive rehabilitation in this trial was slightly higher than the costs of providing the
intervention to people with traumatic brain injury (£209 vs. £167).95 This was due to higher administration
costs and the inclusion of the manual, stationery and refreshments in the cost of the intervention in the
CRAMMS trial. If these are excluded, then the cost of providing the intervention is very similar in the two
trials. However, the overall costs were higher for those with MS than for those with traumatic brain injury,
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largely because of the much higher medication costs for those with MS. The cost of providing cognitive
rehabilitation was also similar to other group psychological interventions for people with multiple
sclerosis.90,107 Overall, the cost of providing cognitive rehabilitation is very low in the context of the overall
costs of the disease.176 The finding that there was little evidence to support the cost-effectiveness of
cognitive rehabilitation was also consistent with the ReMemBrIn trial.95
Strengths and limitations
The findings from this trial should be viewed in the light of its strengths and limitations.
Trial design
The strength of the trial lies in its methodological quality and rigour. The trial was prospectively registered
and the protocol was published.65 There was allocation concealment, meaning that those recruiting
participants had no control over the random allocation or, therefore, who would receive treatment.
Randomisation was conducted by a web-based system prepared in advance of the trial. The clinically
relevant end points were defined a priori. The primary outcome was a questionnaire, so it was completed
independently. The face-to-face outcome assessments were conducted mainly by a researcher who was
blind to group allocation. Treatment sessions were video-recorded in order to assess the fidelity of the
intervention. The SAP was agreed in advance of the data lock stage. The trial was reported in line with
the CONSORT guidelines.177 The content, format and delivery of the intervention was reported in line with
TIDieR and other relevant guidelines.109,178 The trial was adequately powered and recruited the required
sample, and the attrition level was as predicted in the sample size calculation. There were independent
trial steering and data monitoring committees to ensure that the trial was conducted as planned and that
participant safety issues were considered.
One possibility for the small differences in subjective reports of cognitive problems in daily life and mood is
that the effects observed were not due to the strategies taught as part of cognitive rehabilitation, but were
due to additional attention and meeting others with MS. The ideal design would have been to also have a
control condition in which participants met as a group for the same frequency and duration of sessions as the
cognitive rehabilitation group but did not receive the active component of cognitive rehabilitation. In one of
the pilot studies,59 there was an attention placebo self-help group as the control condition. In this condition,
participants met to discuss their health and memory problems and were taught relaxation exercises. The
facilitator did not initiate any memory talk. The fidelity analysis of these sessions130 confirmed that the
self-help control group had significantly less discussion of memory than the active treatment groups.
However, the self-help group was difficult to run, as participants wanted to discuss their memory problems
and they felt that the problems they faced were not being addressed in the sessions. This may have had a
negative effect, rather than controlling for the positive effect of being in a group.
In NHS clinical practice, very few people with MS receive treatment for their cognitive problems. They may
receive some advice from MS nurses and occupational therapists and may be directed to information on MS
charity websites. Therefore, it was decided to use usual care as the control condition rather than attempting
to devise an attention placebo condition, which would be difficult to deliver. This means that the results are
valuable for informing NHS practice, but the mechanism of the changes observed remains unclear.
Recruitment
Recruitment took place in five sites across England; thus, the participants are probably representative of
those attending clinical neurology services in England. The recruitment strategy was to invite as many
people as possible from each site to consider taking part in the CRAMMS trial. This was to ensure that all
those who thought that they had cognitive problems were aware of the trial. As a result, the letters of
invitation were sent to many who were not eligible. There were also a high proportion of people who did
not respond to the invitation. The most probable reason is that they did not consider that they had
cognitive problems, but there is no way of verifying whether or not this is the case.
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Multiple recruitment sources and strategies were used to identify potential participants, including
self-referrals. This is a strength, as it is inclusive, but is also a limitation. Some people may have received
information from more than one source. As there is no demographic data available on all those who were
approached and invited, it is not possible to ascertain the exact proportion of those who were invited who
were eligible for the study and whether or not those recruited differ in any way from those who did not
take part. Also, because some people were recruited through posters and publicity on websites, such as
the MS Society and MS Trust web pages, it is not known how many people viewed the information and,
therefore, what proportion of people chose to self-refer as a result.
The lack of information on the demographic characteristics of those who did not wish to take part in the
CRAMMS trial limits the ability to determine the proportion of people who would be eligible for the
treatment if it were available in the NHS.
Selection of participants
The inclusion criteria were broad in order to involve all those who might be treated in clinical practice,
thereby increasing the generalisability of the findings. The most common reason for exclusion of those
who were screened for eligibility was that they did not meet the criterion score on the MSNQ. Almost half
of those excluded (116/283, 49%) were excluded for not meeting this criterion, yet they wanted to take
part in a trial of cognitive rehabilitation, and so believed that they had cognitive difficulties.
In the pilot study,60 participants were recruited if they reported cognitive problems in daily life, and no
standardised assessment of subjective cognitive impairment was used. In order to maintain consistency
across sites, the MSNQ was used in the CRAMMS trial with a predefined cut-off score. As a result, some
people who reported cognitive problems in daily life were excluded from the CRAMMS trial because
they did not meet the cut-off score on the MSNQ. This may have led to a sample with relatively severe
self-reported cognitive problems. This is supported by the difference in EMQ scores at baseline, which
were lower in the pilot study (intervention, mean score 27; control, mean score 30)60 than in the CRAMMS
trial (mean score 46).
A score of > 27 on the MSNQ was used as an inclusion criterion to identify those with cognitive problems
in daily life, based on the original validation study.66 Benedict et al.66 included 50 participants with MS
and used the informant version of the questionnaire rather than the patient-reported version. This cut-off
score was also used by Vanotti et al.,72 who found high sensitivity and specificity for the informant version.
However, lower cut-off scores have been recommended subsequently in other studies.69,179,180 Benedict
et al.69 found that the optimum cut-off score was > 23 on the patient-reported version and > 22 on the
informant-reported version to identify those with cognitive impairment. O’Brien et al.179 evaluated these
cut-off scores in a sample of 48 people with MS, but found that the optimum cut-off score was > 8 to
indicate impairment, using the same criterion for cognitive impairment as both studies by Benedict et al.66,69
Comparison of cut-off scores for an internet version of the MSNQ181 showed that the MSNQ had a sensitivity
of 69% using 27 as a cut-off score, in contrast to 79% using the lower cut-off score of > 22. In comparison,
the specificity reduced from 42% to 17%. Therefore, the criterion used in the CRAMMS trial required a high
level of reporting of problems in daily life; consequently, some people with fewer problems in daily life, who
may have benefited from the intervention, were excluded.
It is possible that those with very high frequency of cognitive problems in daily life may not benefit from
the intervention. It may be that > 10 sessions are required to address all their difficulties and to ensure
that they are able to retain the information. The subgroup analysis of the MSNQ score at baseline in
relation to 1-year outcomes on the MSIS-Psy, although not providing evidence of an interaction effect,
suggested that the more severe the self-reported cognitive problems, the lower the response to intervention.
Future trials should consider whether or not those with fewer problems in daily life who are less severely
cognitively impaired may benefit more.
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The second most frequent reason for exclusion was that participants were not able to travel to the
treatment site (33/238, 14%). Travel expenses were offered but funding was not sufficient to provide
taxis for all those who could not manage on public transport and who lived a long distance from where
the treatment sessions were held. It is improbable that these people would have attended this treatment
if it were offered in NHS clinical services, as transport would probably not be provided. Treatment sessions
were held at several centres surrounding each site, so those unable to get to these centres would probably
not have been able to get to NHS rehabilitation settings either.
Only a few people were excluded on the basis of being aged > 69 years (11/238, 5%), but in clinical
practice these people probably would have been offered the treatment. In this respect, the group is slightly
more homogeneous that those who would have been offered treatment in NHS clinical practice, but as the
proportion is low it is unlikely to have had any real effect on the results.
Participants were recruited who failed one subtest of the BRBN. As a result, participants with problems
in attention, memory or executive abilities were included. The BRBN was chosen as it is a relatively
short screening test with appropriate normative data. The Minimal Assessment of Cognitive Function in
Multiple Sclerosis (MACFIMS)182 is similar but takes longer to administer. A shorter alternative was the Brief
International Cognitive Assessment for Multiple Sclerosis (BICAMS),183 which has the advantage of being
brief, but at the time of designing the study there was limited information of the psychometric properties
of this measure.184 More information is now available,185–189 and a direct comparison between the two190
suggested that the BICAMS is an acceptable alternative, but is less sensitive to cognitive problems, than
the BRBN. The BICAMS may be a suitable alternative in future studies as a brief measure to detect
cognitive impairment.
The use of a criterion of impairment relative to a healthy control population meant that some people
were excluded who were impaired relative to their own pre-morbid level, but within the average range
of the general population. This problem, highlighted by Sumowski et al.,191 means that not all those with
cognitive impairment from their MS would have been included, even though they may have reported
problems on the subjective measure.
Participant characteristics
Participant demographic characteristics were largely consistent with what would be expected in a sample of
people with MS. The average age was 50 years, with the majority in their late 40s and early 50s. This reflects
the likelihood that they were not recruited very soon after diagnosis, when the average age is more likely to
be < 40 years,192,193 and that some recruitment was through charities, such as the MS Society, whose meetings
tend to be attended by a higher proportion of people with secondary progressive MS, than those attending
neurology clinics.
The proportion of women in the trial was 73%. This is consistent with the expectation that women are
more likely to have MS than men.192,193
Most participants were of white ethnicity, consistent with the general UK population,194 which partly
reflects the communities where participants were recruited.195 The south-west and north-east of England
have relatively low numbers of people from ethnic minority groups.194 However, even in the East Midlands
there were very few participants from an ethnic minority background. Some ethnic minorities may have
been excluded because we required people to have a sufficient level of English proficiency to allow them
to independently complete the standardised tests and questionnaires and because the intervention was
delivered in English; however, the under-representation of ethnic minority groups in health-care research in
Western countries has been observed more widely.196 In addition, the incidence of MS is recognised to be
lower in some non-white ethnic groups than in those who are white.141
Participants were, on average, recruited 11 years after their MS diagnosis; most were recruited > 5 years
after diagnosis. Therefore, they had established problems and were not adjusting to the effect of diagnosis
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at the same time as engaging in the intervention. For some people, their cognitive problems may have
been so long standing that they had established coping strategies and found it difficult to adapt to new
ones. Feedback in the interviews suggested that some people thought that they should have received
cognitive rehabilitation sooner after the onset of their problems, so that they could learn to use strategies
to prevent their cognitive problems affecting their daily life.
Most participants (65%) reported having relapsing–remitting MS. However, this may be an overestimate,
as some commented that this was the diagnosis they had been given and now they thought that they
were probably secondary progressive. As many participants were recruited through community settings,
they may not have received an updated diagnosis from a neurologist. This is consistent with the majority
(76%) reporting no relapses in the previous 6 months at the time of recruitment. Although it would have
been desirable to have the type of MS confirmed by a neurologist at the time of recruitment, there was no
indication of differential effects of cognitive rehabilitation according to reported type of MS.
The cognitive rehabilitation programme was intended to teach participants strategies to cope with both
attention and memory problems. However, the content of the intervention was much more focused on
coping with memory problems and only two of the 10 sessions were devoted to problems of attention.
It is possible that those who primarily had problems with attention did not have enough intervention for
their specific problems to enable them to benefit. It is also possible that attention problems respond to
restitution strategies rather than compensation strategies. Most of the studies of computerised cognitive
rehabilitation have targeted the attention deficit in people with MS, rather than the memory impairment.
Mitolo et al.28 reported that most recent studies have focused on retraining attention, speed of processing
and executive functions, rather than memory, and these have mainly involved computerised practice. It
may be that those with attention problems benefit more from a restitution strategy and that compensation
strategies should be reserved for those with memory problems. This is supported by the finding that there
was a trend for those with more severe attention problems, as assessed on the Symbol Digit Modalities
Test, to respond less well to the intervention than those with milder problems. Future studies of this
rehabilitation programme could select those with memory problems, rather than also including those with
exclusively attention problems, even though the programme does include consideration of strategies to
improve attention.
Intervention
Attendance at sessions was relatively good; therefore, most people received most of the intervention. The
ability to provide catch-up sessions for those who could not attend some sessions also ensured that people
received most of the intervention and reflected procedures used in clinical practice. The attendance rate
[mean 7.7 (SD 3.5) sessions] was consistent with the pilot study60 [mean 7.9 (SD 0.23) sessions] and higher
than in a similar trial of the cognitive rehabilitation programme for people with traumatic brain injury64
[mean 6.3 (SD 3.5) sessions]. However, many studies do not report attendance rates,197 so direct
comparisons of attendance rates across trials are limited.
Many of the reasons for non-attendance reflect aspects of daily life unrelated to cognitive problems, such
as illness and holidays, rather than withdrawing or not wanting to continue in the group. The optimum
‘dose’ of the intervention remains unknown, and so it is not clear whether or not more sessions would
have improved the outcome or fewer sessions would have maintained the outcome. More Phase II trials
are needed to establish the optimum dose of the intervention.
The focus of the intervention was on teaching strategies to cope with cognitive problems, rather than
addressing the underlying cognitive deficit. The strength of this approach is that the effects of rehabilitation
are more likely to persist over time as cognitive abilities deteriorate.
This cognitive rehabilitation programme may not be appropriate to all those with cognitive problems and
some clinicians may select treatments according to participant characteristics or to the nature of their
cognitive problems. However, there is little information available on who might benefit the most from
specific types of cognitive rehabilitation.
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The cognitive rehabilitation was conducted in groups. An advantage of this is that people may benefit
from the experiences of others in a similar situation. Some of the qualitative feedback in previous studies
suggested that this is an important element of the intervention.136 Indeed, the qualitative data from the
interviews did suggest that participants highly valued the group format. However, the groups included
people with a range of cognitive impairments. Those with severe problems may have found that too much
material was covered too quickly; those with mild problems may have found the pace too slow and not
sufficiently tailored to their specific problems. However, there was nothing in the qualitative data that
supported this assumption. Furthermore, in clinical practice, it is unusual to be able to create groups based
on level of ability and so the results reflect the way the intervention would be delivered in clinical practice.
Individual treatment has the advantage that the intervention can be specifically tailored to an individual’s
pattern of cognitive deficits, and may also improve attendance compared with group formats.29 However,
evaluation of such individualised treatment becomes problematic as it is difficult to describe the content of
the intervention in such a way that it can be replicated.
Some people may have declined to take part because they did not wish to be treated in a group. Providing a
few individual sessions before participants are allocated to a group may allow their specific concerns to be
addressed and they can be prepared for sharing their problems with others. A combination of individual
and group treatment may maximise the benefits to be gained from cognitive rehabilitation. This strategy has
been used previously,57,168,170 but there is no clear indication that outcomes are any better using this format.
The intervention was conducted over 10 sessions, which were held approximately once a week. There may
be advantages in spreading the intervention over a longer period of time so that participants can practise
between session tasks for longer, and to get more familiar with one strategy before learning about
another. However, this frequency of sessions is similar to a previous study of cognitive rehabilitation
delivered in groups,57 which provided eight sessions over 13 weeks. In addition, the provision of refresher
sessions after the end of the structured programme may facilitate the maintenance of any gains obtained
from the intervention. There was support for this suggestion in the participant feedback interview data.
Fidelity of the intervention
There were several mechanisms in place to ensure the fidelity of the intervention. The treatment was
standardised by having a manual outlining the content of each session and facilitator notes were provided
to guide the AP. The APs were all trained to deliver the intervention by one of the co-applicants. The
co-applicant also provided one-to-one monthly supervision in addition to the monthly AP peer supervision.
This enabled the APs, who delivered the intervention, to share experiences and to clarify any uncertainties
relating to the manual and facilitator notes.
The video analysis suggested that the cognitive rehabilitation programme was delivered as planned and
as described in the manual. However, the main limitation of the video analysis was that recordings were
incomplete and did not include all sessions at all sites. Some were only partially recorded, as a result of
the camera battery running low or the camera not being turned on again after the break. This limited the
recordings that could be included in the analysis. Therefore, it is not possible to ascertain whether or not
all sessions were delivered consistently in accordance with the manual at all sites. However, based on
feedback obtained during monthly peer and supervisor meetings with the APs, it is improbable that the
unrecorded sessions were different from the recorded ones.
It was not possible to check for drift over time as not enough sessions were recorded from each site. It
would also have been better to observe the videos over the course of the trial, rather than in the final
analysis, so that any minor discrepancies in the delivery of the intervention could have been addressed as
the trial progressed. The video analysis focused on the content of treatment, but there was no assessment
of the skills of the therapists. Important aspects of the group sessions, such as group cohesiveness and the
skill of the therapist in managing group dynamics, were not monitored. However, most participants were
complimentary about the therapists’ skills at facilitating the group.
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Outcome assessment
The outcomes included a broad range of assessments. The primary outcome was a measure of quality of
life, so that it would detect the general effects of receiving cognitive rehabilitation. The more specific effects
of cognitive rehabilitation were assessed using subjective measures, which reflect the effect of cognitive
problems in daily life, and objective tests of cognitive abilities. The potential negative consequences of the
intervention were assessed through measures of fatigue and monitoring the safety outcome. The effect on
relatives/friends was assessed through the MCSI.
Having patient-reported outcomes that rely on recall of information over time can be a challenge for
people with cognitive problems. However, given that the primary outcome had to be a quality-of-life
measure, it was inevitable that this was a patient-reported outcome measure.
The primary outcome questionnaire was completed and returned by post or online, and so was mainly
conducted independently of an outcome assessor. However, when participants failed to return their
questionnaires, they were reminded at the home visit and some opted to complete the questionnaire with
the outcome assessor at the visit. The outcome assessments were conducted by researchers not involved in
delivering treatment so that they were blind to group allocation. However, some unblinding of outcome
assessors occurred. This was largely due to participants telling the assessor about their treatment, despite
having been prompted not to. The cognitive tests were completed by outcome assessors at home visits
and some unblinding occurred. However, the rate of unblinding was low. Comparison between the
guessed group and the allocated group showed very weak correspondence and, in some instances, those
who thought that they were unblinded guessed the allocation incorrectly. However, as noted by Bang,198
it is impossible to eliminate bias even when perfect blinding is achieved.
The follow-up completion rates were good and consistent with planned loss to follow-up. The main
reasons for non-completion of follow-ups were health problems, non-response to postal assessments and
failure to contact participants to arrange assessment visits. The rate of completion of cognitive tests was
slightly lower than the rate for completion of questionnaires. Some participants refused to do some of the
cognitive tests. This was most marked on the Paced Auditory Serial Addition Test (PASAT). It was also not
clear from some records whether the PASAT was missing because it was not offered as a result of time
constraints or technical problems or whether it was refused. If participants were offered a cognitive test
but refused to answer or were unable to provide any responses, they were scored the minimum, consistent
with standard administration procedures, but the outcome assessors did not always make this distinction
clear in their records and some missing data may have occurred when participants were offered the test
but were unable to complete the task. These were recorded as protocol deviations.
There is an inherent problem with using attention and memory tests as outcomes of cognitive rehabilitation,
in that although the rehabilitation focuses on teaching people to effectively use attention and memory aids
to reduce their cognitive problems, these standardised tests themselves do not allow the use of such aids.
Therefore, it is improbable that there will be changes observed on these tests if participants are not allowed
to use any aids, but equally, if aids are permitted, the tests would not have been administered as per the
test manual.
The cognitive assessments were lengthy to administer and, as a result, could not always be completed
in one session. If participants ran out of time or were too tired to continue, they were offered the
opportunity to complete the cognitive assessments at a second visit; however, this sometimes proved
difficult to arrange and did not always occur.
Questionnaires could be completed online or on paper versions that were returned by post. Only 86 (19%)
participants chose to complete outcome questionnaires online, but the completion rate was higher
(6 months: 98% online, 92% postal; 12 months: 92% online, 83% postal) than for the postal questionnaires.
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Outcomes were assessed at both the 6- and 12-month follow-ups. Therefore, the long-term effects of
cognitive rehabilitation could be determined, although it would be desirable to monitor whether or not
the benefits persisted for longer.
Sample size
Most previous studies of cognitive rehabilitation have been small and underpowered. The median total
sample size for MS memory rehabilitation studies is 42 (range 19–240).29 The target sample size of 400
was exceeded, with a total of 449 randomised. The loss to follow-up for the primary outcome of 15%
was consistent with that predicted in the calculation of sample size needed. The baseline characteristics of
participants included in the primary analysis were similar in the two groups, as were the characteristics of
the participants not included.
Economic analysis
Few studies have considered the cost-effectiveness of cognitive rehabilitation. Overall, providing cognitive
rehabilitation cost less than usual care, due to a reduction in the use of other health and social services while
receiving cognitive rehabilitation and differences in medication costs. This occurred mainly in non-disease-
modifying medications, and so could not be attributed to differences in the disease progression between
the two groups. Costs varied widely across participants in both groups, and lower costs for the intervention
group were not robust to sensitivity analysis.
One limitation of the calculation of the costs of the intervention is that it relied on self-report of services
used and medication. There is evidence from people with stroke, who are also likely to have cognitive
impairments, that reporting of health and social services received is not accurate when compared against
formal records.199 Although the inaccuracies would have occurred in both groups, it may have reduced the
ability to detect differences between the groups. In addition, participants were asked to self-report on
medications used and many opted to show the RA their prescription list. However, some disease-modifying
medications would not be listed on prescription lists, as they were issued directly from hospitals. Although
this under-reporting would have affected both groups, it may have also diluted the ability to detect
differences.
The cost-effectiveness analysis relied on the EQ-5D-5L to calculate QALYs. However, as highlighted by
others,90,200 this is relatively insensitive to changes in HRQoL in people with MS and no difference in QALY
gain was observed from the EQ-5D-5L. This is supported by the greater effects observed on the MSIS-8D,
which was designed to assess QALYs in those with MS. However, even when the MSIS-8D was used as an
alternative method for deriving utilities, there was a numerically small, significant, incremental QALY gain.
However, only two of the eight items of the MSIS-8D would be expected to change with cognitive
rehabilitation, and so any overall changes are likely to be small.
In addition, the cost-effectiveness analysis was considered in relation to the primary clinical outcome,
another quality-of-life measure, the MSIS-Psy. This may not be sensitive to the effects of cognitive
rehabilitation, as discussed above; therefore, cognitive rehabilitation was deemed unlikely to be
cost-effective as incremental costs and effects are not statistically significant. Consideration of the
incremental cost per point gained on the EMQ or GHQ-30 may be useful to inform the cost of provision
of cognitive rehabilitation in clinical practice.
Patient and public involvement
The trial was actively supported by service user representatives. They provided suggestions to make the trial
documents and lay summary clearer and more easily understood by service users. They made suggestions
for the recruitment of participants, particularly from MS charities and local MS Society branches. One
service user contributed to the qualitative study by interviewing participants and was involved in
discussions of the analysis of themes. This service user also assisted with the dissemination of results by
contributing to a video for service users. The contribution helped to ensure that the recruitment target was
met. It also demonstrated that service users can be actively involved in data collection. The limitation was
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that some service users were not able to maintain their input over the full 4 years of the study. Two had
relapses that affected their ability to attend meetings. Although six people originally agreed to take part in
the video to disseminate the findings, three dropped out and could not be replaced in time for filming to
take place before the end of the trial.
Conclusions
Implications for health care
l People with MS have problems with attention and memory and are seeking help for these problems.
l This trial has not shown any long-term effect of this cognitive rehabilitation programme on quality
of life for people with MS, measured using the MSIS-Psy subscale, but there was an effect in the
short term.
l There was some evidence that cognitive rehabilitation improved both memory problems in daily life
and mood.
l Participant feedback was positive, with some participants reporting daily life benefits of attending the
cognitive rehabilitation programme.
l Providing cognitive rehabilitation cost no more than usual care.
l It may be appropriate to offer this intervention in clinical practice given the clinical effects and lack of
alternative effective treatments, until there is evidence for alternative effective treatments.
l Further evaluation of those with MS who may benefit most from cognitive rehabilitation is needed.
Recommendations for research
l There needs to be more small-scale efficacy studies to establish the appropriate selection criteria for
cognitive rehabilitation programmes, so that the intervention is tailored to those who may benefit most.
l Future studies should attempt to control for the effects of the group environment, in order to ascertain
whether it is the contact with others with similar problems or the content of the programme that is
most important.
l Further research is needed to explore how short-term benefits of cognitive rehabilitation can be
maintained in the long term.
DISCUSSION
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Appendix 1 Sites
TABLE 25 The CRAMMS trial sites
Lead NHS trust Date opened to recruitment Months open
Nottingham University Hospitals NHS Trust 13 March 2015 24.6
The Walton Centre NHS Foundation Trust 1 April 2015 24.0
Sheffield Teaching Hospitals NHS Foundation Trust 21 May 2015 22.3
North Bristol NHS Trust 24 February 2016 13.2
South Tees Hospitals NHS Foundation Trust 26 September 2016 6.2
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Appendix 2 The CRAMMS trial intervention
details
TABLE 26 The TIDieR checklist criteria
1 Name
Attention and memory rehabilitation or just cognitive rehabilitation
2 Why
Cognitive rehabilitation is a structured set of therapeutic activities designed to retrain an individual’s attention and
memory and help people compensate for these deficits
3 What (materials)
Cognitive rehabilitation sessions followed a treatment manual, which was provided to participants at the start of the
programme. The manual was accompanied by facilitator notes to guide delivery of the sessions
4 What (procedures)
Strategies taught included restitution (including attention retraining) and strategies to improve encoding and retrieval
(such as deep-level processing). Compensation strategies taught included mnemonics (chunking, use of first letter
cues, rhymes), use of external devices (diaries, mobile phones, calendars) and ways of coping with attention and
memory problems. This was a ‘mixed’ approach, because research has found merits for both approaches. Practical
day-to-day problems, such as forgetting people’s names, improving concentration by avoiding distractions, ways to
remember where the car was parked, etc., were discussed as a way to demonstrate how the memory aids could be
used. Examples were drawn from participants’ daily lives, so as to personalise the intervention. Each session began
with a review of the previous session, followed by the teaching of a new strategy and setting of homework.
Homework exercises were prescribed to enable generalisation of what was taught in the sessions to daily life
5 Who provided
Facilitators delivering the intervention were psychology graduates with clinical experience. A clinical psychologist
provided trial-specific training on the delivery of the intervention and monthly teleconferences provided an
opportunity for peer group supervision. Additional monthly one-to-one supervision with a clinical psychologist
allowed for discussion of specific challenges relating to treatment or assessment. Ad hoc supervision for specific
queries was also provided by clinical psychologists at each site
6 How
Face-to-face sessions were held in groups comprising four to six participants, led by a single facilitator at each site
7 Where
Sessions were held at NHS hospitals or community venues
8 When and how much
Participants were offered 10 weekly sessions, lasting approximately 1.5 hours each, with a 15-minute break mid-session
9 Tailoring
The aim was to identify the most appropriate strategies to help individuals overcome their memory problems, and to
provide participants with techniques that they could adapt and use according to the nature of their problems. Participants
were able to review strategies they had previously learned and to discuss the ways in which the strategies could be applied
in a community setting. Homework assignments were set following each session, which encouraged the participants to try
the strategies learnt in the session in their home or work environment
10 Modifications
There were no changes to the intervention during the course of the trial
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TABLE 26 The TIDieR checklist criteria (continued )
11 How well (planned)
Formal fidelity assessment was undertaken through analysis of video-recordings of treatment sessions against a
coding schedule based on the activities and skills described in the manual
12 How well (actual)
The results of the fidelity analysis indicate that the components of therapy described in the manual were delivered to
participants
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Appendix 3 Schedule of assessments
TABLE 27 Trial assessments
Assessment
Telephone
screen
Screening
assessment
Baseline
assessment
Intervention period
6- and 12-month
follow-ups
Postal
Face
to face
Postal or
online
Face
to face
Initial eligibility
screening
✗ ✗a l Intervention group:
memory rehabilitation
(weekly group sessions
for 10 weeks) plus
usual clinical care
l Control group: usual
clinical care only
Informed consent ✗
Demographic
information
✗
MSNQ ✗ ✗a
BRBN ✗ ✗
GNDS ✗ ✗
MSIS ✗ ✗
EMQ-p ✗ ✗
FSS ✗ ✗
GHQ-30 ✗ ✗
Doors and People
test
✗ ✗
Trail Making Test ✗ ✗
EQ-5D-5L ✗ ✗
Service use
questionnaire
✗ ✗
Check availability
for treatment
group
✗
EMQ-r ✗ ✗
MCSI ✗
Feedback
interviews
✗b
a If not completed at optional telephone screening.
b With selected participants who will be consented prior to the interview. The interview will be within 3 months of the
6-month follow-up appointment.
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Appendix 4 Recruitment
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FIGURE 10 Cumulative participant recruitment against target.
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Appendix 5 Reasons for exclusion
TABLE 28 Reasons for non-enrolment
Reason Total (N= 194) (n)
Did not report cognitive problems (scored < 27 points on the MSNQ) 109
Unable to travel to a trial centre and attend group sessions 38
Unable/unsuitable to engage in group treatment if allocated 15
Aged > 69 years 13
No MS diagnosis 10
Have impaired vision or hearing such that unable to complete the cognitive assessments, as judged
by the assessor
8
Involved in other psychological intervention studies 1
TABLE 29 Reasons participants were not eligible after consent
Reason Total (N= 68) (n)
Did not have cognitive deficits (none of the tests on BRBN > 1 SD below age- and
education-corrected norms)
38
Did not report cognitive problems (scored < 27 points on the MSNQ) 22
Have impaired vision or hearing such that unable to complete the cognitive assessments, as judged
by the assessor
4
Did not have relapsing or progressive MS diagnosed at least 3 months prior to the baseline
assessment
1
Concurrent severe medical or psychiatric conditions that would prevent participants from engaging in
treatment, if allocated
1
Unable to travel to one of the centres and attend group sessions 1
Unable to speak English sufficiently to complete the cognitive assessments and take part in group
sessions
1
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Appendix 6 Baseline characteristics and
assessment according to primary outcome completion
and allocated group
TABLE 30 Baseline characteristics by MSIS-Psy completion at 12 months and treatment group
Characteristic
Usual care Cognitive rehabilitation
No primary
outcome (N= 31)
Primary outcome
(N= 173)
No primary
outcome (N= 31)
Primary outcome
(N= 214)
Age at randomisation (years)
Mean (SD) 45.3 (11.3) 49.5 (9.6) 47.6 (12.2) 50.3 (9.4)
Minimum, maximum 27, 67 25, 69 27, 69 18, 69
Gender, n (%)
Men 9 (29) 47 (27) 11 (35) 56 (26)
Women 22 (71) 126 (73) 20 (65) 158 (74)
Ethnicity, n (%)
White 29 (94) 166 (96) 29 (94) 208 (97)
Black 0 (0) 3 (2) 2 (6) 1 (0)
Asian 1 (3) 1 (1) 0 (0) 3 (1)
Mixed 1 (3) 3 (2) 0 (0) 2 (1)
Marital status, n (%)
Single/widowed/divorced 10 (32) 56 (32) 12 (39) 69 (32)
Married/with partner 21 (68) 117 (68) 19 (61) 145 (68)
Participant-reported time since MS diagnosis (years)
Mean (SD) 10.2 (9.3) 11.3 (8.6) 11 (9) 12.3 (7.9)
Minimum, maximum 1, 37 0, 40 2, 36 0, 34
Type of MS (participant reported), n (%)
Relapsing–remitting 24 (77) 108 (62) 22 (71) 137 (64)
Primary progressive 1 (3) 23 (13) 3 (10) 19 (9)
Secondary progressive 6 (19) 42 (24) 6 (19) 58 (27)
Relapses in the previous 6 months, as assessed at screening (participant reported), n (%)
0 23 (74) 132 (76) 24 (77) 162 (76)
1 4 (13) 27 (16) 6 (19) 41 (19)
2 2 (6) 11 (6) 1 (3) 4 (2)
≥ 3 2 (6) 3 (2) – 7 (3)
continued
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TABLE 30 Baseline characteristics by MSIS-Psy completion at 12 months and treatment group (continued )
Characteristic
Usual care Cognitive rehabilitation
No primary
outcome (N= 31)
Primary outcome
(N= 173)
No primary
outcome (N= 31)
Primary outcome
(N= 214)
Relapse between baseline and randomisation (participant reported), n (%)
No 29 (94) 161 (93) 25 (81) 195 (91)
Yes 2 (6) 10 (6) 6 (19) 18 (8)
Not known – 2 (1) – 1 (< 0.5)
Years of education
Mean (SD) 13.1 (2.3) 14.1 (3) 14.1 (3.2) 14.2 (3.5)
Minimum, maximum 11, 18 10, 30 10, 22 10, 35
Employment status, n (%)
Retired 7 (23) 57 (33) 8 (26) 72 (34)
Not employed 14 (45) 56 (32) 12 (39) 71 (33)
Employed part time 3 (10) 28 (16) 5 (16) 39 (18)
Employed full time 7 (23) 31 (18) 4 (13) 27 (13)
In education full time – – – 1 (< 0.5)
In education part time – – 2 (6) 4 (2)
Not known – 1 (1) – –
Any employment (full or
part time)
10 (32) 59 (34) 9 (29) 66 (31)
Living arrangements, n (%)
Lives alone 6 (19) 32 (18) 7 (23) 42 (20)
Lives with others 25 (81) 141 (82) 24 (77) 172 (80)
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TABLE 31 Scores on baseline assessments prior to randomisation, by MSIS-Psy completion at 12 months and
treatment group
Assessment
Usual care, mean (SD) Cognitive rehabilitation, mean (SD)
No primary
outcome (N= 31)
Primary outcome
(N= 173)
No primary
outcome (N= 31)
Primary outcome
(N= 214)
MSNQ 40.5 (8.4) 38.8 (7.3) 40.6 (7.7) 38.7 (7)
BRBN
Selective Reminding
Total recall 38.8 (9.2) 40.4 (10.7) 36.8 (14.2) 41.2 (10.4)
Long-term storage 28.8 (13) 31.2 (14.8) 27 (19.2) 31.8 (15.1)
Consistent long-term
retrieval
16.3 (11.6) 19.2 (13.9) 16.3 (17.9) 19.4 (13.5)
Delayed recall 4.7 (3) 5.9 (2.8) 4.8 (3.3) 5.9 (2.7)
10/36 Spatial Recall
Total correct 18.1 (4.9) 18.4 (5) 17.5 (5.5) 18.2 (4.4)
Total confabulations 11 (4.7) 11.3 (5) 12.1 (5.5) 11.4 (4.5)
Delayed recall 6.3 (1.8) 6.3 (2.1) 5.4 (2.2) 6.1 (2.2)
Symbol Digit Modalities 36.2 (10.7) 38.1 (12.3) 31.9 (12.1) 36.9 (11.3) (n = 213)
Paced Auditory Serial Addition
Easy total correct 25.3 (18) 32.2 (15.9) (n = 168) 25.2 (15.8) (n = 29) 32.5 (16.1) (n = 210)
Hard total correct 10.7 (13.1) 16.8 (16.1) (n = 168) 10.6 (15.3) (n = 29) 18.2 (16.5) (n = 210)
Word fluency 23.3 (7.3) 25.4 (9.1) (n = 172) 21.5 (7.8) 25.2 (8.8)
GNDS total score 21.2 (6.3) 19.8 (6.8) 21.4 (7.9) 19.7 (7)
Doors and People n = 31 n = 172 n = 31 n = 214
Overall age-scaled score 6.1 (4.1) 7.2 (3.9) 4.8 (3.8) 7.4 (3.6)
Verbal total score 7.2 (4.1) 7.8 (3.8) 6 (3.4) 8 (3.7)
Non-verbal total score 7 (4.2) 7.8 (3.4) 5.6 (3.2) 7.8 (3.4)
Total forgetting score 9 (2.9) 8.7 (3) 8.4 (4.1) 8.9 (2.9)
Trail Making Score n = 30 n = 170 n = 31 n = 213
Part B – part A 75.2 (41.4) 68.6 (41.4) 80.1 (47.5) 70.5 (40)
EQ-5D-5L health status VAS score 52.2 (24.4) 60.9 (19.3), n = 172 62.1 (21.8) 59.6 (21.1)
MSIS-Psy subscale 27.6 (6.2), n = 27 24.2 (5.9), n = 170 25.6 (6.2), n = 27 23 (5.7), n = 206
MSIS-Phy subscale 58.1 (12.3), n = 27 52.6 (13), n = 170 55.6 (16.3), n = 26 51.6 (13.2), n = 206
EMQ-p 54.9 (25.2), n = 27 45.8 (22.7), n = 167 53.1 (26.9), n = 25 44 (22.2), n = 204
FSS 1.5 (1.3), n = 27 1.3 (1.3), n = 170 1.6 (1.4), n = 27 1.3 (1.4), n = 203
GHQ-30 48.1 (16.4), n = 27 38.3 (15.4), n = 170 40.5 (16.5), n = 26 35.9 (13.8), n = 204
EMQ-r 43.8 (24.3), n = 24 37.4 (26.1), n = 161 40.6 (23.7), n = 24 34 (23.4), n = 189
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Appendix 7 Unblinding
TABLE 32 Research assistant opinion of treatment allocation at the follow-up visits
Opinion at each follow-up time point
Trial group, n (%)
Usual care Cognitive rehabilitation
6-month assessment n = 187 n = 225
Opinion of treatment allocation at the start of the visit
Definitely usual care 8 (4) 1 (< 0.5)
Probably usual care 173 (93) 216 (96)
Probably intervention 4 (2) 3 (1)
Definitely intervention 2 (1) 5 (2)
Opinion of treatment allocation at the end of the visit
Definitely usual care 13 (7) 4 (2)
Probably usual care 125 (67) 123 (55)
Probably intervention 44 (24) 67 (30)
Definitely intervention 5 (3) 31 (14)
12-month assessment n = 175 n = 212
Opinion of treatment allocation at the start of the visit
Definitely usual care 1 (1) –
Probably usual care 171 (98) 204 (96)
Probably intervention 2 (1) 4 (2)
Definitely intervention 1 (1) 4 (2)
Opinion of treatment allocation at the end of the visit
Definitely usual care 3 (2) 2 (1)
Probably usual care 121 (69) 133 (63)
Probably intervention 47 (27) 62 (29)
Definitely intervention 4 (2) 15 (7)
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Appendix 8 Subgroup analysis
TABLE 33 Subgroup analysis for MSIS-Psy score at 12 months
Time point, mean (SD), n
Adjusted difference in
means (95% CI)
Adjusted interaction
effect (95% CI)Baseline 12 months
MS type
Relapsing–remitting
Usual care 24.8 (5.6), 107 23.5 (5.9), 108
Cognitive rehabilitation 23.0 (5.9), 133 21.9 (6.1), 137 –0.5 (–1.6 to 0.7)
Progressive
Usual care 23.2 (6.1), 63 23.3 (6.2), 65
Cognitive rehabilitation 23.1 (5.4), 73 22.6 (6.3), 77 –0.8 (–2.3 to 0.8) –0.3 (–2.2 to 1.6)
Cognitive problems using MSNQ
MSNQ tertile 1: 28 to 35
Usual care 22.2 (5.3), 70 21.5 (5.3), 70
Cognitive rehabilitation 21.4 (5.2), 76 20.4 (5.5), 77 –0.9 (–2.3 to 0.6)
MSNQ tertile 2: 36 to 42
Usual care 24.6 (5.3), 43 23.4 (5.3), 44
Cognitive rehabilitation 22.9 (5.3), 71 21.6 (5.8), 75 –0.8 (–2.5 to 0.9) 0.1 (–2.1 to 2.3)
MSNQ tertile 3: 43 to 60
Usual care 26.3 (6.2), 57 25.8 (6.5), 59
Cognitive rehabilitation 25.3 (6.0), 59 25.1 (6.3), 62 0.0 (–1.6 to 1.6) 0.8 (–1.3 to 3.0)
Memory function using the Doors and People test overall age-scaled score
Tertile 1: 0 to 5
Usual care 25.2 (5.7), 56 25.0 (6.0), 58
Cognitive rehabilitation 24.9 (6.1), 55 24.2 (6.2), 61 –0.7 (–2.3 to 0.9)
Tertile 2: 6 to 9
Usual care 24.9 (5.5), 64 23.4 (5.7), 65
Cognitive rehabilitation 23.4 (5.1), 89 22.1 (5.8), 89 –0.3 (–1.8 to 1.1) 0.3 (–1.8 to 2.5)
Tertile 3: 10 to 18
Usual care 22.1 (6.1), 49 21.7 (6.1), 49
Cognitive rehabilitation 20.9 (5.5), 62 20.3 (6.0), 64 –0.8 (–2.4 to 0.9) –0.1 (–2.4 to 2.3)
continued
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TABLE 33 Subgroup analysis for MSIS-Psy score at 12 months (continued )
Time point, mean (SD), n
Adjusted difference in
means (95% CI)
Adjusted interaction
effect (95% CI)Baseline 12 months
Speed of information processing using Symbol Digit Modalities from the BRBN
Tertile 1: 5 to 32
Usual care 25.1 (5.7), 51 24.7 (5.7), 51
Cognitive rehabilitation 23.8 (6.0), 68 22.3 (6.1), 71 –1.5 (–3.1 to 0.1)
Tertile 2: 33 to 42
Usual care 24.6 (5.1), 54 24.7 (5.7), 56
Cognitive rehabilitation 23.2 (5.4), 78 23.0 (6.3), 81 –0.9 (–2.4 to 0.6) 0.6 (–1.7 to 2.8)
Tertile 3: 43 to 76
Usual care 23.1 (6.5), 65 21.4 (6.1), 66
Cognitive rehabilitation 21.8 (5.4), 59 20.7 (5.6), 61 0.1 (–1.5 to 1.7) 1.6 (–0.7 to 3.8)
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Appendix 9 Employment status at 6 and
12 months
TABLE 34 Summary of employment status at follow-up
Follow-up time point
Trial group, n (%)
Usual care Cognitive rehabilitation
6 months
Visit completed within 9 months of randomisation n = 187 n = 224
Retired 68 (36) 75 (33)
Not employed or in education 59 (32) 81 (36)
Employed part time 27 (14) 35 (16)
Employed full time 30 (16) 27 (12)
In education full time – 1 (< 0.5)
In education part time 3 (2) 5 (2)
12 months
Visit completed within 15 months of randomisation n = 173 n = 209
Retired 71 (41) 72 (34)
Not employed or in education 49 (28) 74 (35)
Employed part time 27 (16) 40 (19)
Employed full time 23 (13) 20 (10)
In education full time – 2 (1)
In education part time 3 (2) 1 (< 0.5)
Note
Percentages use the number of visits completed within 3 months of the scheduled time point as the denominator.
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TABLE 35 Employment at 6 and 12 months by allocated group and employment at baseline
Time point and group
Baseline, n (%)
Total (N)No employment Any employment
6 months
Usual-care group
No employment 119 (97) 10 (16) 129
Any employment 4 (3) 53 (84) 57
Total 123 (100) 63 (100) 186
Cognitive rehabilitation group
No employment 153 (98) 9 (13) 162
Any employment 3 (2) 59 (87) 62
Total 156 (100) 68 (100) 224
12 months
Usual-care group
No employment 111 (97) 11 (19) 122
Any employment 3 (3) 47 (81) 50
Total 114 (100) 58 (100) 172
Cognitive rehabilitation group
No employment 140 (97) 9 (14) 149
Any employment 5 (3) 55 (86) 60
Total 145 (100) 64 (100) 209
Note
Employment status at baseline is used as the denominator.
Employment status at baseline was not known for one participant in the usual-care group as the visit was not completed.
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Appendix 10 Relapse
TABLE 36 Participant-reported number of relapses in the previous 6 months at 6 and 12 months
Time point and relapse Usual care Cognitive rehabilitation
6 months
Questionnaire completed within 9 months of randomisation (n) 187 217
Relapse in the previous 6 months, n (%)
No 138 (74) 174 (80)
Yes 39 (21) 37 (17)
Not answered 10 (5) 6 (3)
Number of relapses, n (%)
1 23 (12) 25 (12)
2 13 (7) 9 (4)
≥ 3 – 1 (< 0.5)
Not given 3 (2) 2 (1)
12 months
Questionnaire completed within 15 months of randomisation (n) 173 215
Relapse in the previous 6 months, n (%)
No 132 (76) 157 (73)
Yes 34 (20) 41 (19)
Not answered 7 (4) 17 (8)
Number of relapses,a n (%)
1 23 (13) 34 (16)
2 3 (2) 6 (3)
≥ 3 4 (2) –
Not given 4 (2) 2 (1)
a One participant in the intervention group answered ‘no’ to the question about whether or not they had had a relapse in
the previous 6 months, but reported that they had had one relapse in response to ‘If yes, how many relapses have
you had?’.
Note
Percentages use the number of questionnaires completed within 3 months of the scheduled time point as the denominator.
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Appendix 11 Safety
TABLE 37 Safety outcome
Safety outcome
Trial group, n (%)
Usual care (n= 187) Cognitive rehabilitation (n= 218)
Increase of ≥ 30 points on the GHQ-30 between baseline and the 6-month assessment, n (%)
No 174 (93) 202 (93)
Yes 4 (2) 3 (1)
Change in score not able to be calculateda 9 (5) 13 (6)
a Change in score not able to be calculated because:
l four participants completed the 6-month questionnaire fully online; however, the response options were not correct
so the GHQ-30 cannot be scored (usual care, n = 1; cognitive rehabilitation, n = 3)
l 12 participants did not complete the questionnaire booklet at baseline (usual care, n = 5; cognitive
rehabilitation, n = 7)
l two participants did not complete the GHQ-30 in the baseline questionnaire booklet (usual care, n = 1; cognitive
rehabilitation, n = 1)
l three participants did not complete the GHQ-30 at 6 months (usual care, n = 1; cognitive rehabilitation, n = 2)
l one participant did not complete enough items on the GHQ-30 at 6 months for it to be scored (usual care, n = 1,
10 items missed).
Note
All participants who completed a questionnaire at 6 months are included (i.e. including the participant who completed the
questionnaire more than 9 months after randomisation in the cognitive rehabilitation group).
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Appendix 12 Fidelity analysis: additional tables
TABLE 38 The CRAMMS trial video analysis codes applicable to all sessions
Activity Code
Therapist activities
Discussing administrative aspects DAA
Discussing CRAMMS trial research activities/research process, for example outcome visits TFRA
Discussing MS, for example diagnosis, living with MS, impact on family and/or caregivers TLM
Facilitating discussion (non-specific prompts) and providing encouragement/reassurance FD
Paraphrasing PP
Presenting/discussing educational material PE
Presenting/discussing strategies PS
Providing explanation of memory and attention and/or strategies EP
Providing feedback PF
Summarising SU
Therapist social chat TSC
Participant activities
Asking for information related to intervention content AI
Asking questions not related to intervention content AQ
Describing emotions and coping strategies DE
Discussing CRAMMS trial research activities/research process, for example outcome visits PFRA
Describing problems related to memory and attention DP
Discussing MS, for example diagnosis, living with MS, impact on family and/or caregivers and hospital visit
discussion
PLM
Discussing strategies DS
Discussing/filling in educational material PEM
Discussing/conducting administrative aspects PDAA
Social chat PSC
Treatment manual content: all sessions
Summarise previous session P
Reflect on personal experience R
Discuss take-home activities D
Learn about attention and memory L
Learn about strategies to address attention and memory problems ST
Other content (not cognitive rehabilitation, not related to treatment)
Administration, for example reimburse participant travel and travel arrangements AD
Discussing CRAMMS trial research activities/research process, for example outcome visits FRA
Discussing living with/general information MS, for example symptoms such as fatigue GI
Hospital visits, accessing other MS services HV
Providing information on organisation of sessions, venue, date, group, etc. and housekeeping (fire exits,
no smoking policy, toilets, drinks, breaks)
ISP
Social chat SC
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TABLE 39 The CRAMMS trial video analysis codes applicable to specific sessions
Activity Description Code
Session 1: introduction to the programme
Introduction to others Reintroduce self and then encourage people to introduce themselves – briefly
state why they are part of the study (wear name badges)
IO
Discuss format of session and
memory programme
Present the aims of the programme and the structure – use to motivate people FS
Establish group rules Discuss group rules GR
Explore attention and memory Discussing what attention and memory are AM
Things that participant forgets Can compare memory before MS diagnosis TF
How do you feel when you are
having difficulty with memory?
Emphasise that it’s difficult to evaluate own memory against other peoples.
Instil confidence in the group that there are techniques/strategies that can be
done to deal with the problems better
FD
Own techniques to help Have you come up with any techniques to reduce these problems or help you
cope better?
OT
What else do you want to
know?
Making each session work – want to know more about the programme – can
illustrate will be looking at that in session . . .
WK
Session 2: memory and memory problems
What is memory Can you discuss what you think memory is and why is it important? M
Processes involved in memory Attention, encoding, storage, consolidation, retrieval. Where do people’s
problems lie?
PI
Memory storage l Sensory memory: group asked to close their eyes and imagine a scene.
Explain that sights, touch, sound and smells imagined are assembled from
various sensory memories
l Working memory: mental arithmetic task to illustrate working memory
demand, for example 5+ 3 × 2
l Long-term memory: role of long-term memory and consequence if
information is not practised or rehearsed. Talk through diagram
MS
Memory retrieval Immediate recall/delayed recall/distractors MR
Memory systems Aim to illustrate how memory works/how complicated it is MSY
Session 3: attention I
Different types of attention What is attention? Why is it important? What makes us pay attention? DA
Different types of distractors What is sustained/divided attention? Distracters? – Sustained, for example
staying attentive in a meeting, watching a television programme, reading a
book. Divided, for example talking on the telephone while cooking, cleaning
while listening to music, singing while washing in the shower
DD
Attention exercise: newspaper
exercise
l Some tasks compete with one another – others do not. How can we
improve our attention skills when reading a newspaper article with an
added task? (Focus on prioritising, remove distractions, practise attention
exercises to improve concentration, breaking task into smaller chunks)
l Same as above but with distractor
AE
Techniques to improve
attention
l How can we improve our attention skills?
l Parked your car:
l Remembering a face (pictures of faces hand-out): what techniques can be
used . . . Control the environment
TI
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TABLE 39 The CRAMMS trial video analysis codes applicable to specific sessions (continued )
Activity Description Code
Session 4: attention II
Story recall exercise l Group given 2 minutes and instructed to recall as much information
as possible
l Discussion: how did you go about recalling the information?
SR
5Ws and the H: who, what,
where, when, why and how?
Introduce the 5Ws and the H strategy and how it can help. This technique
teaches you to focus and pick out the important information – filtering out
irrelevant background information (distractors). The information is also
simplified making recollection easier
WH
Story recall with the 5Ws and
the H
l Read story focusing on the 5Ws and the H questions as prompts for
memory retrieval – count number of correct points for first story versus
second story
l Discussion: usefulness of strategy – how useful did you find the 5Ws and
the H strategy? How did recalling the two stories compare?
SRW
When difficult When is it difficult to pay attention? WD
How attention improved How can our attention be improved? AI
Strategies to remember STR
Exercise 3: case study handout Based on the 5Ws and the H, and the information about attention that we
know of, what are the best strategies to improve attention in the following
case studies?
EX
Session 5: introducing internal memory aids
Use of internal memory aids l What is meant by internal memory aids? Techniques to recall information
when we can only rely on our memory
l What kinds of memory strategies do people use now?
IA
Rehearsal Rehearsal and repetition? Think of a script for a presentation that you have
had to remember in the past. How did you remember it?
REH
Chunking l Exercise: remember the telephone number using chunking strategy
l Discussion: how did you remember the number? How many chunks did you
divide the number into?
CH
Categorisation l Look at the grid of pictures. Discuss ways of grouping the information into
common themes
l Assign each item to a theme, then turn over the page and try to remember
as many items as possible
l Why can we remember more when items are put into themes?
l Chunking the items into categories decreases the amount to remember and
the other items that are remembered, that is a category for animals can
be used as a prompt to remember more information. The categorisation
also adds meaning to the items to be remembered – making them more
memorable
l What other pieces of information can we organise (chunk/categorise) in our
everyday lives to help us remember something?
CT
Session 6: internal memory aids II
Levels of processing l Exercise 1: shallow-level processing task
l Discussion topic 2: discuss the difference between deep-level and
shallow-level processing. What are some ways we can process information
more deeply?
l Discuss examples of deep and shallow processing in everyday life
l Deep and shallow processing
l Exercise 2: discuss the difference between deep-level and shallow-level
processing. What are some ways we can process information more deeply?
l Discuss examples of deep and shallow processing in everyday life
l Deep-level processing task
LP
continued
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TABLE 39 The CRAMMS trial video analysis codes applicable to specific sessions (continued )
Activity Description Code
Visual imagery l Take a few minutes to think of a mental image of how you would
remember the names of Susan and Andy Wright who have met at a BBQ.
Be inventive!
l Discuss effective visual imagery: interaction, vividness, bizarreness, emotion
VI
Associations What do we mean by associations? For example, remembering to carry out
a new activity by linking it to an existing routine, taking medication with
mealtimes, learning the name of someone you have just met by thinking of
somebody you already know with the same name (friend/movie star), leaving
your walking boots by the door to remember you are going out walking with
a friend
AS
Story method Spend 5 minutes devising a way of linking and remembering the information
using the story method and share with the group
SM
First-letter cues First-letter cues: practise on additional lists FL
Rhymes RH
Session 7: internal memory aids III
Little-and-often strategy l Read out a list of 20 words
l Discuss primacy/recency effect
l Discuss examples of the little-and-often rule in everyday life
LO
PQRST method l Read the article and try out the PQRST method – make notes and test
yourself. Handout PQRST
l Ask a few questions for article comprehension
l How else could this method be used in our everyday lives? (letters, articles,
reading books, watching television, listening to audio books)
PQ
Learning strategies l Discussion topic 2: learning
l When can you use learning? For example, learning a new route, learning to
use a new gadget or smartphone, learning new programme on computer,
remembering names
l Exercise 3: chocolate truffles recipe
CTR
Relaxation l Relax
l Use mental retracing
l Context-dependent memory
l Alphabetical searching
l Understand that everyone experiences memory difficulties at times
REL
Session 8: introduction to external memory aids and diaries
Memory aids – internal and
external
Complete the table reflecting on internal and external memory aids MA
Diary use – using a diary
effectively, useful tips when
using a diary
l Do you currently use a diary?
l What is your diary currently like? (views/uses)
l How do you store the information if you do not use a diary?
l Other ways of storing information?
l Tips and potential problems encountered and possible solutions
DU
Pacing: making the most of
your energy – pacing activity
(3Ps)
For example, avoid rushing; pre plan and organise activities; eliminate
unnecessary tasks; use good posture and body mechanics; avoid unnecessary
motion or energy expenditure; use assistive devices or appliances to decrease
work; ensure work heights, lighting, ventilation, noise levels are appropriate;
delegate/ask for help; allow adequate time for sleep, meals and exercise;
spread out tasks throughout the day/week; set time limits for tasks
PC
Positive attitude: developing a
positive attitude to memory
aids
Everyone uses them; experiment; recognise a purpose for the strategy; be
flexible – use different strategies for different situations; try to use 3–6 aids for
better memory
PA
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TABLE 39 The CRAMMS trial video analysis codes applicable to specific sessions (continued )
Activity Description Code
Session 9: external memory aids II
Problems with external aids Discuss external memory aids already use. Potential problems and solutions
with various memory aids
PA
Memory aids use in future? l Are there any memory aids that you would like to use but have not?
l What prevents you from using these? Problems and possible solutions
– NEW
MF
Case studies: making life a bit
easier
Which external memory aids can each individual use to help him/her
remember better?
CST
Useful tips when using external
memory aids
For example, incorporate things into daily routine, keep list in prominent
position, writing things down as soon as you remember, use different colours,
marker pens, sticky notes, etc. – NEW
UT
Session 10: review and fine-tuning
Overview of sessions Look back through workbook OS
Favourite strategies List favourite and most effective strategies – attention, internal, external FAS
Reflecting on memory problems
identified in session 1
Reflect on the memory problems you recorded in session 1 (take-home activity)
and state how often each occurs now, how much they affect you now and the
techniques used to deal with each strategy
PS
Group feedback – changes
since the programme started
l Group feedback
l What did the group gain from the programme?
l What were the difficulties you faced and how were the
difficulties overcome?
GF
5Ws, who, what, when, where, why; H, how; PQRST, preview, question, read, state, test.
TABLE 40 Sessions video-recorded for the analysis of treatment fidelity
Site Group
Sessions recorded
Total complete
sessions (n)1 2 3 4 5 6 7 8 9 10
01 01 ✓ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗ ✗ 3
01 03 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
01 04 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
01 08 ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9
01 09 ✓ ✓ ✓ ✓ ○ ✗ ✓ ✗ ✓ ✓ 7
01 12 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 10
01 14 ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ○ ✓ 8
01 18 ✗ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ 8
01 19 ✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 8
01 27 ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓ 9
01 31 ○ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9
continued
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TABLE 40 Sessions video-recorded for the analysis of treatment fidelity (continued )
Site Group
Sessions recorded
Total complete
sessions (n)1 2 3 4 5 6 7 8 9 10
01 32 ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9
01 34 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 10
01 36 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
01 38 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ○ ✗ 8
01 42 ✓ ✓ ✓ ✓ ✓ ○ ✓ ✓ ✓ ✓ 9
02 02 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
02 06 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
02 10 ✗ ✗ ✓ ✓ ○ ✗ ✗ ✗ ✗ ✗ 2
02 15 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
02 23 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
02 43 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
02 45 ✗ ✗ ✗ ✓ ✗ ✓ ✓ ✓ ✓ ✓ 8
03 05 ✗ ✗ ✗ ✗ ✗ ✗ ✓ ✓ ✓ ✓ 4
03 07 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ○ ✓ ✓ 9
03 11 ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ 9
03 13 ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✗ ✓ ✓ 8
03 21 ✓ ✗ ✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ 7
03 24 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ○ ✓ 9
03 28 ✗ ✓ ○ ✓ ✓ ✓ ✓ ✓ ✓ ○ 7
03 29 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ 8
03 35 ✓ ✓ ✓ ○ ✓ ✓ ✓ ✓ ✓ ✓ 9
03 37 ✓ ✓ ✓ ✓ ○ ✓ ✓ ✓ ✓ ✓ 9
03 39 ○ ✓ ✓ ✓ ✓ ✗ ✗ ○ ✓ ○ 5
04 16 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
04 17 ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 0
04 20 ✓ ✓ ✓ ○ ✓ ✓ ✗ ○ ✓ ✓ 7
04 22 ○ ✓ ✓ ✓ ✓ ○ ✗ ✓ ○ ✓ 6
04 30 ✓ ✓ ✓ ✓ ✗ ✓ ✗ ✓ ✓ ✓ 8
04 33 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ○ ✓ ✓ 9
04 41 ✗ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ? ✓ 7
04 44 ✓ ✓ ✗ ✓ ✓ ✓ ✓ ? ✓ ✓ 9
05 25 ✗ ✓ ✓ ✓ ✓ ○ ✓ ✓ ✓ ✓ 8
05 26 ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9
05 40 ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9
✓, fully recorded; ✗, not recorded; ○, partially recorded.
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
TABLE 41 Distribution of AP and participant activities across sessions
Category
Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total
n % n % n % n % n % n % n % n % n % n % n %
Therapist activity
Discussing/conducting
administrative aspects
80 5.9 40 2.3 36 1.9 32 1.4 24 1.3 29 1.6 20 1.3 24 1.3 14 0.8 32 1.6 331 1.8
Providing explanation 180 13.2 513 29 219 11.7 66 2.8 35 1.9 77 4.3 69 4.3 23 13 10 0.6 72 3.6 1264 7
Facilitating discussion 179 13.2 125 7.1 99 9.3 49 2.1 42 2.3 59 3.3 66 4.1 105 5.9 87 5.1 75 3.8 886 4.9
Providing feedback 21 1.5 64 3.6 90 4.8 58 2.5 43 2.3 55 3.1 57 3.6 100 5.6 57 3.3 94 4.7 639 3.5
Summarising 13 1 38 2.2 28 1.5 35 1.5 10 0.5 6 0.3 10 0.6 14 0.8 10 0.6 66 3.3 230 1.3
Paraphrasing 27 2 51 2.9 23 1.2 21 0.9 9 0.5 18 1 9 0.6 33 1.9 15 0.9 21 1.1 227 1.3
Presenting/discussing
educational material
129 9.5 240 13.6 278 14.8 267 11.4 165 8.9 203 11.4 199 12.5 157 8.8 226 13.2 210 10.6 2074 11.5
Presenting/discussing
strategies
54 4 58 3.3 133 7.1 517 22.1 483 26.2 410 23 323 20.2 12 0.7 359 20.5 238 12 3054 16.9
Discussing CRAMMS
trial research process
11 0.8 0 0 0 0 1 0 1 0.1 1 0.1 1 0.1 0 0 0 0 76 3.8 91 0.5
Discussing diagnosis/
living with MS
2 0.1 0 0 0 0 0 0 0 0 0 0 0 0 1 0.1 0 0 0 0 3 0
Therapist social chat 14 1 8 0.5 3 0.2 10 0.4 3 0.2 5 0.3 2 0.1 7 0.4 6 0.4 14 0.7 72 0.4
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TABLE 41 Distribution of AP and participant activities across sessions (continued )
Category
Session 1 Session 2 Session 3 Session 4 Session 5 Session 6 Session 7 Session 8 Session 9 Session 10 Total
n % n % n % n % n % n % n % n % n % n % n %
Participant activities
Social chat 64 4.7 69 3.9 85 4.5 81 3.5 72 3.9 61 3.4 53 3.3 85 4.8 69 4 95 4.8 734 4.1
Discussing/filling in
educational material
38 2.8 125 7.1 425 22.7 669 28.6 437 23.7 429 24.1 466 29.2 92 5.2 143 8.3 319 16.1 3143 17.4
Discussing strategies 146 10.7 86 4.9 108 5.8 318 13.6 362 19.6 293 16.5 214 13.4 422 23.7 602 35.1 271 13.7 2822 15.6
Asking for information
related to intervention
content
19 1.4 39 2.2 20 1.1 10 0.4 3 0.2 9 0.5 5 0.3 0 0 1 0.1 7 0.4 113 0.6
Asking for information
not related to
intervention content
2 0.1 3 0.2 1 0.1 2 0.1 1 0.1 3 0.2 0 0 0 0 1 0.1 0 0 13 0.1
Describing problems 225 16.6 225 12.7 277 14.8 170 7.3 115 6.2 91 5.1 61 3.8 77 4.3 54 3.2 82 4.1 1377 7.6
Describing emotions
and coping strategies
57 4.2 28 1.6 11 0.6 6 0.3 12 0.7 9 0.5 13 0.8 12 0.6 7 0.4 26 1.3 181 1
Discussing MS
diagnosis/hospital visit
80 5.9 43 2.4 33 1.8 22 0.9 25 1.4 14 0.8 25 1.6 126 7.1 38 2.2 72 3.6 478 2.6
Discussing/conducting
administrative aspects
8 0.6 5 0.3 1 0.1 1 0 1 0.1 4 0.2 2 0.1 2 0.1 4 0.2 5 0.3 33 0.2
Missing 3 0.2 1 0.1 1 0.1 0 0 0 0 3 0.2 1 0.1 6 0.3 2 0.1 2 0.1 19 0.1
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Appendix 13 Unit costs
TABLE 42 Unit costs of health and social service resource use
Resource
Cost (£) per
contact
Average
consultation
time
Source
(service code/
currency code) Assumptions
General practice and community nursing
GP (surgery) 36 9.22 minutes aPSSRU 2016,201
page 145
Based on consultation lasting
9.22 minutes (PSSRU 2016201)
GP (home) 120 23.4 minutes aPSSRU 2013,202
page 191
Based on consultation time of
23.4 minutes
GP (telephone) 28 7.1 minutes aPSSRU 2015,203
page 171
Nurse (general practice) 11.11 15.5 minutes aPSSRU 2015,203
page 192
Based on consultation time of
15.5 minutes (PSSRU 2015203)
Nurse (home) 16.77 23.4 minutes Assume same consultation time
Nurse (telephone) 4.70 6.56 minutes aPSSRU 2016,201
pages 143 and 147
Counsellor (surgery) 42 per hour
Other
Midwife 44 per hour aPSSRU 2016,201
pages 188 and
198
Based on band 6 hospital-
based nurses
Chiropodist 32 per hour aPSSRU 2016,201
pages 200 and
136
Costed at band 5 community
professional staff
Dietitian 32 per hour aPSSRU 2016,201
pages 200 and
136
Costed at band 5 community
professional staff
District nurse 44 per hours aPSSRU 2016,201
page 142
Costed at band 6 community-
based nurses
Mental health practitioner 38 per hour aPSSRU 2016,201
page 168
Community mental health
team for adults with mental
health problems
Phlebotomist 24 per hour
Urine test (using urinalysis
analyser)
4.25 aPSSRU 2017,147
page 216; NICE
2015, page 7204
Inflated to 2016/17 prices using
HCHS index
Hospital and community services
Neurologist 217 NHS Reference
Costs 2015 to
2016148
l Non-admitted face-to-face
attendance first
l Code: WF01B-400
MS nurse (hospital) 53 per hour 30 minutes aPSSRU 2016,201
page 188; MS Trust
[www.mstrust.org.uk
(last accessed
9 September 2019)]
Based on band 7. Costed per
working hour
continued
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TABLE 42 Unit costs of health and social service resource use (continued )
Resource
Cost (£) per
contact
Average
consultation
time
Source
(service code/
currency code) Assumptions
MS nurse (home) 52 per hour aPSSRU 2016,201
page 142; MS
Trust (www.
mstrust.org.uk)
Based on band 7. Costed per
working hour
Therapy services
Physiotherapist (hospital) 34 per hour aPSSRU 2016,201
pages 183–5
Based on band 5
Physiotherapist
(community)
32 per hour aPSSRU 2016,201
pages 135–7
Based on band 5
Occupational therapist
(hospital)
34 per hour aPSSRU 2016,201
pages 183–5
Based on band 5
Occupational therapist
(community)
44 per hour aPSSRU 2016,201
page 159
Psychologist 55 per hour aPSSRU 2016,201
pages 183–5
Based on band 7 clinical
psychologist
Pharmacist 42 per hour aPSSRU 2016,201
pages 135–7
Based on band 6
NHS 111 service 13.29 per call Turner et al.205 Inflated from £12.26 to 2016
prices
Social services
Social worker 79 per hour 30 minutes aPSSRU 2016,201
page 156
Counsellor 43 per hour 30 minutes aPSSRU 2017,147
pages 153–5
Based on band 6 community-
based health-care staff,
scientific and professional staff
Home help 25 per hour 30 minutes aPSSRU 2016,201
pages 198 and
135–7
Based on band 3 community-
based health-care staff
Care assistant 25 per hour 30 minutes aPSSRU 2016,201
pages 198 and
135–7
Based on band 3 community-
based health-care staff
Day centre 41 per day aPSSRU 2013,202
page 128 (inflated
to 2016 prices)
Based on community care for
older people: high cost
Other
Crisis resolution team 195 per team
contact
5 team-member
hours
aPSSRU 2016,201
page 169
Based on assumption that each
team contact requires a total of
5 hours from team members
Care assistant (telephone) 25 per hour 6.56 minutes aPSSRU 2016,201
pages 198 and
135–7
Assumes same consultation
time as general practice nurse
(telephone)
Clinical support worker 23.50 per hour 30 minutes aPSSRU 2017,147
pages 153–5
Based on band 3 community-
based health-care staff,
scientific and professional staff
Social worker (home visit) 79 per hour 23.4 minutes aPSSRU 2016,201
page 156
Assumes same consultation
time as GP home visit
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TABLE 42 Unit costs of health and social service resource use (continued )
Resource
Cost (£) per
contact
Average
consultation
time
Source
(service code/
currency code) Assumptions
District nurse (telephone) 44 per hour 6.56 minutes aPSSRU 2016,201
page 142
Costed at band 6 community-
based nurses. Assumes same
consultation time as general
practice nurse (telephone)
Occupational therapist
(telephone)
44 per hour 6.56 minutes aPSSRU 2016,201
page 159
Uses community occupational
therapist costs. Assumes same
consultation time as general
practice nurse (telephone)
Home improvement agency
administrator (visit)
23 per hour 1 hour
Home improvement agency
administrator (telephone)
23 per hour 6.56 minutes
Home adaptations
Bath board 28.99 Mobility Smart
(Preston, UK)
Product: Marina bath board
(Inracare Ltd, Bridgend, UK)
Bath seat 268.69 Mobility Smart Product: width-adjustable
swivelling bath seat
Bath stool 26.29 Mobility Smart Product: bath stool with
rotating seat
Commode 41.66 Mobility Smart Product: Mobility Smart Super
Light Folding Commode
Electric bed 535.69 Mobility Smart Product: Mobility Smart Devon
Electric Adjustable Bed, 3 ft
Fit handrail (external) 42 – aPSSRU 2016,201
page 98
Equipment and adaptations –
minor adaptations
Fit handrail (internal) 28 – aPSSRU 2016,201
page 98
Equipment and adaptations –
minor adaptations
Fit handrail to bath 18 – aPSSRU 2016,201
page 98
Equipment and adaptations –
minor adaptations
Perching stool 71.29 Mobility Smart Product: bariatric perching stool
Profiling bed 899.00 Mobility Smart Product: Mobility Smart
Profiling Standard Bed
Raised toilet seat 16.49 Mobility Smart Product Savanah Raised Toilet
Seat (Homecraft, Patterson
Medical, Sutton-in-Ashfield, UK)
Ramp 316 – aPSSRU 2016,201
page 98
Equipment and adaptations –
minor adaptations
Rollator 100.89 Mobility Smart Product: Genesis Rollator
(Mobility Smart)
Seat assist 152.59 Mobility Smart Product: UpEasy Seat Assist
(Patterson Medical,
Sutton-in-Ashfield, UK)
Shower chair 108.19 Mobility Smart Product: folding shower
chair – polyurethane seat
Slide sheet 19.19 Mobility Smart Product: Mobility Smart Slide
Sheets (150 × 70 cm)
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TABLE 42 Unit costs of health and social service resource use (continued )
Resource
Cost (£) per
contact
Average
consultation
time
Source
(service code/
currency code) Assumptions
Stair lift (straight) 1927 – aPSSRU 2016,201
page 97
Equipment and adaptations –
major adaptations
Step 481 – aPSSRU 2016,201
page 98
Equipment and adaptations –
major adaptations
Tap turner 8.98 Mobility Smart Product: Universal Tap Turners
(Drive DeVilbiss Healthcare Ltd,
Birkenshaw, UK)
Toilet frame 41.99 Mobility Smart Product: Stamford Combi
Scandia Toilet Frame (Drive
DeVilbiss Healthcare Ltd)
Bed transfer aid 28.19 Mobility Smart Product: Solo Fixed Height Bed
Transfer Mobility Smart Aid
Trolley walker 93.79 Mobility Smart Product: adjustable-height
trolley walker
Walker 61.99 Mobility Smart Product: Days Lightweight
Tri-Wheel Walker [Days
Healthcare (Patterson Medical),
Sutton-in-Ashfield, UK]
Crutches 22.79 Mobility Smart Product: Coopers Elbow Double
Adjustable Crutches (Sunrise
Medical Limited, West
Midlands, UK)
Level-access shower 5,160 aPSSRU 2017,147
page 112
Walking frame/Zimmer
frame (Zimmer Biomet
Holdings, Inc. Warsaw,
IN, USA)
37.59 Mobility Smart Product: folding walking/
Zimmer frame with wheels
Walking stick/cane 10.99 Mobility Smart Product: folding walking stick
Magnifying glass 3.79 Mobility Smart Product: Mobility Smart
Magnifying Glass
Bed rail 103.49 Mobility Smart Product: 30-inch safety bed rail
Bed lever 37.39 Mobility Smart Product: bed lever, double-ended
Bed raiser 82.69 Mobility Smart Product: Langham Multi-Purpose
Furniture Raiser (Langham,
Castle Donington, UK)
Kettle tipper 14.19 Mobility Smart Product: cordless kettle tipper
Hoist 823.69 Mobility Smart Product: Samsoft 150 Patient
Hoist (Drive DeVilbiss
Healthcare Ltd)
Hoist sling 58.99 Mobility Smart Product: Economy Universal
Sling (Mobility Smart)
Bath lift 818.89 Mobility Smart Product: Relaxa Belt Bath Lift
(CR Manufacturing Ltd,
Aylesbury, UK)
Foot supports/orthotics 38.59 Mobility Smart Product: foot supports
metatarsal raise
Air pressure mattress 892.49 Mobility Smart Product: UTS Air Pressure
Mattress System (Mobility
Smart)
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TABLE 42 Unit costs of health and social service resource use (continued )
Resource
Cost (£) per
contact
Average
consultation
time
Source
(service code/
currency code) Assumptions
Electric door opener 6000 UHS/SQ response Social Service partial
contribution
Widen front door 578 aPSSRU 2017147
Transfer board 14.69 Mobility Smart Product: short transfer board
Hospital bed 899.98 Mobility Smart Product: Invacare Medley Ergo
Bed (Invacare Corporation,
Elyria, OH, USA)
Central heating 0.00b
A&E services
Visit to A&E by ambulance 236
A&E attendance 137.82 NHS Reference
Costs 2015 to
2016148
Weighted average of emergency
medicine (all investigation/
treatment categories)
Other hospital services
Day hospital 477 Day cases NHS Reference Costs
2015 to 2016148
AA30C/D/E/F
Weighted average of medical
care of patients with MS
Nights on hospital ward for
planned admission
2575 Elective
inpatient
NHS Reference Costs
2015 to 2016148
(AA30C/D/E/F)
Weighted average of medical
care of patients with MS
Contact Unit cost (£) Area
Number of contacts with anyone else from the hospital
Acupuncture 111 Outpatient
procedures
NHS Reference
Costs 2015
to 2016148
(191-AB23Z)
Pain management:
acupuncture for pain
management
Clinical haematology 136 Consultant led NHS Reference
Costs 2015 to
2016148 (WF01D)
Non-admitted face-to-face
attendance, first; national
average unit cost
Consultant (no specific
details)
64 Hospital-based
scientific and
professional
staff
aPSSRU 2016,201
pages 183–85
Cost per working hour:
band 8a
Radiology 182 Consultant led NHS Reference
Costs 2015 to
2016148 (WF01B)
Non-admitted face-to-face
attendance, first; national
average unit cost
Walk-in clinic 44 per hour Community-
based health-
care staff
aPSSRU 2017,147
page 160; PSSRU
2015203
Nurses – assumed at band 6
with an average consultation
time of 15.5 minutes
Wheelchair assessment 247 Community
health services
NHS Reference
Costs 2015
to 2016148
(WCA-WC02)
Wheelchair services adults –
assessment, medium need
HCHS, Hospital and Community Health Service; PSSRU, Personal Social Services Research Unit.
a Where available, costs include qualifications.
b The cost of these adaptations cannot be estimated accurately. Prices vary considerably, with grants of up to £30,000
available for patients in England (dependent on household income and household savings); see www.gov.uk/disabled-
facilities-grants (accessed 9 September 2019).
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Appendix 14 Plan for longer-term
cost-effectiveness modelling
Modelling approach
A Markov model was developed, given the chronic properties of MS. The decision-analytic model was
developed using Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) and Visual Basic for
Applications (Microsoft Corporation). The model simulated costs and QALYs over a lifetime horizon.
For horizons exceeding 12 months, future costs and QALYs were discounted at 3.5% per year, as
recommended by NICE.206
Model structure
Figure 11 illustrates the outline structure of the Markov model used to evaluate the longer-term
cost-effectiveness of cognitive rehabilitation.
The psychological impact of MS was categorised into three mutually exclusive states of mild impact,
moderate impact and severe impact, as follows:
1. For participants with MSIS-Psy scores of 9–17, the psychological impact of their MS was classified
as mild.
2. For participants with MSIS-Psy scores of 18–26, the psychological impact of their MS was classified
as moderate.
3. For participants with MSIS-Psy scores of ≥ 27, the psychological impact of their MS was classified
as severe.
The probabilistic structure of the model, uncertainty of the input parameters and repeated simulation
requires assumptions to be made regarding the distributions to be applied.
Low
psychological
impact
Moderate
psychological
impact
High
psychological
impact
Dead
FIGURE 11 Markov model structure.
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Transition probabilities are constrained to the unit interval between 0 and 1. To satisfy this property, the
beta distribution was used to estimate transition probability. The probability of remaining in a state was
calculated as 1 minus the sum of the other transition probabilities.
Utilities were estimated from the EQ-5D-5L trial data over the interval –0.594 to 1.000. Despite estimating
over the unit interval, the beta distribution was employed, as the proportion of trial participants with
HRQoL worse than death is low.
Cost data are bounded in the 0 – infinity interval, but are often skewed. Although the Poisson distribution
would be a suitable candidate for these counts, we used the gamma distribution (conjugate to the Poisson
distribution) as this was considered better able to account for the skewness in cost data.
Transitions are permitted between any two live health states, or between any live state and the absorbing
death state. Aside from death, it was assumed that there were no intervention-related adverse events that
affected an individual’s HRQoL or the psychological impact of MS.
Model Inputs
We assumed that the population adhered to the trial protocol, with participants randomly allocated to
either cognitive rehabilitation or usual care. The base-case analysis was to be estimated using a cohort of
10,000 patients aged 49 years, corresponding with the average age of participants in the CRAMMS trial.
The CRAMMS trial did not report any deaths. Therefore, we assumed that patients would not be at
increased risk of death from the intervention. Nevertheless, individuals with MS are recognised to face a
higher all-cause mortality rate and shorter life expectancy than those of the general population,154 with risk
factors dependent on a range of factors including MS type, disability status (as defined by the EDSS), age
at MS diagnosis and comorbidities. All-cause, age-related mortality rates were based on the 2014–16
Office for National Statistics National Life Tables: England and Wales,207 with adjustment for the gender-
specific MS standardised mortality ratio presented in a meta-analysis.208
To convert the standardised mortality ratio-adjusted mortality probability for a cycle length of 6 months, the
formulae below were used, in which pn and rn are the n-month probability and rate of death, respectively:209
r1 = −
ln(1−p12)
 
12
. (3)
p6 = 1− e
−6r1 . (4)
Namely, the 12-month mortality probability was transformed to the monthly death rate, which was
subsequently transformed back to a 6-month probability.
All costs in the model were reported as Great British pounds and inflated to 2016 prices, based on the
within-trial costs reported. Costs associated with each health state defined by the model concern the costs
relating to the delivery of the intervention and any health-care service usage recorded by participants over
the preceding interval.
For the deterministic analyses, mean costs per participant obtained from the within-trial analysis were used.
For the probabilistic analyses, the gamma distribution utilising mean costs and associated standard errors
obtained from the trial were used, as recommended by Briggs et al.209 Similarly, mean utilities observed in
the within-trial analysis were used for the deterministic analysis, whereas the beta distribution utilising
mean utility and associated standard errors were used, as recommended by Briggs et al.209
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Appendix 15 Intervention costs
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TABLE 43 Cost of cognitive rehabilitation
Resource area Resource Explanation/details Resource use Unit cost Source
Intervention
total (£)
Training Training in CRAMMS
trial provided by clinical
psychologist to AP
1× clinical psychologist (band 8a) to
deliver a half-day training session to
1× AP. Training is delivered once
per site
4 hours per site Clinical psychologist:
£62 per hour (£248 per site)
l PSSRU 2017,147
pages 153–5
l Trial team
1240.00
Training provided to 1× AP
(band 5) in order to appropriately
conduct CRAMMS trial sessions
4 hours per trainee
at each site
AP: £33 per hour
(£132 per site)
l PSSRU 2017,147
pages 153–5
l Trial team
660.00
Cognitive assessment Assessment conducted
by clinical psychologist
Following referral of a patient by a
neurologist to clinical psychology,
an assessment is conducted by a
clinical psychologist (band 8a) to
determine patient eligibility for the
CRAMMS trial
2 hours per
participant
Clinical psychologist: £62 per
hour (£124 per participant)
l PSSRU 2017,147
pages 153–5
Trial team
30,380.00
Delivery of cognitive
rehabilitation
Sessions delivered by AP AP (band 5) delivers 10 sessions
individually to each group. Each
session lasts for 1 hour and
30 minutes. An additional
30 minutes is required for both
set-up and close-down. Provision
for a 30-minute catch-up session
has been included for 137 of
450 sessions, for those participants
missing the previous session
2 hours 45 minutes
per session
AP: £33 per hour
(£90.75 per session)
l PSSRU 2017,147
pages 153–5
Trial team
39,385.50
Supervision conducted
by clinical psychologist
1× clinical psychologist (band 8a)
conducts supervision of AP.
Supervision sessions of 1 hour
occur on a weekly basis, of which,
it is assumed, 30 minutes is
attributable to the CRAMMS trial
30 minutes per site l Clinical psychologist:
£62 per hour
l AP: £33 per hour
l (£47.50 per site, per week)
l PSSRU 2017,147
pages 153–5
Trial team
2375.00
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Resource area Resource Explanation/details Resource use Unit cost Source
Intervention
total (£)
Administration 1× administrator (band 3) required
for 30 minutes per session to send
reminders to patients of upcoming
intervention session
30 minutes per
session
Administration: £25 per hour
(£12.50 per session)
l PSSRU 2017,147
pages 153–5
Trial team
5625.00
Intervention manual One intervention manual per
participant for the full length of
the intervention plus one set of
facilitator notes for the AP required.
No provision for spare copies has
been included
1× manual per
participant
£2.00 per participant manual/
facilitator notes
Trial team 500.00
Stationery Stationery required for participants
to complete various session tasks
and the intervention manual
Estimated on
per-participant
basis
£1.00 per participant Trial team 245.00
Refreshments Offered as part of the rehabilitation
session, with participants
encouraged to share experiences
with one another
Estimated on
per-participant,
per-session basis
£0.50 per participant per
session
Trial team 1225.00
Total cost (£) of cognitive rehabilitation (including cognitive assessment) 81,635.50
Total cost (£) of cognitive rehabilitation per participant (including cognitive assessment) 333.21
Total cost (£) of cognitive rehabilitation (excluding cognitive assessment) 51,255.50
Total cost (£) of cognitive rehabilitation per participant (excluding cognitive assessment) 209.21
PSSRU, Personal Social Services Research Unit.
Notes
Based on 245 participants, across 45 groups receiving 10 cognitive rehabilitation sessions across five sites.
A total of 450 sessions were delivered.
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Appendix 16 Resource use for available cases
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TABLE 44 Resource and service use costs: baseline
Resource Trial group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI)
General practice and community nursing services
Number of times you saw a GP at the surgery Usual care (n = 203) 270 1.33 (4.17) 0 50 –0.06 (–0.68 to 0.55)
Cognitive rehabilitation (n = 245) 311 1.27 (2.34) 0 20
Number of times you saw a GP at your home Usual care (n = 203) 7 0.03 (0.21) 0 2 0.01 (–0.04 to –0.07)
Cognitive rehabilitation (n = 245) 12 0.05 (0.37) 0 5
Number of times you spoke to a GP on the
telephone
Usual care (n = 203) 141 0.70 (3.30) 0 45 –0.25 (–0.69 to 0.19)
Cognitive rehabilitation (n = 245) 108 0.44 (1.06) 0 10
Number of times you saw a nurse at the surgery Usual care (n = 203) 93 0.46 (1.16) 0 12 –0.02 (–0.22 to 0.19)
Cognitive rehabilitation (n = 245) 108 0.44 (1.05) 0 8
Number of times you saw a nurse at your home Usual care (n = 203) 38 0.19 (1.46) 0 20 –0.05 (–0.29 to 0.19)
Cognitive rehabilitation (n = 245) 33 0.13 (1.11) 0 12
Number of times you saw a counsellor at the
surgery
Usual care (n = 203) 25 0.12 (0.94) 0 10 –0.03 (–0.20 to 0.015)
Cognitive rehabilitation (n = 245) 24 0.10 (0.90) 0 12
Number of contacts with anyone else from the
surgery
Usual care (n = 203) 33 0.16 (0.96) 0 10 –0.01 (–0.19 to 0.016)
Cognitive rehabilitation (n = 245) 37 0.15 (0.92) 0 12
Number of times you saw a GP outside usual
surgery hours (e.g. out-of-hours GP service)
Usual care (n = 203) 0 – 0 0 –
Cognitive rehabilitation (n = 245) 0 – 0 0
Total cost (£) of general practice and community
nursing services
Usual care (n = 203) 88.77 (267.78) 0 3430 –11.35 (–49.29 to 26.59)
Cognitive rehabilitation (n = 245) 77.42 (127.90) 0 790.22
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Resource Trial group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI)
Hospital and community services
Number of times you saw a neurologist at the
hospital
Usual care (n = 203) 89 0.43 (0.63) 0 3 0.01 (–0.11 to 0.13)
Cognitive rehabilitation (n = 245) 110 0.45 (0.65) 0 5
Number of times you saw a MS nurse at the
hospital
Usual care (n = 203) 140 0.69 (1.20) 0 12 –0.05 (–0.26 to 0.15)
Cognitive rehabilitation (n = 245) 156 0.64 (1.03) 0 8
Number of times you saw a MS nurse at your
home
Usual care (n = 203) 17 0.08 (0.48) 0 5 –0.01 (–0.10 to 0.07)
Cognitive rehabilitation (n = 245) 17 0.07 (0.042) 0 5
Total cost (£) of hospital and community services Usual care (n = 203) 115.02 (145.63) 0 730.50 1.08 (–26.60 to –28.77)
Cognitive rehabilitation (n = 245) 116.11 (151.07) 0 1164.50
A&E services
Number of times you went to an A&E unit Usual care (n = 55) 5 0.09 (0.29) 0 1 –0.01 (–0.12 to 0.09)
Cognitive rehabilitation (n = 79) 6 0.08 (0.31) 0 2
Of these, how many were by ambulance? Usual care (n = 55) 3 0.05 (0.23) 0 1 –0.02 (–0.10 to 0.07)
Cognitive rehabilitation (n = 79) 3 0.04 (0.25) 0 2
Did your visit to A&E result in an overnight stay in
hospital?
Usual care (n = 55) 0 0.03 (–0.01 to 0.06)
Cognitive rehabilitation (n = 79) 2
Total number of nights spent in night as a result
of A&E visits
Usual care (n = 55) 0 0 (0) 0 0 0.06 (–0.04 to 0.17)
Cognitive rehabilitation (n = 79) 5 0.06 (0.05) 0 3
Total cost (£) of A&E services Usual care (n = 55) 6.85 (46.96) 0 373.82 29.26 (–22.18 to 80.70)
Cognitive rehabilitation (n = 79) 36.11 (371.33) 4403.64
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TABLE 44 Resource and service use costs: baseline (continued )
Resource Trial group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI)
Other hospital services
Number of times you attended a day hospital Usual care (n = 203) 35 0.17 (0.63) 0 4 0.17 (–0.02 to 0.36)
Cognitive rehabilitation (n = 245) 84 0.34 (1.26) 0 12
Number of times you went to a hospital
outpatient clinic
Usual care (n = 203) 103 0.51 (0.84) 0 4 –0.05 (–0.21 to 0.11)
Cognitive rehabilitation (n = 245) 111 0.45 (0.87) 0 5
Number of nights you spent on a hospital ward
as a result of a planned admission
Usual care (n = 203) 4 0.02 (0.17) 0 2 0.17 (–0.04 to 0.38)
Cognitive rehabilitation (n = 245) 47 0.19 (1.53) 0 22
Number of contacts with anyone else from the
hospital
Usual care (n = 203) 40 0.20 (0.71) 0 6 0.04 (–0.11 to 0.20)
Cognitive rehabilitation (n = 245) 59 0.24 (0.92) 0 10
Total cost (£) of other hospital services Usual care (n = 203) 246.44 (553.37) 0 5150.00 498.12 (–54.53 to 1050.77)
Cognitive rehabilitation (n = 245) 744.56 (3983.82) 56,832.50
Therapy services
Number of contacts with a hospital-based
physiotherapist
Usual care (n = 203) 112 0.55 (1.60) 0 12 0.15 (–0.18 to 0.48)
Cognitive rehabilitation (n = 245) 172 0.70 (1.92) 0 12
Number of contacts with a community-based
physiotherapist
Usual care (n = 203) 65 0.32 (1.27) 0 12 0.09 (–0.19 to 0.37)
Cognitive rehabilitation (n = 245) 100 0.41 (1.66) 0 12
Number of contacts with a hospital-based
occupational therapist
Usual care (n = 203) 29 0.14 (0.67) 0 5 –0.04 (–0.14 to 0.06)
Cognitive rehabilitation (n = 245) 25 0.10 (0.43) 0 4
Number of contacts with a community-based
occupational therapist
Usual care (n = 203) 32 0.16 (0.58) 0 5 0.06 (–0.07 to 0.18)
Cognitive rehabilitation (n = 245) 53 0.22 (0.74) 0 7
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Resource Trial group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI)
Number of contacts with a psychologist Usual care (n = 203) 52 0.26 (0.91) 0 6 –0.04 (–0.20 to 0.12)
Cognitive rehabilitation (n = 245) 53 0.22 (0.83) 0 6
Number of contacts with a pharmacist Usual care (n = 203) 365 1.80 (2.69) 0 12 –0.61 (–1.05 to -0.18)
Cognitive rehabilitation (n = 245) 290 1.18 (2.03) 0 12
Number of times you contacted the NHS 111
service
Usual care (n = 203) 15 0.07 (0.30) 0 2 –0.00 (–0.7 to 0.07)
Cognitive rehabilitation (n = 245) 18 0.07 (0.41) 0 5
Total cost (£) of therapy services Usual care (n = 203) 130.74 (163.29) 0 834.00 –18.23 (–47.45 to 10.98)
Cognitive rehabilitation (n = 245) 112.51 (151.28) 0 846.00
Social services
Number of times you saw a social worker Usual care (n = 203) 17 0.08 (0.41) 0 4 0.00 (–0.09 to 0.09)
Cognitive rehabilitation (n = 245) 21 0.09 (0.52) 0 5
Number of times you saw a home help Usual care (n = 203) 520 2.56 (15.05) 0 168 –0.05 (–2.93 to 2.83)
Cognitive rehabilitation (n = 245) 616 2.51 (15.74) 0 180
Number of times you saw a care assistant Usual care (n = 203) 1140 5.62 (28.77) 0 275 –1.34 (–6.34 to 3.66)
Cognitive rehabilitation (n = 245) 1048 4.28 (25.08) 0 336
Number of times you visited a day centre Usual care (n = 203) 65 0.32 (1.86) 0 15 0.18 (–0.26 to 0.62)
Cognitive rehabilitation (n = 245) 123 0.50 (2.70) 0 20
Number of contacts with anyone else from social
services
Usual care (n = 203) 48 0.24 (2.00) 0 24 –0.19 (–0.45 to 0.07)
Cognitive rehabilitation (n = 245) 11 0.04 (0.43) 0 6
Total cost (£) of social services Usual care (n = 203) 715.55 (2414.36) 0 12,684.00 –179.38 (–610.23 to 251.47)
Cognitive rehabilitation (n = 245) 536.17 (2225.14) 20,776.63
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TABLE 44 Resource and service use costs: baseline (continued )
Resource Trial group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI)
Medications
Number of medications taken Usual care (n = 203) 4.86 (3.22) 0 18 –0.34 (–0.95 to 0.26)
Cognitive rehabilitation (n = 245) 4.51 (3.25) 0 17
Cost (£) of medications taken Usual care (n = 203) 1758.24
(2232.84)
0 15,173.91 –109.43 (–527.73 to 308.87)
Cognitive rehabilitation (n = 245) 1648.81
(2250.62)
0 18,551.35
Number of medications taken (excluding
disease-modifying therapies)
Usual care (n = 203) 4.44 (3.29) 0 18 –0.32 (–0.93 to 0.30)
Cognitive rehabilitation (n = 245) 4.12 (3.26) 0 16
Cost (£) of medications taken (excluding
disease-modifying therapies)
Usual care (n = 203) 261.06 (1232.32) 0 15,173.91 –120.03 (–289.28 to 49.22)
Cognitive rehabilitation (n = 245) 141.03 (497.77) 0 6582.07
A&E, accident and emergency.
a In accordance with CONSORT guidelines, significance tests of baseline differences were not done.
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TABLE 45 Resource and service use costs: 6-month follow-up
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
General practice and community nursing services
Number of times you saw a GP at the surgery Usual care (n = 187) 165 0.88 (1.55) 0 12 –0.03 (–0.35 to 0.30) 0.880
Cognitive rehabilitation (n = 224) 192 0.86 (1.78) 0 20
Number of times you saw a GP at your home Usual care (n = 187) 3 0.02 (0.22) 0 3 0.01 (–0.03 to 0.05) 0.593
Cognitive rehabilitation (n = 224) 6 0.03 (0.01) 0 2
Number of times you spoke to a GP on the
telephone
Usual care (n = 187) 93 0.50 (1.39) 0 12 –0.11 (–0.33 to 0.12) 0.342
Cognitive rehabilitation (n = 224) 87 0.39 (0.92) 0 7
Number of times you saw a nurse at the surgery Usual care (n = 187) 64 0.34 (0.78) 0 7 0.01 (–0.14 to 0.17) 0.852
Cognitive rehabilitation (n = 224) 80 0.36 (0.83) 0 5
Number of times you saw a nurse at your home Usual care (n = 187) 12 0.06 (0.47) 0 6 0.16 (–0.14 to 0.45) 0.289
Cognitive rehabilitation (n = 224) 50 0.22 (2.00) 0 26
Number of times you saw a counsellor at the
surgery
Usual care (n = 187) 27 0.14 (0.98) 0 10 0.02 (–0.18 to 0.21) 0.869
Cognitive rehabilitation (n = 224) 36 0.16 (1.02) 0 12
Number of contacts with anyone else from the
surgery
Usual care (n = 187) 30 0.16 (0.79) 0 6 –0.09 (–0.21 to 0.02) 0.121
Cognitive rehabilitation (n = 224) 15 0.07 (0.39) 0 4
Number of times you saw a GP outside usual
surgery hours (e.g. out-of-hours GP service)
Usual care (n = 187) 0 – 0 0 – –
Cognitive rehabilitation (n = 224) 0 – 0 0
Total cost (£) of general practice and community
nursing services
Usual care (n = 187) 61.42 (106.77) 0 792.00 –1.32 (–22.52 to 19.88) 0.903
Cognitive rehabilitation (n = 224) 60.10 (110.76) 0 957.76
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TABLE 45 Resource and service use costs: 6-month follow-up (continued )
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Hospital and community services
Number of times you saw a neurologist at the
hospital
Usual care (n = 187) 78 0.42 (0.69) 0 3 –0.00 (–0.14 to 0.14) 0.979
Cognitive rehabilitation (n = 224) 93 0.42 (0.76) 0 6
Number of times you saw a MS nurse at the
hospital
Usual care (n = 187) 101 0.54 (0.99) 0 6 0.01 (–0.17 to 0.20) 0.887
Cognitive rehabilitation (n = 224) 124 0.55 (0.93) 0 5
Number of times you saw a MS nurse at your
home
Usual care (n = 187) 12 0.06 (0.42) 0 5 –0.00 (–0.07 to 0.07) 0.964
Cognitive rehabilitation (n = 224) 14 0.06 (0.32) 0 3
Total cost (£) of hospital and community services Usual care (n = 187) 106.49 (163.28) 0 810.00 –0.58 (–33.93 to 32.77) 0.973
Cognitive rehabilitation (n = 224) 105.92 (177.94) 0 1408.00
Therapy services
Number of contacts with a hospital-based
physiotherapist
Usual care (n = 187) 133 0.71 (2.12) 0 16 –0.13 (–0.52 to 0.26) 0.50
Cognitive rehabilitation (n = 225) 130 0.58 (1.90) 0 15
Number of contacts with community-based
physiotherapist
Usual care (n = 187) 209 1.12 (3.49) 0 26 –0.34 (–0.94 to 0.26) 0.27
Cognitive rehabilitation (n = 225) 175 0.78 (2.72) 0 26
Number of contacts with a hospital-based
occupational therapist
Usual care (n = 187) 51 0.27 (1.24) 0 10 –0.16 (–0.35 to 0.03) 0.10
Cognitive rehabilitation (n = 225) 25 0.11 (0.68) 0 6
Number of contacts with a community-based
occupational therapist
Usual care (n = 187) 31 0.17 (0.53) 0 3 0.09 (–0.07 to 0.24) 0.27
Cognitive rehabilitation (n = 225) 57 0.25 (0.97) 0 7
Number of contacts with a psychologist Usual care (n = 187) 44 0.24 (1.18) 0 12 –0.03 (–0.24 to 0.18) 0.77
Cognitive rehabilitation (n = 225) 46 0.20 (1.01) 0 12
Number of contacts with a pharmacist Usual care (n = 187) 329 1.76 (3.27) 0 24 –0.45 (–0.98 to 0.08) 0.10
Cognitive rehabilitation (n = 225) 295 1.31 (2.21) 0 12
Number of times you contacted the NHS 111 service Usual care (n = 187) 10 0.05 (0.36) 0 4 0.02 (–0.05 to 0.09) 0.62
Cognitive rehabilitation (n = 225) 16 0.07 (0.36) 0 3
Total cost (£) of therapy services Usual care (n = 187) 164.06 (211.92) 0 1084.00 –37.34 (–74.45 to 0.24) 0.05*
Cognitive rehabilitation (n = 225) 127.71 (171.19) 0 930.00
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Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Social services
Number of times you saw a social worker Usual care (n = 187) 11 0.06 (0.33) 0 3 0.08 (–0.06 to 0.21) 0.25
Cognitive rehabilitation (n = 225) 31 0.14 (0.88) 0 10
Number of times you saw a home help Usual care (n = 187) 149 0.80 (3.89) 0 24 1.71 (–0.50 to 3.91) 0.13
Cognitive rehabilitation (n = 225) 563 2.50 (14.94) 0 180
Number of times you saw a care assistant Usual care (n = 187) 2483 13.28 (51.12) 0 364 –9.15 (–16.51 to –1.80) 0.01**
Cognitive rehabilitation (n = 225) 928 4.12 (21.14) 0 182
Number of times you visited a day centre Usual care (n = 187) 135 0.72 (3.69) 0 36 0.07 (–0.60 to 0.74) 0.84
Cognitive rehabilitation (n = 225) 178 0.79 (3.25) 0 24
Number of contacts with anyone else from
social services
Usual care (n = 187) 37 0.20 (1.49) 0 16 –0.12 (–0.32 to 0.09) 0.26
Cognitive rehabilitation (n = 225) 18 0.08 (0.41) 0 4
Total cost (£) of social services Usual care (n = 187) 510.40 (1664.66) 0 10,544.00 –66.26 (–392.55 to 260.02) 0.69
Cognitive rehabilitation (n = 225) 444.14 (1687.85) 0 11,170.19
A&E services
Number of times you went to an A&E unit Usual care (n = 132) 7 0.05 (0.26) 0 2 0.05 (–0.02 to 0.12) 0.19
Cognitive rehabilitation (n = 167) 17 0.10 (0.36) 0 2
Of these, how many were by ambulance? Usual care (n = 132) 2 0.02 (0.12) 0 1 0.01 (–0.02 to 0.05) 0.46
Cognitive rehabilitation (n = 167) 5 0.03 (0.20) 0 2
Did your visit to A&E result in an overnight stay
in hospital?
Usual care (n = 132) 1 0.02 (–0.01 to 0.04) 0.27
Cognitive rehabilitation (n = 167) 4
Total number of nights spent in night as a result
of A&E visits
Usual care (n = 132) 1 0.01 (0.32) 0 1 0.18 (–0.05 to 0.41) 0.12
Cognitive rehabilitation (n = 167) 5 0.19 (1.32) 0 12
Total cost (£) of A&E services Usual care (n = 132) 27.23 (280.63) 0 3793.82 94.54 (–37.74 to 226.82) 0.16
Cognitive rehabilitation (n = 167) 121.77 (58.92) 0 8059.64
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TABLE 45 Resource and service use costs: 6-month follow-up (continued )
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Other hospital services
Number of times you attended a day hospital Usual care (n = 187) 23 0.12 (0.53) 0 4 0.13 (–0.04 to 0.30) 0.14
Cognitive rehabilitation (n = 225) 57 0.25 (1.11) 0 12
Number of times you went to a hospital
outpatient clinic
Usual care (n = 187) 119 0.64 (1.27) 0 7 –0.04 (–0.28 to 0.21) 0.77
Cognitive rehabilitation (n = 225) 135 0.60 (1.21) 0 9
Number of nights you spent on a hospital ward
as a result of a planned admission
Usual care (n = 187) 1 0.01 (0.07) 0 1 0.03 (–0.01 to 0.07) 0.18
Cognitive rehabilitation (n = 225) 8 0.04 (0.30) 0 3
Number of contacts with anyone else from the
hospital
Usual care (n = 187) 95 0.51 (1.33) 0 9 0.11 (–0.25 to 0.48) 0.54
Cognitive rehabilitation (n = 225) 140 0.62 (2.23) 0 24
Total cost (£) of other hospital services Usual care (n = 187) 173.01 (398.26) 0 3217.00 136.50 (–36.97 to 309.97) 0.12
Cognitive rehabilitation (n = 225) 309.51 (1150.64) 13 to
568.00
Medications
Number of medications taken Usual care (n = 187) 5.29 (4.10) 0 20 –0.33 (–1.10 to 0.45) 0.41
Cognitive rehabilitation (n = 225) 4.97 (3.89) 0 26
Cost of medications taken Usual care (n = 187) 1987.31
(3478.53)
0 26,516.08 –313.55 (–860.86 to 233.77) 0.26
Cognitive rehabilitation (n = 225) 1673.76
(2107.78)
0 8557.67
Number of medications taken (excluding
disease-modifying therapies)
Usual care (n = 187) 4.89 (4.12) 0 20 –0.29 (–1.08 to 0.49) 0.46
Cognitive rehabilitation (n = 225) 4.59 (3.94) 0 26
Cost (£) of medications taken (excluding
disease-modifying therapies)
Usual care (n = 187) 428.61 (2390.56) 0 24,841.15 –181.13 (–522.38 to 160.12) 0.30
Cognitive rehabilitation (n = 225) 247.48 (942.13) 0 8557.67
*Significant at the 5% level, **significant at the 1% level.
A&E, accident and emergency.
a In accordance with CONSORT guidelines, significance tests of baseline differences were not done.
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TABLE 46 Resource and service use costs: 12-month follow-up
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
General practice and community nursing services
Number of times you saw a GP at the surgery Usual care (n = 172) 106 0.62 (1.22) 0 10 0.31 (–0.09 to 0.72) 0.130
Cognitive rehabilitation (n = 211) 196 0.93 (2.46) 0 30
Number of times you saw a GP at your home Usual care (n = 172) 10 0.06 (0.43) 0 5 –0.02 (–0.09 to 0.05) 0.576
Cognitive rehabilitation (n = 211) 8 0.04 (0.27) 0 3
Number of times you spoke to a GP on the
telephone
Usual care (n = 172) 66 0.38 (1.07) 0 10 –0.02 (–0.22 to 0.18) 0.856
Cognitive rehabilitation (n = 211) 77 0.36 (0.96) 0 7
Number of times you saw a nurse at the surgery Usual care (n = 172) 52 0.30 (0.62) 0 3 0.04 (–0.11 to 0.19) 0.603
Cognitive rehabilitation (n = 211) 72 0.34 (0.80) 0 6
Number of times you saw a nurse at your home Usual care (n = 172) 11 0.06 (0.57) 0 7 0.04 (–0.12 to 0.20) 0.623
Cognitive rehabilitation (n = 211) 22 0.10 (0.94) 0 13
Number of times you saw a counsellor at the
surgery
Usual care (n = 172) 12 0.07 (0.53) 0 6 0.17 (–0.04 to 0.38) 0.109
Cognitive rehabilitation (n = 211) 51 0.24 (0.09) 0 13
Number of contacts with anyone else from the
surgery
Usual care (n = 172) 12 0.07 (0.33) 0 3 0.15 (–0.01 to 0.32) 0.069
Cognitive rehabilitation (n = 211) 47 0.22 (1.06) 0 10
Number of times you saw a GP outside usual
surgery hours (e.g. out-of-hours GP service)
Usual care (n = 172) 0 – 0 0 – –
Cognitive rehabilitation (n = 211) 0 – 0 0
Total cost (£) of general practice and community
services
Usual care (n = 172) 48.07 (86.43) 0 600.00 17.07 (–6.93 to 41.07) 0.163
Cognitive rehabilitation (n = 211) 65.15 (141.08) 0 1488.43
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TABLE 46 Resource and service use costs: 12-month follow-up (continued )
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Hospital and community services
Number of times you saw a neurologist at the
hospital
Usual care (n = 172) 65 0.38 (0.62) 0 3 0.01 (–0.11 to 0.13) 0.863
Cognitive rehabilitation (n = 211) 82 0.39 (0.59) 0 3
Number of times you saw a MS nurse at the
hospital
Usual care (n = 172) 82 0.48 (0.83) 0 4 0.01 (–0.15 to 0.17) 0.935
Cognitive rehabilitation (n = 211) 102 0.48 (0.76) 0 3
Number of times you saw a MS nurse at your
home
Usual care (n = 172) 8 0.05 (0.26) 0 2 –0.00 (–0.06 to 0.07) 0.979
Cognitive rehabilitation (n = 211) 10 0.05 (0.36) 0 4
Total cost (£) of hospital and community services Usual care (n = 172) 95.75 (144.23) 0 730.50 2.16 (–25.72 to 30.04) 0.879
Cognitive rehabilitation (n = 211) 97.91 (134.23) 0 677.50
Therapy services
Number of contacts with a hospital-based
physiotherapist
Usual care (n = 175) 72 0.41 (1.40) 0 11 0.30 (–0.06 to 0.65) 0.11
Cognitive rehabilitation (n = 212) 150 0.71 (2.05) 0 13
Number of contacts with community-based
physiotherapist
Usual care (n = 175) 156 0.89 (7.05) 0 90 –0.26 (–1.32 to 0.80) 0.63
Cognitive rehabilitation (n = 212) 134 0.63 (3.14) 0 39
Number of contacts with a hospital-based
occupational therapist
Usual care (n = 175) 27 0.15 (0.71) 0 7 –0.10 (–0.21 to 0.02) 0.09
Cognitive rehabilitation (n = 212) 12 0.06 (0.41) 0 5
Number of contacts with a community-based
occupational therapist
Usual care (n = 175) 26 0.15 (0.54) 0 4 –0.12 (–0.06 to 0.30) 0.19
Cognitive rehabilitation (n = 212) 57 0.27 (1.12) 0 12
Number of contacts with a psychologist Usual care (n = 175) 51 0.29 (1.54) 0 13 –0.09 (–0.34 to 0.15) 0.45
Cognitive rehabilitation (n = 212) 42 0.20 (0.86) 0 8
Number of contacts with a pharmacist Usual care (n = 175) 204 1.17 (2.24) 0 12 –0.04 (–0.48 to 0.39) 0.85
Cognitive rehabilitation (n = 212) 238 1.12 (2.10) 0 20
Number of times you contacted the NHS 111
service
Usual care (n = 175) 16 0.09 (0.38) 0 3 0.02 (–0.11 to 0.08) 0.73
Cognitive rehabilitation (n = 212) 16 0.08 (0.52) 0 6
Total cost (£) of therapy services Usual care (n = 175) 120.50 (293.59) 0 3054.00 –3.41 (–51.83 to 45.01) 0.89
Cognitive rehabilitation (n = 212) 117.09 (187.12) 0 1457.00
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Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Social services
Number of times you saw a social worker Usual care (n = 175) 27 0.15 (0.88) 0 10 0.09 (–0.21 to 0.39) 0.57
Cognitive rehabilitation (n = 212) 51 0.24 (1.85) 0 26
Number of times you saw a home help Usual care (n = 175) 250 1.43 (12.81) 0 156 0.46 (–1.90 to 2.81) 0.70
Cognitive rehabilitation (n = 212) 400 1.89 (10.77) 0 90
Number of times you saw a care assistant Usual care (n = 175) 2249 12.93 (55.10) 0 364 –6.75 (–15.99 to 2.50) 0.15
Cognitive rehabilitation (n = 212) 1310 6.18 (2.53) 0 364
Number of times you visited a day centre Usual care (n = 175) 47 0.27 (1.99) 0 22 0.03 (–0.33 to 0.40) 0.86
Cognitive rehabilitation (n = 212) 64 0.30 (1.65) 0 13
Number of contacts with anyone else from social
services
Usual care (n = 175) 124 0.71 (4.85) 0 45 –0.53 (–1.21 to 0.15) 0.12
Cognitive rehabilitation (n = 212) 38 0.18 (1.16) 0 13
Total cost (£) of social services Usual care (n = 175) 568.80 (2194.07) 0 19,607.40 –112.61 (–502.44 to 277.23) 0.570
Cognitive rehabilitation (n = 212) 456.19 (1704.96) 0 10,134.00
A&E services
Number of times you went to an A&E unit Usual care (n = 148) 10 0.07 (0.32) 0 3 –0.05 (–0.10 to 0.01) 0.09
Cognitive rehabilitation (n = 183) 4 0.02 (0.15) 0 1
Of these, how many were by ambulance? Usual care (n = 148) 6 0.04 (0.28) 0 3 –0.04 (–0.08 to 0.01) 0.11
Cognitive rehabilitation (n = 183) 1 0.01 (0.07) 0 1
Did your visit to A&E result in an overnight stay
in hospital?
Usual care (n = 148) 3 –0.02 (–0.04 to 0.00) 0.05
Cognitive rehabilitation (n = 183) 0
Total number of nights spent in night as a result
of A&E visits
Usual care (n = 148) 13 0.09 (0.06) 0 6 –0.09 (–0.18 to 0.01) 0.07
Cognitive rehabilitation (n = 183) 0 0.00 (0.00) 0 0
Total cost (£) of A&E services Usual care (n = 148) 78.64 (511.47) 0 4029.82 –74.93 (–144.12 to –5.73) 0.03*
Cognitive rehabilitation (n = 183) 3.71 (30.31) 0 373.82
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TABLE 46 Resource and service use costs: 12-month follow-up (continued )
Resource Group
Number of
appointments Mean (SD) Minimum Maximum Differencea (95% CI) p-valuea
Other hospital services
Number of times you attended a day hospital Usual care (n = 175) 28 0.16 (0.64) 0 3 –0.00 (–0.14 to 0.13) 0.95
Cognitive rehabilitation (n = 212) 33 0.16 (0.71) 0 6
Number of times you went to a hospital
outpatient clinic
Usual care (n = 175) 77 0.44 (0.93) 0 6 0.10 (–0.14 to 0.34) 0.43
Cognitive rehabilitation (n = 212) 114 0.54 (1.38) 0 13
Number of nights you spent on a hospital ward
as a result of a planned admission
Usual care (n = 175) 38 0.22 (2.33) 0 30 –0.16 (–0.48 to 0.17) 0.35
Cognitive rehabilitation (n = 212) 13 0.06 (0.55) 0 6
Number of contacts with anyone else from the
hospital
Usual care (n = 175) 100 0.57 (1.57) 0 11 –0.12 (–0.42 to 0.18) 0.43
Cognitive rehabilitation (n = 212) 96 0.45 (1.41) 0 12
Total cost (£) of other hospital services Usual care (n = 175) 730.47 (6036.85) 0 77,727.00 –422.64 (–1267.77 to 422.49) 0.33
Cognitive rehabilitation (n = 212) 307.83 (1505.38) 0 16,103.00
Medications
Number of medications taken Cognitive rehabilitation (n = 212) 5.23 (3.55) 0 20 –0.08 (–0.834 to 0.68) 0.84
Usual care (n = 175) 5.15 (3.93) 0 25
Cost (£) of medications taken Cognitive rehabilitation (n = 212) 2040.97 (3847.59) 0 34,929.11 –320.45 (–928.61 to 287.71) 0.30
Usual care (n = 175) 1720.52 (2127.86) 0 7394.58
Number of medications taken (excluding
disease-modifying therapies)
Cognitive rehabilitation (n = 212) 4.82 (3.58) 0 20 –0.04 (–0.80 to 0.72) 0.91
Usual care (n = 175) 4.77 (3.95) 0 25
Cost (£) of medications taken (excluding
disease-modifying therapies)
Cognitive rehabilitation (n = 212) 581.48 (3408.86) 0 34,929.11 –332.33 (–812.80 to 148.14) 0.17
Usual care (n = 175) 249.15 (929.10) 0 7037.20
*Significant at the 5% level, **significant at the 1% level.
A&E, accident and emergency.
a In accordance with CONSORT guidelines, significance tests of baseline differences were not done.
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Appendix 17 Available-case analyses
TABLE 47 Total cumulative costs (available cases)
Trial group Baseline, mean (SD), n 12 months, mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: total cumulative costs at 12 months
Usual care 3067.70 (3214.14), 203 6573.95 (9188.35), 170 –808.33 (–2248.22 to 631.56) 0.27
Cognitive rehabilitation 3271.68 (5130.30), 245 5885.49 (5640.75), 208
Panel B: total cumulative costs at 6 months
6 months, mean (SD), n
Usual care 3067.70 (3214.14), 203 3029.93 (3877.71), 187 –12.51 (–682.88 to 657.86) 0.97
Cognitive rehabilitation 3271.68 (5130.30), 245 2841.92 (3438.15), 225
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline costs, gender, MS type and site as covariates
TABLE 48 The QALYs derived from the EQ-5D-5L (available cases)
Trial group and
QALY gain Baseline, mean (SD), n 12 months, mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: EQ-5D-5L QALYs at 12 months (available cases)
Usual care 0.57 (0.25), 204 0.57 (0.27), 172
Cognitive rehabilitation 0.60 (0.26), 245 0.60 (0.25), 211 0.01 (–0.03 to 0.05) 0.52
QALY gain 0.00 (–0.01 to 0.02) 0.52
Panel B: EQ-5D-5L QALYs at 6 months (available cases)
6 months, mean (SD), n
Usual care 0.57 (0.25), 204 0.57 (0.27), 187
Cognitive rehabilitation 0.60 (0.26), 245 0.60 (0.25), 224 0.01 (–0.03 to 0.05) 0.54
QALY gain 0.00 (–0.01 to 0.01) 0.54
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline EQ-5D-5L utility, gender, MS type and site as covariates.
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TABLE 49 The QALYs derived from the MSIS-8D (available cases)
Trial group and
QALY gain
Baseline,
mean (SD), n
12 months,
mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: MSIS-8D QALYs at 12 months (available cases)
Usual care 0.51 (0.18), 204 0.55 (0.19), 176
Cognitive rehabilitation 0.53 (0.17), 245 0.57 (0.18), 215 0.02 (–0.01 to 0.04) 0.23
QALY gain 0.01 (–0.01 to 0.02) 0.23
Panel B: MSIS-8D QALYs at 6 months (available cases)
6 months, mean (SD), n
Usual care 0.51 (0.18), 204 0.52 (0.20), 187
Cognitive rehabilitation 0.53 (0.17), 245 0.57 (0.18), 216 0.03 (0.00 to 0.06) 0.03
QALY gain 0.01 (0.00 to 0.01) 0.03
a Difference in means (cognitive rehabilitation compared with usual care) estimated using a multilevel linear model,
including baseline MSIS-8D utility, gender, MS type, and site as covariates.
TABLE 50 Incremental cost-effectiveness ratios (cost per QALY gain, ACA)
Outcome measure Incremental cost (95% CI) Incremental effect (95% CI) ICER
EQ-5D-5L QALY 6 months –12.51 (–682.88 to 657.86) 0.00 (–0.01 to 0.01) NA
EQ-5D-5L QALY 12 months –808.33 (–2248.22 to 631.56) 0.00 (–0.01 to 0.02) NA
MSIS-8D QALY 6 months –12.51 (–682.88 to 657.86) 0.01 (0.00 to 0.01) NA
MSIS-8D QALY 12 months –808.33 (–2248.22 to 631.56) 0.01 (–0.01 to 0.02) NA
MSIS-Psy 6 months –12.51 (–682.88 to 657.86) –0.9 (–1.7 to –0.1) NA
MSIS-Psy 12 months –808.33 (–2248.22 to 631.56) –0.6 (–1.5 to 0.3) NA
NA, not applicable due to dominance.
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FIGURE 12 Total costs and EQ-5D-5L QALYs at 12 months (available cases). (a) Cost-effectiveness plane; and (b) CEAC.
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FIGURE 13 Total costs and MSIS-8D QALYs at 12 months (available cases). (a) Cost-effectiveness plane; and (b) CEAC.
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FIGURE 14 Total costs and EQ-5D-5L QALYs at 6 months (available cases). (a) Cost-effectiveness plane; and (b) CEAC.
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FIGURE 15 Total costs and MSIS-8D QALYs at 6 months (available cases). (a) Cost-effectiveness plane; and (b) CEAC.
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Appendix 18 One-way sensitivity analyses
TABLE 51 The OWSA of incremental cost-effectiveness: QALYs derived from the EQ-5D-5L
Scenario
12 months 6 months
Incremental
cost (95% CI)
Incremental
effect (95% CI) ICER
Incremental
cost (95% CI)
Incremental
effect (95% CI) ICER
Base case –574.93
(–1878.93 to 729.07)
0.00
(–0.02 to 0.02)
NA –19.91
(–777.13 to 737.31)
0.00
(–0.01 to 0.01)
NA
U95% Cost
U95% Effect
729.07 0.02 31,055 737.31 0.01 60,269
U95% Cost
L95% Effect
729.07 –0.02 NA 737.31 –0.01 NA
L95% Cost
U95% Effect
–1878.93 0.02 NA –777.13 0.01 NA
L95% Cost
L95% Effect
–1878.93 –0.02 89,306 –777.13 –0.01 110,917
Intervention
cost, including
cognitive
assessment
–450.93
(–1754.93 to 853.07)
0.00 NA 104.09
(–653.13 to 861.31)
0.00 39,826
Outlier
removala
–38.85
(–1162.14 to 1084.45)
0.00 NA – – –
L95%, lower 95% CI bound; U95%, upper 95% CI bound.
a Conducted on ACA. All other OWSAs were conducted on multiple imputation analysis.
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TABLE 52 The OWSA of incremental cost-effectiveness: QALYs derived from the MSIS-8D
Scenario
12 months 6 months
Incremental cost
(95% CI)
Incremental
effect (95% CI) ICER
Incremental cost
(95% CI)
Incremental
effect (95% CI) ICER
Base case –575.93
(–1878.93 to 729.07)
0.01
(–0.00 to 0.01)
NA –19.91
(–777.13 to 737.31)
0.01
(–0.01 to 0.03)
NA
U95% Cost
U95% Effect
729.07 0.01 27,529 737.31 0.03 50,902
U95% Cost
L95% Effect
729.07 –0.00 NA 737.31 –0.01 NA
L95% Cost
U95% Effect
–1878.93 0.01 NA –777.13 0.03 NA
L95% Cost
L95% Effect
–1878.93 –0.00 348,007 –777.13 –0.01
418,261
Intervention
Cost inc.
Cognitive
Assessment
–450.93 0.01 NA 104.09 0.01 14,559
Outlier
removala
–38.85
(–1162.14 to 1084.45)
0.00 NA – – –
L95%, lower 95% CI bound; U95%, upper 95% CI bound.
a Conducted on ACA. All other OWSAs were conducted on multiple imputation analysis.
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Appendix 19 Sensitivity analysis: intervention
costs
TABLE 53 Sensitivity analysis on cost of cognitive rehabilitation inclusive of cognitive assessment (total costs)
Trial group
Baseline,
mean (SD), n
12 months,
mean (SD), n
Adjusted difference in
means (95% CI)a p-value
Panel A: total cumulative costs at 12 months
Usual care 3067.70 (3214.14), 203 6773.03 (9573.36), 170 –886.25 (–2369.55 to 597.06) 0.24
Cognitive rehabilitation 3271.68 (5130.30), 245 6009.49 (5640.75), 208
Panel B: total cumulative costs at 6 months
6 months, mean (SD), n
Usual care 3067.70 (3214.14), 203 3029.93 (3877.71), 187 111.49 (–558.88 to 781.86) 0.74
Cognitive rehabilitation 3271.68 (5130.30), 245 3175.12 (3438.15), 225
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